{"5ba9e2ea21bf3cc7431d0118965a53762aae28c1": [["IntroductionFeline coronavirus (FCoV) is a viral pathogen infecting cats worldwide.", [["IntroductionFeline coronavirus", "ORGANISM", 0, 30], ["FCoV", "ORGANISM", 32, 36], ["cats", "ORGANISM", 68, 72], ["coronavirus", "SPECIES", 19, 30], ["cats", "SPECIES", 68, 72], ["IntroductionFeline coronavirus", "SPECIES", 0, 30], ["FCoV", "SPECIES", 32, 36], ["IntroductionFeline coronavirus (FCoV", "PROBLEM", 0, 36], ["a viral pathogen", "PROBLEM", 41, 57]]], ["It is highly contagious [1] : nearly 100% of cats become infected when exposed, usually horizontally via the fecal-oral route [2, 3] .", [["oral", "ANATOMY", 115, 119], ["cats", "ORGANISM", 45, 49], ["oral", "ORGANISM_SUBDIVISION", 115, 119], ["cats", "SPECIES", 45, 49], ["highly", "OBSERVATION_MODIFIER", 6, 12], ["contagious", "OBSERVATION_MODIFIER", 13, 23], ["infected", "OBSERVATION", 57, 65], ["fecal", "ANATOMY", 109, 114]]], ["Additionally, the virus can persist in excretions in the environment for up to several weeks [4] , rendering indirect transmission, e.g., via caregivers, a possible route of infection.", [["infection", "DISEASE", 174, 183], ["the virus", "PROBLEM", 14, 23], ["infection", "PROBLEM", 174, 183], ["virus", "OBSERVATION", 18, 23], ["infection", "OBSERVATION", 174, 183]]], ["The prevalence of FCoV in the cat population is very high; this is especially true for multi-cat households, in which prevalence can be as high as 90% [5] [6] [7] .", [["FCoV", "DISEASE", 18, 22], ["FCoV", "CANCER", 18, 22], ["cat", "ORGANISM", 30, 33], ["cat", "ORGANISM", 93, 96], ["cat", "SPECIES", 30, 33], ["FCoV", "PROBLEM", 18, 22], ["FCoV", "OBSERVATION", 18, 22], ["very", "OBSERVATION_MODIFIER", 48, 52], ["high", "OBSERVATION", 53, 57]]], ["Only about 7-14% of FCoV-infected cats go on to develop FCoV more frequently throughout the study period and (3) whether cats shedding FCoV in all four fecal samples collected would have higher antibody titers and shed higher concentrations of FCoV than cats that shed virus only intermittently.", [["fecal samples", "ANATOMY", 152, 165], ["FCoV", "CHEMICAL", 135, 139], ["FCoV", "GENE_OR_GENE_PRODUCT", 20, 24], ["cats", "ORGANISM", 34, 38], ["cats", "ORGANISM", 121, 125], ["FCoV", "GENE_OR_GENE_PRODUCT", 135, 139], ["FCoV", "GENE_OR_GENE_PRODUCT", 244, 248], ["cats", "ORGANISM", 254, 258], ["cats", "SPECIES", 34, 38], ["cats", "SPECIES", 121, 125], ["cats", "SPECIES", 254, 258], ["FCoV", "SPECIES", 56, 60], ["FCoV", "PROBLEM", 56, 60], ["cats shedding FCoV", "PROBLEM", 121, 139], ["all four fecal samples", "TEST", 143, 165], ["higher antibody titers", "PROBLEM", 187, 209], ["FCoV", "OBSERVATION", 56, 60]]], ["Indeed, the results obtained suggest that in cats from German catteries, the antibody titer is correlated with mean fecal virus load.", [["cats", "ORGANISM", 45, 49], ["fecal virus", "ORGANISM", 116, 127], ["cats", "SPECIES", 45, 49], ["German catteries", "TEST", 55, 71], ["the antibody titer", "TEST", 73, 91], ["mean fecal virus load", "PROBLEM", 111, 132]]], ["Cats with antibodies were more likely to be FCoV shedders than non-shedders.", [["antibodies", "PROTEIN", 10, 20], ["antibodies", "TEST", 10, 20]]], ["Cats with higher antibody titers shed FCoV more frequently and with a higher mean fecal virus load than cats with lower FCoV antibody titers or without antibodies.", [["Cats", "ORGANISM", 0, 4], ["FCoV", "GENE_OR_GENE_PRODUCT", 38, 42], ["fecal virus", "ORGANISM", 82, 93], ["cats", "ORGANISM", 104, 108], ["FCoV antibody", "PROTEIN", 120, 133], ["antibodies", "PROTEIN", 152, 162], ["cats", "SPECIES", 104, 108], ["FCoV", "SPECIES", 120, 124], ["Cats", "TEST", 0, 4], ["higher antibody titers", "PROBLEM", 10, 32], ["a higher mean fecal virus load", "PROBLEM", 68, 98], ["lower FCoV antibody titers", "TEST", 114, 140], ["antibodies", "PROBLEM", 152, 162], ["FCoV antibody titers", "OBSERVATION", 120, 140], ["without", "UNCERTAINTY", 144, 151]]], ["Cats shedding FCoV in all four fecal samples had higher FCoV antibody titers and shed higher concentrations of FCoV than cats shedding FCoV intermittently.", [["fecal samples", "ANATOMY", 31, 44], ["FCoV", "CHEMICAL", 14, 18], ["FCoV", "CHEMICAL", 135, 139], ["Cats", "ORGANISM", 0, 4], ["FCoV", "GENE_OR_GENE_PRODUCT", 14, 18], ["FCoV", "SIMPLE_CHEMICAL", 111, 115], ["cats", "ORGANISM", 121, 125], ["FCoV", "SIMPLE_CHEMICAL", 135, 139], ["FCoV antibody", "PROTEIN", 56, 69], ["cats", "SPECIES", 121, 125], ["FCoV", "SPECIES", 56, 60], ["FCoV", "SPECIES", 135, 139], ["Cats shedding FCoV", "PROBLEM", 0, 18], ["all four fecal samples", "TEST", 22, 44], ["higher FCoV antibody titers", "PROBLEM", 49, 76], ["FCoV", "OBSERVATION", 14, 18], ["FCoV antibody titers", "OBSERVATION", 56, 76]]], ["However, there were nine cats without antibodies that shed FCoV.", [["cats", "ORGANISM", 25, 29], ["antibodies", "PROTEIN", 38, 48], ["FCoV", "PROTEIN", 59, 63], ["antibodies", "PROBLEM", 38, 48]]], ["Thus, antibody testing cannot replace fecal testing by RT-qPCR.ResultsAnti-FCoV antibodies were detected in 64 of the 82 cats (78%) included in the study (Figure 1 ).", [["fecal", "ANATOMY", 38, 43], ["fecal", "ORGANISM_SUBSTANCE", 38, 43], ["cats", "ORGANISM", 121, 125], ["ResultsAnti-FCoV antibodies", "PROTEIN", 63, 90], ["antibody testing", "TEST", 6, 22], ["fecal testing", "TEST", 38, 51], ["RT", "TEST", 55, 57], ["ResultsAnti-FCoV antibodies", "TEST", 63, 90], ["the study", "TEST", 144, 153]]], ["All 19 catteries homed at least one cat with antibodies.", [["cat", "ORGANISM", 36, 39], ["antibodies", "PROTEIN", 45, 55]]], ["FCoV RNA could be detected in at least one of the four fecal samples collected at intervals of 5-30 days by RT-qPCR in 58 of the 82 included cats (71%), and all 19 catteries homed at least one cat that was shedding FCoV in at least one fecal sample.ResultsOf the 18 cats without detectable antibodies, nine cats (50%) shed FCoV at least once.", [["fecal samples", "ANATOMY", 55, 68], ["fecal sample", "ANATOMY", 236, 248], ["FCoV", "CHEMICAL", 323, 327], ["FCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["fecal samples", "ORGANISM_SUBSTANCE", 55, 68], ["cats", "ORGANISM", 141, 145], ["cat", "ORGANISM", 193, 196], ["FCoV", "CANCER", 215, 219], ["cats", "ORGANISM", 266, 270], ["cats", "ORGANISM", 307, 311], ["FCoV", "CANCER", 323, 327], ["FCoV RNA", "RNA", 0, 8], ["antibodies", "PROTEIN", 290, 300], ["cats", "SPECIES", 141, 145], ["cats", "SPECIES", 266, 270], ["cats", "SPECIES", 307, 311], ["FCoV", "SPECIES", 0, 4], ["FCoV RNA", "PROBLEM", 0, 8], ["RT-qPCR", "TEST", 108, 115], ["cats", "TEST", 141, 145], ["shedding FCoV", "PROBLEM", 206, 219], ["FCoV", "OBSERVATION", 215, 219]]], ["Of the cats with antibodies, 20/28 (71%) with an antibody titer of 1:25, 21/26 (81%) with a titer of 1:100, and 8/10 (80%) with a titer of 1:400 shed FCoV at least once.", [["cats", "ORGANISM", 7, 11], ["antibodies", "PROTEIN", 17, 27], ["cats", "SPECIES", 7, 11], ["antibodies", "TEST", 17, 27], ["an antibody titer", "TEST", 46, 63], ["a titer", "TEST", 90, 97], ["a titer", "TEST", 128, 135]]], ["None of the cats had an antibody titer of 1:1600.", [["cats", "ORGANISM", 12, 16], ["cats", "SPECIES", 12, 16], ["the cats", "TEST", 8, 16], ["an antibody titer", "TEST", 21, 38]]], ["Most (71%) of the 24 cats that were not shedding FCoV either did not have antibodies (9/24; 38%) or only a very low titer of 1:25 (8/24; 33%).", [["cats", "ORGANISM", 21, 25], ["antibodies", "PROTEIN", 74, 84], ["cats", "SPECIES", 21, 25], ["shedding FCoV", "PROBLEM", 40, 53], ["antibodies", "TEST", 74, 84]]], ["Nevertheless, 7/24 (29%) cats that were RT-qPCR-negative in all four fecal samples had an antibody titer of at least 1:100.Correlation between Mean Fecal FCoV Load and Antibody TiterFecal virus load ranged from 2.2 \u00d7 10 6 to 4.5 \u00d7 10 12 per gram (g) of feces (median 6.8 \u00d7 10 9 per g feces) in cats shedding FCoV (Table 1) .", [["fecal samples", "ANATOMY", 69, 82], ["feces", "ANATOMY", 253, 258], ["cats", "ORGANISM", 25, 29], ["Antibody TiterFecal virus", "ORGANISM", 168, 193], ["feces", "ORGANISM", 253, 258], ["feces", "ORGANISM_SUBDIVISION", 284, 289], ["cats", "ORGANISM", 294, 298], ["cats", "SPECIES", 25, 29], ["cats", "SPECIES", 294, 298], ["TiterFecal virus", "SPECIES", 177, 193], ["cats", "TEST", 25, 29], ["RT-qPCR", "TEST", 40, 47], ["all four fecal samples", "TEST", 60, 82], ["an antibody titer", "TEST", 87, 104], ["Correlation", "TEST", 123, 134], ["Mean Fecal FCoV Load", "TEST", 143, 163], ["Antibody TiterFecal virus load", "TEST", 168, 198], ["feces", "TEST", 253, 258], ["median", "TEST", 260, 266], ["negative", "OBSERVATION", 48, 56], ["Fecal", "ANATOMY", 148, 153], ["FCoV Load", "OBSERVATION", 154, 163]]], ["Cats with higher anti-FCoV antibody titers also had significantly higher mean fecal virus loads.", [["fecal virus", "ORGANISM", 78, 89], ["anti-FCoV antibody", "PROTEIN", 17, 35], ["Cats", "TEST", 0, 4], ["higher anti-FCoV antibody titers", "TEST", 10, 42], ["significantly higher mean fecal virus loads", "PROBLEM", 52, 95], ["fecal virus loads", "OBSERVATION", 78, 95]]], ["There was a weak positive correlation between the Figure 1 .", [["a weak positive correlation", "PROBLEM", 10, 37], ["weak", "OBSERVATION_MODIFIER", 12, 16], ["positive", "OBSERVATION", 17, 25]]], ["Antibody titers of cats not shedding feline coronavirus (FCoV) and of cats with one, two, three, or four fecal samples positive for FCoV RNA by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR).", [["fecal samples", "ANATOMY", 105, 118], ["feline coronavirus", "DISEASE", 37, 55], ["cats", "ORGANISM", 19, 23], ["feline coronavirus", "ORGANISM", 37, 55], ["FCoV", "CANCER", 57, 61], ["cats", "ORGANISM", 70, 74], ["FCoV RNA", "RNA", 132, 140], ["reverse transcriptase", "PROTEIN", 157, 178], ["cats", "SPECIES", 19, 23], ["feline coronavirus", "SPECIES", 37, 55], ["cats", "SPECIES", 70, 74], ["feline coronavirus", "SPECIES", 37, 55], ["FCoV", "SPECIES", 57, 61], ["FCoV", "SPECIES", 132, 136], ["Antibody titers", "TEST", 0, 15], ["cats", "TEST", 19, 23], ["shedding feline coronavirus", "PROBLEM", 28, 55], ["cats", "TEST", 70, 74], ["four fecal samples", "TEST", 100, 118], ["FCoV RNA", "PROBLEM", 132, 140], ["quantitative reverse transcriptase polymerase chain reaction", "PROBLEM", 144, 204]]], ["Fecal samples with weak positive RT-qPCR results were considered positive; samples below the limit of quantification were considered negative.Correlation between Mean Fecal FCoV Load and Antibody TiterOf the 18 cats without detectable antibodies, nine cats (50%) shed FCoV at least once.", [["Fecal samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 75, 82], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["cats", "ORGANISM", 211, 215], ["cats", "ORGANISM", 252, 256], ["antibodies", "PROTEIN", 235, 245], ["cats", "SPECIES", 211, 215], ["cats", "SPECIES", 252, 256], ["Fecal samples", "TEST", 0, 13], ["positive", "PROBLEM", 65, 73], ["samples", "TEST", 75, 82], ["Correlation", "TEST", 142, 153], ["Mean Fecal FCoV Load", "TEST", 162, 182], ["Antibody TiterOf", "TEST", 187, 203], ["detectable antibodies", "PROBLEM", 224, 245], ["Fecal", "ANATOMY", 167, 172], ["FCoV Load", "OBSERVATION", 173, 182]]], ["Of the cats with antibodies, 20/28 (71%) with an antibody titer of 1:25, 21/26 (81%) with a titer of 1:100, and 8/10 (80%) with a titer of 1:400 shed FCoV at least once.", [["cats", "ORGANISM", 7, 11], ["antibodies", "PROTEIN", 17, 27], ["cats", "SPECIES", 7, 11], ["antibodies", "TEST", 17, 27], ["an antibody titer", "TEST", 46, 63], ["a titer", "TEST", 90, 97], ["a titer", "TEST", 128, 135]]], ["None of the cats had an antibody titer of 1:1600.", [["cats", "ORGANISM", 12, 16], ["cats", "SPECIES", 12, 16], ["the cats", "TEST", 8, 16], ["an antibody titer", "TEST", 21, 38]]], ["Most (71%) of the 24 cats that were not shedding FCoV either did not have antibodies (9/24; 38%) or only a very low titer of 1:25 (8/24; 33%).", [["cats", "ORGANISM", 21, 25], ["antibodies", "PROTEIN", 74, 84], ["cats", "SPECIES", 21, 25], ["shedding FCoV", "PROBLEM", 40, 53], ["antibodies", "TEST", 74, 84]]], ["Nevertheless, 7/24 (29%) cats that were RT-qPCR-negative in all four fecal samples had an antibody titer of at least 1:100.Correlation between Mean Fecal FCoV Load and Antibody TiterFecal virus load ranged from 2.2 \u00d7 10 6 to 4.5 \u00d7 10 12 per gram (g) of feces (median 6.8 \u00d7 10 9 per g feces) in cats shedding FCoV (Table 1) .", [["fecal samples", "ANATOMY", 69, 82], ["feces", "ANATOMY", 253, 258], ["cats", "ORGANISM", 25, 29], ["Antibody TiterFecal virus", "ORGANISM", 168, 193], ["feces", "ORGANISM", 253, 258], ["feces", "ORGANISM_SUBDIVISION", 284, 289], ["cats", "ORGANISM", 294, 298], ["cats", "SPECIES", 25, 29], ["cats", "SPECIES", 294, 298], ["TiterFecal virus", "SPECIES", 177, 193], ["cats", "TEST", 25, 29], ["RT-qPCR", "TEST", 40, 47], ["all four fecal samples", "TEST", 60, 82], ["an antibody titer", "TEST", 87, 104], ["Correlation", "TEST", 123, 134], ["Mean Fecal FCoV Load", "TEST", 143, 163], ["Antibody TiterFecal virus load", "TEST", 168, 198], ["feces", "TEST", 253, 258], ["median", "TEST", 260, 266], ["negative", "OBSERVATION", 48, 56], ["Fecal", "ANATOMY", 148, 153], ["FCoV Load", "OBSERVATION", 154, 163]]], ["Cats with higher anti-FCoV antibody titers also had significantly higher mean fecal virus loads.", [["fecal virus", "ORGANISM", 78, 89], ["anti-FCoV antibody", "PROTEIN", 17, 35], ["Cats", "TEST", 0, 4], ["higher anti-FCoV antibody titers", "TEST", 10, 42], ["significantly higher mean fecal virus loads", "PROBLEM", 52, 95], ["fecal virus loads", "OBSERVATION", 78, 95]]], ["There was a weak positive correlation between the antibody titer and the calculated mean fecal virus load (mean of all four fecal samples) (Spearman r = 0.2984, 95% confidence interval 0.07761-0.4913; p = 0.0072).", [["fecal samples", "ANATOMY", 124, 137], ["fecal virus", "ORGANISM", 89, 100], ["a weak positive correlation", "PROBLEM", 10, 37], ["the antibody titer", "TEST", 46, 64], ["the calculated mean fecal virus load", "TEST", 69, 105], ["mean", "TEST", 107, 111], ["Spearman r", "TEST", 140, 150], ["p", "TEST", 201, 202], ["weak", "OBSERVATION_MODIFIER", 12, 16], ["positive", "OBSERVATION", 17, 25]]], ["Fecal feline coronavirus (FCoV) load per gram of feces of cats with different antibody titers detected by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR).", [["feces", "ANATOMY", 49, 54], ["Fecal feline coronavirus", "ORGANISM", 0, 24], ["FCoV", "ORGANISM", 26, 30], ["feces", "ORGANISM_SUBSTANCE", 49, 54], ["cats", "ORGANISM", 58, 62], ["reverse transcriptase", "PROTEIN", 119, 140], ["feline coronavirus", "SPECIES", 6, 24], ["cats", "SPECIES", 58, 62], ["feline coronavirus", "SPECIES", 6, 24], ["FCoV", "SPECIES", 26, 30], ["Fecal feline coronavirus", "PROBLEM", 0, 24], ["cats", "TEST", 58, 62], ["different antibody titers", "TEST", 68, 93], ["quantitative reverse transcriptase polymerase chain reaction", "PROBLEM", 106, 166], ["RT-qPCR", "TEST", 168, 175], ["feline coronavirus", "OBSERVATION", 6, 24]]], ["Fecal FCoV load was calculated as the mean of all four fecal samples from each cat.", [["Fecal", "ANATOMY", 0, 5], ["fecal samples", "ANATOMY", 55, 68], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["fecal samples", "ORGANISM_SUBSTANCE", 55, 68], ["cat", "ORGANISM", 79, 82], ["cat", "SPECIES", 79, 82], ["Fecal FCoV load", "TEST", 0, 15], ["FCoV load", "OBSERVATION", 6, 15]]], ["The two cats with only one weak RT-qPCR-positive or one sample below the limit of quantification and three RT-qPCR-negative fecal samples each were excluded from analysis.Correlation between Frequency of Fecal FCoV Shedding and Antibody Titer and Mean Fecal FCoV LoadIn addition to shedding larger amounts of FCoV with their feces, cats with higher antibody titers also shed FCoV more frequently.", [["sample", "ANATOMY", 56, 62], ["fecal samples", "ANATOMY", 124, 137], ["feces", "ANATOMY", 325, 330], ["cats", "ORGANISM", 8, 12], ["FCoV", "GENE_OR_GENE_PRODUCT", 309, 313], ["feces", "ORGANISM_SUBDIVISION", 325, 330], ["cats", "ORGANISM", 332, 336], ["Antibody Titer", "PROTEIN", 228, 242], ["FCoV", "PROTEIN", 309, 313], ["FCoV", "PROTEIN", 375, 379], ["cats", "SPECIES", 8, 12], ["cats", "SPECIES", 332, 336], ["qPCR", "TEST", 35, 39], ["quantification", "TEST", 82, 96], ["three RT-qPCR", "TEST", 101, 114], ["Fecal FCoV Shedding", "TEST", 204, 223], ["Antibody Titer", "TEST", 228, 242], ["Mean Fecal FCoV LoadIn", "TREATMENT", 247, 269], ["shedding larger amounts of FCoV", "TREATMENT", 282, 313], ["cats", "TREATMENT", 332, 336], ["higher antibody titers", "TREATMENT", 342, 364], ["fecal", "ANATOMY", 124, 129], ["Fecal", "ANATOMY", 204, 209], ["FCoV", "OBSERVATION", 210, 214], ["FCoV LoadIn", "OBSERVATION", 258, 269]]], ["Antibody titers were significantly higher in cats with more frequent than in cats with less frequent FCoV shedding (p = 0.0063; Figure 1 ).", [["FCoV", "ANATOMY", 101, 105], ["cats", "ORGANISM", 45, 49], ["cats", "ORGANISM", 77, 81], ["cats", "SPECIES", 45, 49], ["cats", "SPECIES", 77, 81], ["FCoV", "SPECIES", 101, 105], ["Antibody titers", "TEST", 0, 15], ["less frequent FCoV shedding", "PROBLEM", 87, 114]]], ["However, when comparing the cats in different groups (based on their frequency of FCoV shedding), this difference was only significant between cats that were RT-qPCR-negative in all four fecal samples and cats that were RT-qPCR-positive in all four fecal samples (Dunn's test; p < 0.05).", [["fecal samples", "ANATOMY", 187, 200], ["fecal samples", "ANATOMY", 249, 262], ["cats", "ORGANISM", 28, 32], ["cats", "ORGANISM", 143, 147], ["fecal samples", "ORGANISM_SUBSTANCE", 187, 200], ["cats", "ORGANISM", 205, 209], ["cats", "SPECIES", 28, 32], ["cats", "SPECIES", 143, 147], ["cats", "SPECIES", 205, 209], ["RT-qPCR", "TEST", 158, 165], ["cats", "TEST", 205, 209], ["RT-qPCR", "TEST", 220, 227], ["Dunn's test", "TEST", 264, 275], ["fecal", "ANATOMY", 249, 254]]], ["Two cats that were RT-qPCR-positive in all four fecal samples did not have antibodies and two cats that were RT-qPCR-negative in all four fecal samples had a high antibody titer of 1:400.Correlation between Frequency of Fecal FCoV Shedding and Antibody Titer and Mean Fecal FCoV LoadWhen considering the mean fecal virus load and frequency of FCoV shedding, there was a slight tendency that cats shedding FCoV more frequently shed higher concentrations of FCoV RNA, but that association was not significant (p = 0.1323; Table 2 ).", [["fecal samples", "ANATOMY", 48, 61], ["fecal samples", "ANATOMY", 138, 151], ["cats", "ORGANISM", 4, 8], ["cats", "ORGANISM", 94, 98], ["fecal virus", "ORGANISM", 309, 320], ["FCoV", "GENE_OR_GENE_PRODUCT", 343, 347], ["cats", "ORGANISM", 391, 395], ["FCoV", "GENE_OR_GENE_PRODUCT", 456, 460], ["antibodies", "PROTEIN", 75, 85], ["Fecal FCoV", "PROTEIN", 220, 230], ["FCoV RNA", "RNA", 456, 464], ["cats", "SPECIES", 4, 8], ["cats", "SPECIES", 94, 98], ["FCoV", "SPECIES", 343, 347], ["FCoV", "SPECIES", 405, 409], ["Two cats", "TEST", 0, 8], ["RT-qPCR", "TEST", 19, 26], ["all four fecal samples", "TEST", 39, 61], ["antibodies", "PROBLEM", 75, 85], ["two cats", "TEST", 90, 98], ["RT-qPCR", "TEST", 109, 116], ["all four fecal samples", "TEST", 129, 151], ["a high antibody titer", "TEST", 156, 177], ["Fecal FCoV Shedding", "TEST", 220, 239], ["Antibody Titer", "TEST", 244, 258], ["Mean Fecal FCoV LoadWhen", "TEST", 263, 287], ["the mean fecal virus load", "PROBLEM", 300, 325], ["FCoV shedding", "PROBLEM", 343, 356], ["a slight tendency that cats shedding FCoV", "PROBLEM", 368, 409], ["FCoV RNA", "PROBLEM", 456, 464], ["Fecal", "ANATOMY", 220, 225], ["FCoV", "OBSERVATION", 226, 230], ["Fecal FCoV", "OBSERVATION", 268, 278], ["slight", "OBSERVATION_MODIFIER", 370, 376], ["tendency", "OBSERVATION_MODIFIER", 377, 385], ["FCoV RNA", "OBSERVATION", 456, 464]]], ["Mean fecal feline coronavirus (FCoV) load per gram of feces of cats with different frequencies of FCoV shedding detected by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR).", [["feces", "ANATOMY", 54, 59], ["fecal feline coronavirus", "ORGANISM", 5, 29], ["FCoV", "GENE_OR_GENE_PRODUCT", 31, 35], ["feces", "ORGANISM_SUBSTANCE", 54, 59], ["cats", "ORGANISM", 63, 67], ["reverse transcriptase", "PROTEIN", 137, 158], ["feline coronavirus", "SPECIES", 11, 29], ["cats", "SPECIES", 63, 67], ["feline coronavirus", "SPECIES", 11, 29], ["FCoV", "SPECIES", 31, 35], ["FCoV", "SPECIES", 98, 102], ["Mean fecal feline coronavirus", "PROBLEM", 0, 29], ["FCoV shedding", "PROBLEM", 98, 111], ["quantitative reverse transcriptase polymerase chain reaction", "PROBLEM", 124, 184], ["fecal feline coronavirus", "OBSERVATION", 5, 29], ["FCoV", "OBSERVATION", 98, 102]]], ["Fecal FCoV load was calculated as the mean of all four fecal samples from each cat.", [["Fecal", "ANATOMY", 0, 5], ["fecal samples", "ANATOMY", 55, 68], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["fecal samples", "ORGANISM_SUBSTANCE", 55, 68], ["cat", "ORGANISM", 79, 82], ["cat", "SPECIES", 79, 82], ["Fecal FCoV load", "TEST", 0, 15], ["FCoV load", "OBSERVATION", 6, 15]]], ["Fecal samples with weak positive RT-qPCR results were considered positive; samples below the limit of quantification were considered negative.", [["Fecal samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 75, 82], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["Fecal samples", "TEST", 0, 13], ["positive", "PROBLEM", 65, 73], ["samples", "TEST", 75, 82]]], ["The two cats with only one weak RT-qPCR-positive or one sample below the limit of quantification and three RT-qPCR-negative fecal samples each were excluded from analysis.Shedding Frequency Number of Cats Fecal FCoV LoadOne sample RT-qPCR-positive 9 2.2 \u00d7 10 6 -3.1 \u00d7 10 11 (median 5.2 \u00d7 10 9 ) Two samples RT-qPCR-positive 6 5.1 \u00d7 10 8 -4.9 \u00d7 10 11 (median 3.7 \u00d7 10 9 ) Three samples RT-qPCR-positive 5 2.5 \u00d7 10 9 -5.5 \u00d7 10 11 (median 1.1 \u00d7 10 10 ) Four samples RT-qPCR-positive 37 3.4 \u00d7 10 8 -1.3 \u00d7 10 12 (median 2.5 \u00d7 10 10 )Correlation between FCoV Shedding in All Four vs. One to Three Samples and Antibody TiterFifty-eight of the 82 cats (71%) were positive for FCoV RNA by RT-qPCR in at least one of the four fecal samples collected.", [["sample", "ANATOMY", 56, 62], ["fecal samples", "ANATOMY", 124, 137], ["fecal samples", "ANATOMY", 716, 729], ["cats", "ORGANISM", 8, 12], ["cats", "ORGANISM", 639, 643], ["FCoV", "GENE_OR_GENE_PRODUCT", 668, 672], ["FCoV RNA", "RNA", 668, 676], ["cats", "SPECIES", 8, 12], ["cats", "SPECIES", 639, 643], ["FCoV", "SPECIES", 668, 672], ["qPCR", "TEST", 35, 39], ["quantification", "TEST", 82, 96], ["three RT-qPCR", "TEST", 101, 114], ["Cats", "TEST", 200, 204], ["LoadOne", "TEST", 216, 223], ["RT", "TEST", 231, 233], ["qPCR", "TEST", 234, 238], ["median", "TEST", 275, 281], ["Two samples RT", "TEST", 295, 309], ["qPCR", "TEST", 310, 314], ["median", "TEST", 351, 357], ["Three samples RT", "TEST", 371, 387], ["qPCR", "TEST", 388, 392], ["median", "TEST", 429, 435], ["Four samples RT", "TEST", 450, 465], ["qPCR", "TEST", 466, 470], ["\u00d7", "TEST", 487, 488], ["median", "TEST", 508, 514], ["Antibody TiterFifty", "TEST", 603, 622], ["FCoV RNA", "PROBLEM", 668, 676], ["qPCR", "TEST", 683, 687], ["fecal", "ANATOMY", 124, 129], ["FCoV RNA", "OBSERVATION", 668, 676]]], ["Of those 58 cats, 37 (64%) were RT-qPCR-positive in all four fecal samples.", [["fecal samples", "ANATOMY", 61, 74], ["cats", "ORGANISM", 12, 16], ["cats", "SPECIES", 12, 16], ["cats", "TEST", 12, 16], ["RT-qPCR", "TEST", 32, 39]]], ["These 37 cats shedding in all four fecal samples had significantly higher antibody titers than cats that were RT-qPCR-positive in only one, two, or three fecal samples (p = 0.0014; Table 3 ).", [["fecal samples", "ANATOMY", 35, 48], ["fecal samples", "ANATOMY", 154, 167], ["cats", "ORGANISM", 9, 13], ["cats", "ORGANISM", 95, 99], ["cats", "SPECIES", 9, 13], ["cats", "SPECIES", 95, 99], ["all four fecal samples", "TEST", 26, 48], ["significantly higher antibody titers", "PROBLEM", 53, 89], ["RT-qPCR", "TEST", 110, 117], ["three fecal samples", "TEST", 148, 167]]], ["Moreover, when comparing shedders with four RT-qPCR-positive fecal samples and shedders with one to three RT-qPCR-positive fecal samples, shedders with four RT-qPCR-positive fecal samples shed significantly higher mean fecal virus loads (3.45 \u00d7 10 8 -1.31 \u00d7 10 12 viral copies per g feces, median 2.53 \u00d7 10 10 ; p = 0.0475; Figure 2 ) than shedders with one to three RT-qPCR-positive fecal samples (2.27 \u00d7 10 6 -5.50 \u00d7 10 11 viral copies per g feces, median 5.47 \u00d7 10 9 ).Correlation between FCoV Shedding in All Four vs. One to Three Samples and Antibody TiterPathogens 2020, 9, x 5 of 13 Moreover, when comparing shedders with four RT-qPCR-positive fecal samples and shedders with one to three RT-qPCR-positive fecal samples, shedders with four RT-qPCR-positive fecal samples shed significantly higher mean fecal virus loads (3.45 \u00d7 10 8 -1.31 \u00d7 10 12 viral copies per g feces, median 2.53 \u00d7 10 10 ; p = 0.0475; Figure 2 ) than shedders with one to three RT-qPCR-positive fecal samples (2.27 \u00d7 10 6 -5.50 \u00d7 10 11 viral copies per g feces, median 5.47 \u00d7 10 9 ).", [["fecal samples", "ANATOMY", 61, 74], ["shedders", "ANATOMY", 79, 87], ["fecal samples", "ANATOMY", 123, 136], ["shedders", "ANATOMY", 138, 146], ["fecal samples", "ANATOMY", 174, 187], ["fecal samples", "ANATOMY", 384, 397], ["fecal samples", "ANATOMY", 651, 664], ["shedders", "ANATOMY", 669, 677], ["fecal samples", "ANATOMY", 713, 726], ["shedders", "ANATOMY", 728, 736], ["fecal samples", "ANATOMY", 764, 777], ["fecal samples", "ANATOMY", 974, 987], ["fecal samples", "ORGANISM_SUBSTANCE", 61, 74], ["shedders", "CANCER", 79, 87], ["fecal virus", "ORGANISM", 219, 230], ["fecal virus", "ORGANISM", 809, 820], ["four RT-qPCR", "TEST", 39, 51], ["shedders", "TREATMENT", 79, 87], ["RT-qPCR", "TEST", 106, 113], ["four RT-qPCR", "TEST", 152, 164], ["positive fecal samples", "PROBLEM", 165, 187], ["significantly higher mean fecal virus loads", "PROBLEM", 193, 236], ["viral copies", "TEST", 264, 276], ["median", "TEST", 290, 296], ["p", "TEST", 312, 313], ["Figure", "TEST", 324, 330], ["qPCR", "TEST", 370, 374], ["fecal samples", "TEST", 384, 397], ["viral copies", "TEST", 425, 437], ["g feces", "TEST", 442, 449], ["median", "TEST", 451, 457], ["Three Samples", "TEST", 529, 542], ["Antibody TiterPathogens", "TEST", 547, 570], ["four RT-qPCR", "TEST", 629, 641], ["shedders", "TEST", 669, 677], ["qPCR", "TEST", 699, 703], ["four RT-qPCR", "TEST", 742, 754], ["positive fecal samples", "PROBLEM", 755, 777], ["significantly higher mean fecal virus loads", "PROBLEM", 783, 826], ["viral copies", "TEST", 854, 866], ["median", "TEST", 880, 886], ["p", "TEST", 902, 903], ["Figure", "TEST", 914, 920], ["qPCR", "TEST", 960, 964], ["fecal samples", "TEST", 974, 987], ["viral copies", "TEST", 1015, 1027], ["g feces", "TEST", 1032, 1039], ["median", "TEST", 1041, 1047], ["fecal", "ANATOMY", 123, 128], ["fecal", "ANATOMY", 174, 179], ["fecal", "ANATOMY", 384, 389], ["FCoV", "OBSERVATION", 492, 496], ["fecal", "ANATOMY", 713, 718], ["fecal", "ANATOMY", 974, 979]]], ["Fecal samples with weak positive RT-qPCR results were considered positive; samples below the limit of quantification were considered negative.", [["Fecal samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 75, 82], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["Fecal samples", "TEST", 0, 13], ["positive", "PROBLEM", 65, 73], ["samples", "TEST", 75, 82]]], ["The two cats with only one weak RT-qPCR-positive or one sample below the limit of quantification and three RT-qPCR-negative fecal samples each were excluded from analysis.DiscussionThe aim of this study was to investigate a possible correlation between FCoV antibody titer and fecal virus shedding in healthy cats living in German catteries.", [["sample", "ANATOMY", 56, 62], ["fecal samples", "ANATOMY", 124, 137], ["cats", "ORGANISM", 8, 12], ["FCoV", "GENE_OR_GENE_PRODUCT", 253, 257], ["fecal virus", "ORGANISM", 277, 288], ["cats", "ORGANISM", 309, 313], ["FCoV antibody", "PROTEIN", 253, 266], ["cats", "SPECIES", 8, 12], ["cats", "SPECIES", 309, 313], ["qPCR", "TEST", 35, 39], ["quantification", "TEST", 82, 96], ["three RT-qPCR", "TEST", 101, 114], ["this study", "TEST", 192, 202], ["FCoV antibody titer", "TEST", 253, 272], ["fecal virus shedding", "PROBLEM", 277, 297], ["fecal", "ANATOMY", 124, 129], ["fecal virus", "ANATOMY", 277, 288]]], ["The majority of antibody-positive cats Mean fecal virus load per gram (g) of feces of cats with four RT-qPCR-positive samples was significantly higher compared to cats with only one, two, or three RT-qPCR-positive samples (p = 0.0475).", [["feces", "ANATOMY", 77, 82], ["samples", "ANATOMY", 118, 125], ["samples", "ANATOMY", 214, 221], ["cats", "ORGANISM", 34, 38], ["fecal virus", "ORGANISM", 44, 55], ["feces", "ORGANISM_SUBDIVISION", 77, 82], ["cats", "ORGANISM", 86, 90], ["cats", "ORGANISM", 163, 167], ["cats", "SPECIES", 34, 38], ["cats", "SPECIES", 86, 90], ["cats", "SPECIES", 163, 167], ["antibody", "TEST", 16, 24], ["positive cats", "PROBLEM", 25, 38], ["cats", "TEST", 86, 90], ["four RT-qPCR", "TEST", 96, 108], ["positive samples", "PROBLEM", 109, 125], ["cats", "TEST", 163, 167], ["three RT-qPCR", "TEST", 191, 204]]], ["Mean fecal FCoV load was calculated as the mean of all four fecal samples from each cat.", [["fecal", "ANATOMY", 5, 10], ["fecal samples", "ANATOMY", 60, 73], ["fecal", "ORGANISM_SUBSTANCE", 5, 10], ["fecal samples", "ORGANISM_SUBSTANCE", 60, 73], ["cat", "ORGANISM", 84, 87], ["cat", "SPECIES", 84, 87], ["Mean fecal FCoV load", "TEST", 0, 20], ["fecal", "OBSERVATION", 5, 10], ["FCoV load", "OBSERVATION", 11, 20]]], ["Fecal samples with weak positive RT-qPCR results were considered positive; samples below the limit of quantification were considered negative.", [["Fecal samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 75, 82], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["Fecal samples", "TEST", 0, 13], ["positive", "PROBLEM", 65, 73], ["samples", "TEST", 75, 82]]], ["The two cats with only one weak RT-qPCR-positive or one sample below the limit of quantification and three RT-qPCR-negative fecal samples each were excluded from analysis.DiscussionThe aim of this study was to investigate a possible correlation between FCoV antibody titer and fecal virus shedding in healthy cats living in German catteries.", [["sample", "ANATOMY", 56, 62], ["fecal samples", "ANATOMY", 124, 137], ["cats", "ORGANISM", 8, 12], ["FCoV", "GENE_OR_GENE_PRODUCT", 253, 257], ["fecal virus", "ORGANISM", 277, 288], ["cats", "ORGANISM", 309, 313], ["FCoV antibody", "PROTEIN", 253, 266], ["cats", "SPECIES", 8, 12], ["cats", "SPECIES", 309, 313], ["qPCR", "TEST", 35, 39], ["quantification", "TEST", 82, 96], ["three RT-qPCR", "TEST", 101, 114], ["this study", "TEST", 192, 202], ["FCoV antibody titer", "TEST", 253, 272], ["fecal virus shedding", "PROBLEM", 277, 297], ["fecal", "ANATOMY", 124, 129], ["fecal virus", "ANATOMY", 277, 288]]], ["The majority of antibody-positive cats in this study (49/64, 77%) shed FCoV in their feces.", [["feces", "ANATOMY", 85, 90], ["FCoV", "CHEMICAL", 71, 75], ["cats", "ORGANISM", 34, 38], ["FCoV", "GENE_OR_GENE_PRODUCT", 71, 75], ["feces", "ORGANISM_SUBSTANCE", 85, 90], ["antibody", "PROTEIN", 16, 24], ["cats", "SPECIES", 34, 38], ["antibody", "TEST", 16, 24], ["this study", "TEST", 42, 52], ["positive cats", "OBSERVATION", 25, 38]]], ["However, the study also showed that this assumption is not absolute, since 9/18 (50%) of cats without antibodies also were FCoV shedders and Pathogens 2020, 9, 598 6 of 13 2/10 (20%) of the cats with a high antibody titer of 1:400 did not shed FCoV.", [["cats", "ORGANISM", 89, 93], ["cats", "ORGANISM", 190, 194], ["1:400 did not shed FCoV", "PROTEIN", 225, 248], ["cats", "SPECIES", 89, 93], ["cats", "SPECIES", 190, 194], ["FCoV", "SPECIES", 123, 127], ["the study", "TEST", 9, 18], ["antibodies", "PROBLEM", 102, 112], ["Pathogens", "TEST", 141, 150], ["the cats", "TEST", 186, 194], ["a high antibody titer", "TEST", 200, 221], ["FCoV", "OBSERVATION", 244, 248]]], ["Previously, only 30% antibody-positive cats were reported to shed FCoV [30] .", [["cats", "ORGANISM", 39, 43], ["cats", "SPECIES", 39, 43], ["30% antibody", "TEST", 17, 29]]], ["A possible reason for this disagreement is the way in which shedding was confirmed in the two studies.", [["this disagreement", "PROBLEM", 22, 39], ["possible reason for", "UNCERTAINTY", 2, 21]]], ["In the present study, FCoV RNA was detected in fecal samples by RT-qPCR.", [["fecal samples", "ANATOMY", 47, 60], ["FCoV", "GENE_OR_GENE_PRODUCT", 22, 26], ["fecal samples", "ORGANISM_SUBSTANCE", 47, 60], ["FCoV RNA", "RNA", 22, 30], ["FCoV", "SPECIES", 22, 26], ["the present study", "TEST", 3, 20], ["FCoV RNA", "TEST", 22, 30], ["fecal samples", "TEST", 47, 60], ["FCoV RNA", "OBSERVATION", 22, 30]]], ["This technique is very sensitive.", [["This technique", "TEST", 0, 14]]], ["In the previously published study, RT-PCR was not yet available, so the classification of a cat as shedder occurred via its infectivity to other cats.", [["cat", "ORGANISM", 92, 95], ["cats", "ORGANISM", 145, 149], ["cats", "SPECIES", 145, 149], ["RT-PCR", "TEST", 35, 41]]], ["More precisely, kittens of antibody-positive queens were monitored for the development of antibodies and it was shown that 38% of the litters developed antibodies, indicating viral shedding occurred in around 30% of the queens [30] .", [["kittens", "ORGANISM", 16, 23], ["antibodies", "PROTEIN", 90, 100], ["antibodies", "PROTEIN", 152, 162], ["kittens of antibody", "TEST", 16, 35], ["antibodies", "PROBLEM", 90, 100], ["antibodies", "PROBLEM", 152, 162], ["viral shedding", "PROBLEM", 175, 189], ["viral", "OBSERVATION_MODIFIER", 175, 180]]], ["Of course, this approach is not directly comparable to the testing of feces by molecular methods such as RT-qPCR, as performed in the present study.DiscussionAccording to previous studies, FCoV antibody titers are significantly higher in cats that shed FCoV with their feces than in cats that do not shed FCoV [3, 30, 31] .", [["feces", "ANATOMY", 70, 75], ["feces", "ANATOMY", 269, 274], ["feces", "ORGANISM_SUBSTANCE", 70, 75], ["FCoV antibody", "GENE_OR_GENE_PRODUCT", 189, 202], ["cats", "ORGANISM", 238, 242], ["FCoV", "GENE_OR_GENE_PRODUCT", 253, 257], ["feces", "ORGANISM_SUBSTANCE", 269, 274], ["cats", "ORGANISM", 283, 287], ["FCoV antibody", "PROTEIN", 189, 202], ["cats", "SPECIES", 238, 242], ["cats", "SPECIES", 283, 287], ["the testing of feces", "TEST", 55, 75], ["RT-qPCR", "TEST", 105, 112], ["the present study", "TEST", 130, 147], ["previous studies", "TEST", 171, 187], ["FCoV antibody titers", "TEST", 189, 209]]], ["Additionally, it was proposed that cats without FCoV antibodies are not shedding FCoV and that, as a consequence, it would be safe to introduce an antibody-negative cat into a FCoV-free household [3, 30, 31] .", [["cats", "ORGANISM", 35, 39], ["FCoV antibodies", "GENE_OR_GENE_PRODUCT", 48, 63], ["cat", "ORGANISM", 165, 168], ["FCoV antibodies", "PROTEIN", 48, 63], ["antibody", "PROTEIN", 147, 155], ["cats", "SPECIES", 35, 39], ["FCoV", "SPECIES", 48, 52], ["FCoV antibodies", "PROBLEM", 48, 63], ["shedding FCoV", "PROBLEM", 72, 85], ["an antibody", "TEST", 144, 155]]], ["However, a smaller number of studies reported discordant results, refuting a correlation between FCoV antibody titer and the likelihood of FCoV shedding [32] [33] [34] .", [["FCoV", "CHEMICAL", 139, 143], ["FCoV antibody", "GENE_OR_GENE_PRODUCT", 97, 110], ["FCoV", "SIMPLE_CHEMICAL", 139, 143], ["FCoV antibody", "PROTEIN", 97, 110], ["FCoV antibody titer", "TEST", 97, 116], ["FCoV shedding", "TEST", 139, 152], ["smaller", "OBSERVATION_MODIFIER", 11, 18]]], ["Pedersen et al. [3] tried to explain this discrepancy by different ways of data evaluation.", [["this discrepancy", "PROBLEM", 37, 53], ["data evaluation", "TEST", 75, 90]]], ["Correlation between antibody titer and fecal virus shedding was significant when shedding and non-shedding cats were looked at as groups.", [["fecal virus", "ORGANISM", 39, 50], ["cats", "ORGANISM", 107, 111], ["Correlation between antibody titer", "TEST", 0, 34], ["fecal virus shedding", "PROBLEM", 39, 59], ["fecal", "ANATOMY", 39, 44], ["virus", "OBSERVATION", 45, 50]]], ["This, at least in part, is also true for the cats in the present study.", [["cats", "ORGANISM", 45, 49], ["the present study", "TEST", 53, 70], ["at least", "OBSERVATION_MODIFIER", 6, 14]]], ["Most cats with a high antibody titer of 1:400 were shedding FCoV (and shed FCoV in all four fecal samples), but two cats with a titer of 1:400 did not shed FCoV in any of the four fecal samples.", [["fecal samples", "ANATOMY", 92, 105], ["fecal samples", "ANATOMY", 180, 193], ["cats", "ORGANISM", 5, 9], ["FCoV", "GENE_OR_GENE_PRODUCT", 60, 64], ["FCoV", "CANCER", 75, 79], ["cats", "ORGANISM", 116, 120], ["FCoV", "GENE_OR_GENE_PRODUCT", 156, 160], ["FCoV", "PROTEIN", 60, 64], ["FCoV", "PROTEIN", 75, 79], ["FCoV", "PROTEIN", 156, 160], ["cats", "SPECIES", 5, 9], ["cats", "SPECIES", 116, 120], ["FCoV", "SPECIES", 60, 64], ["a high antibody titer", "TEST", 15, 36], ["FCoV", "OBSERVATION", 156, 160]]], ["Even more discrepancy could be seen among the cats without antibodies: 9/18 of the cats without antibodies shed FCoV at least once during the study period.", [["cats", "ORGANISM", 46, 50], ["cats", "ORGANISM", 83, 87], ["antibodies", "PROTEIN", 59, 69], ["antibodies", "PROTEIN", 96, 106], ["cats", "SPECIES", 46, 50], ["cats", "SPECIES", 83, 87]]], ["This is a result that, despite the initial belief that antibody-negative cats would never shed FCoV [30] [31] [32] , has been reported in the literature before [18, 34] .", [["FCoV", "CHEMICAL", 95, 99], ["FCoV", "CHEMICAL", 95, 99], ["cats", "ORGANISM", 73, 77], ["antibody", "TEST", 55, 63]]], ["It is possible that the contamination of fecal samples by other FCoV-positive cats had occurred in the same multi-cat household.", [["fecal samples", "ANATOMY", 41, 54], ["FCoV", "CHEMICAL", 64, 68], ["fecal samples", "ORGANISM_SUBSTANCE", 41, 54], ["FCoV", "GENE_OR_GENE_PRODUCT", 64, 68], ["cats", "ORGANISM", 78, 82], ["cat", "ORGANISM", 114, 117], ["cats", "SPECIES", 78, 82], ["the contamination of fecal samples", "PROBLEM", 20, 54], ["other FCoV", "TEST", 58, 68], ["positive cats", "PROBLEM", 69, 82]]], ["In order to avoid contamination, rectal swabs could be used for testing purposes by cat breeders [31] , but this would reduce the amount of available fecal material.", [["rectal swabs", "ANATOMY", 33, 45], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 33, 45], ["cat", "ORGANISM", 84, 87], ["fecal material", "MULTI-TISSUE_STRUCTURE", 150, 164], ["contamination", "PROBLEM", 18, 31], ["rectal swabs", "TREATMENT", 33, 45], ["testing purposes", "TEST", 64, 80], ["rectal", "ANATOMY", 33, 39]]], ["Contamination of samples in the laboratory cannot fully be excluded, but seems rather unlikely given that extensive quality controls were included in the RT-qPCR protocol.", [["samples", "ANATOMY", 17, 24], ["Contamination of samples in the laboratory", "TEST", 0, 42], ["the RT-qPCR protocol", "TREATMENT", 150, 170]]], ["More likely, it is conceivable that serum/plasma samples were obtained early in an infection, at a time before the cats developed antibodies, but at which they already shed FCoV with their feces.", [["serum", "ANATOMY", 36, 41], ["plasma samples", "ANATOMY", 42, 56], ["feces", "ANATOMY", 189, 194], ["infection", "DISEASE", 83, 92], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["plasma samples", "ORGANISM_SUBSTANCE", 42, 56], ["cats", "ORGANISM", 115, 119], ["FCoV", "GENE_OR_GENE_PRODUCT", 173, 177], ["feces", "ORGANISM_SUBSTANCE", 189, 194], ["antibodies", "PROTEIN", 130, 140], ["serum/plasma samples", "TEST", 36, 56], ["an infection", "PROBLEM", 80, 92], ["antibodies", "PROBLEM", 130, 140], ["infection", "OBSERVATION", 83, 92], ["FCoV", "OBSERVATION", 173, 177]]], ["Shedding of FCoV before the time of antibody development has already been reported in kittens [34] .", [["FCoV", "GENE_OR_GENE_PRODUCT", 12, 16], ["FCoV", "PROTEIN", 12, 16], ["antibody development", "PROBLEM", 36, 56], ["FCoV", "OBSERVATION", 12, 16]]], ["Since serial antibody measurements were not performed in the present study, such scenario cannot be confirmed.", [["serial antibody measurements", "TEST", 6, 34], ["the present study", "TEST", 57, 74]]], ["Alternatively, the documentation of fecal FCoV shedding in antibody-negative cats could be explained by localized infection.", [["fecal", "ANATOMY", 36, 41], ["FCoV", "CHEMICAL", 42, 46], ["infection", "DISEASE", 114, 123], ["fecal", "ORGANISM_SUBDIVISION", 36, 41], ["FCoV", "GENE_OR_GENE_PRODUCT", 42, 46], ["cats", "ORGANISM", 77, 81], ["fecal FCoV shedding in antibody", "TEST", 36, 67], ["localized infection", "PROBLEM", 104, 123], ["fecal FCoV", "OBSERVATION", 36, 46], ["could be explained", "UNCERTAINTY", 82, 100], ["localized", "OBSERVATION_MODIFIER", 104, 113], ["infection", "OBSERVATION", 114, 123]]], ["It is known that FCoV replication can stay confined to the gastrointestinal tract in some FCoV-infected cats, resulting in fecal FCoV shedding without the development of antibodies [18] .", [["gastrointestinal tract", "ANATOMY", 59, 81], ["fecal FCoV", "ANATOMY", 123, 133], ["FCoV", "GENE_OR_GENE_PRODUCT", 17, 21], ["gastrointestinal tract", "ORGAN", 59, 81], ["FCoV", "GENE_OR_GENE_PRODUCT", 90, 94], ["cats", "ORGANISM", 104, 108], ["fecal", "ORGANISM_SUBSTANCE", 123, 128], ["FCoV", "GENE_OR_GENE_PRODUCT", 129, 133], ["antibodies", "PROTEIN", 170, 180], ["cats", "SPECIES", 104, 108], ["FCoV replication", "TREATMENT", 17, 33], ["the gastrointestinal tract", "PROBLEM", 55, 81], ["fecal FCoV shedding", "PROBLEM", 123, 142], ["antibodies", "PROBLEM", 170, 180], ["FCoV", "OBSERVATION", 17, 21], ["gastrointestinal tract", "ANATOMY", 59, 81], ["infected cats", "OBSERVATION", 95, 108], ["fecal FCoV", "OBSERVATION", 123, 133]]], ["This might also have occurred in the cats in the present study.DiscussionAntibody testing and the separation of antibody-negative cats in the past has been suggested as method to clear FCoV infection from a breeding cattery [42] or prevent the introduction of FCoV infection into the FCoV-free geographical area of the Falkland Islands [43] .", [["infection", "DISEASE", 190, 199], ["FCoV", "CHEMICAL", 260, 264], ["infection", "DISEASE", 265, 274], ["cats", "ORGANISM", 37, 41], ["cats", "ORGANISM", 130, 134], ["FCoV", "CANCER", 185, 189], ["FCoV", "GENE_OR_GENE_PRODUCT", 260, 264], ["antibody", "PROTEIN", 112, 120], ["cats", "SPECIES", 130, 134], ["FCoV", "SPECIES", 260, 264], ["the present study", "TEST", 45, 62], ["DiscussionAntibody testing", "TEST", 63, 89], ["antibody", "TEST", 112, 120], ["clear FCoV infection", "PROBLEM", 179, 199], ["FCoV infection", "PROBLEM", 260, 274], ["FCoV infection", "OBSERVATION", 260, 274], ["FCoV", "OBSERVATION_MODIFIER", 284, 288], ["free", "OBSERVATION_MODIFIER", 289, 293], ["geographical", "OBSERVATION_MODIFIER", 294, 306]]], ["However, as clearly shown by the results of the present study, although the antibody titer can give an idea on a cat's shedding status, a negative antibody titer in a cat does not exclude fecal shedding.", [["fecal", "ANATOMY", 188, 193], ["cat", "ORGANISM", 113, 116], ["cat", "ORGANISM", 167, 170], ["fecal", "ORGANISM_SUBSTANCE", 188, 193], ["cat", "SPECIES", 113, 116], ["cat", "SPECIES", 167, 170], ["the present study", "TEST", 44, 61], ["the antibody titer", "TEST", 72, 90], ["a cat's shedding status", "TEST", 111, 134], ["a negative antibody titer", "TEST", 136, 161], ["fecal shedding", "PROBLEM", 188, 202]]], ["Thus, the introduction of cats into FCoV-free environments on the basis of a negative antibody test still bears the risk of introducing a FCoV-shedding cat.", [["FCoV", "CHEMICAL", 36, 40], ["FCoV", "CHEMICAL", 138, 142], ["cats", "ORGANISM", 26, 30], ["FCoV", "GENE_OR_GENE_PRODUCT", 138, 142], ["cat", "ORGANISM", 152, 155], ["cats", "SPECIES", 26, 30], ["a negative antibody test", "TEST", 75, 99], ["a FCoV-shedding cat", "TREATMENT", 136, 155]]], ["On the other hand, the separation of all antibody-positive cats might not be necessary, because not all cats with antibodies shed FCoV with their feces.DiscussionThe next question to be answered was whether cats with higher antibody titers also shed higher concentrations of FCoV RNA with their feces.", [["feces", "ANATOMY", 146, 151], ["cats", "ORGANISM", 59, 63], ["cats", "ORGANISM", 104, 108], ["FCoV", "GENE_OR_GENE_PRODUCT", 130, 134], ["feces", "ORGANISM_SUBSTANCE", 146, 151], ["cats", "ORGANISM", 207, 211], ["FCoV", "GENE_OR_GENE_PRODUCT", 275, 279], ["feces", "ORGANISM_SUBSTANCE", 295, 300], ["antibody", "PROTEIN", 41, 49], ["antibodies", "PROTEIN", 114, 124], ["FCoV RNA", "RNA", 275, 283], ["cats", "SPECIES", 59, 63], ["cats", "SPECIES", 104, 108], ["FCoV", "SPECIES", 275, 279], ["all antibody", "TEST", 37, 49], ["antibodies", "TREATMENT", 114, 124], ["higher antibody titers", "PROBLEM", 217, 239], ["FCoV RNA", "OBSERVATION", 275, 283]]], ["In this study, there was a weak positive correlation between the quantity of antibodies and the mean fecal virus load determined by RT-qPCR, indicating that cats with higher antibody titers were more likely to shed FCoV more intensely compared to cats with low antibody titers and cats without antibodies.", [["fecal virus", "ORGANISM", 101, 112], ["cats", "ORGANISM", 157, 161], ["FCoV", "GENE_OR_GENE_PRODUCT", 215, 219], ["cats", "ORGANISM", 247, 251], ["cats", "ORGANISM", 281, 285], ["antibodies", "PROTEIN", 77, 87], ["antibodies", "PROTEIN", 294, 304], ["cats", "SPECIES", 157, 161], ["cats", "SPECIES", 247, 251], ["cats", "SPECIES", 281, 285], ["FCoV", "SPECIES", 215, 219], ["this study", "TEST", 3, 13], ["a weak positive correlation between the quantity of antibodies", "PROBLEM", 25, 87], ["the mean fecal virus load", "TEST", 92, 117], ["RT-qPCR", "TEST", 132, 139], ["cats", "TEST", 157, 161], ["higher antibody titers", "PROBLEM", 167, 189], ["FCoV", "PROBLEM", 215, 219], ["cats", "TEST", 247, 251], ["low antibody titers", "PROBLEM", 257, 276], ["antibodies", "PROBLEM", 294, 304]]], ["It is possible that a higher amount of viral replication, as demonstrated by a higher fecal virus load, also leads to increased antibody production, Pathogens 2020, 9, 598 7 of 13 and thus, higher antibody titers.", [["fecal virus", "ORGANISM", 86, 97], ["viral replication", "PROBLEM", 39, 56], ["a higher fecal virus load", "PROBLEM", 77, 102], ["increased antibody production", "PROBLEM", 118, 147], ["Pathogens", "TEST", 149, 158], ["higher antibody titers", "PROBLEM", 190, 212], ["higher", "OBSERVATION_MODIFIER", 22, 28], ["amount", "OBSERVATION_MODIFIER", 29, 35], ["viral replication", "OBSERVATION", 39, 56], ["fecal virus load", "OBSERVATION", 86, 102], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["antibody production", "OBSERVATION", 128, 147], ["antibody titers", "OBSERVATION", 197, 212]]], ["However, since there is some overlap, this correlation is only weak, demonstrating that antibody measurement alone is not sufficient to differentiate high intensity from low intensity shedders.", [["antibody measurement", "TEST", 88, 108], ["high intensity", "PROBLEM", 150, 164], ["low intensity shedders", "PROBLEM", 170, 192], ["some", "OBSERVATION_MODIFIER", 24, 28], ["overlap", "OBSERVATION", 29, 36], ["low intensity", "OBSERVATION_MODIFIER", 170, 183]]], ["So far, there is only one report, which was not published in a peer-reviewed journal, that also suggested a correlation between FCoV antibody titer and the intensity of fecal virus shedding [36] .", [["FCoV antibody", "GENE_OR_GENE_PRODUCT", 128, 141], ["fecal virus", "ORGANISM", 169, 180], ["FCoV antibody", "PROTEIN", 128, 141], ["FCoV antibody titer", "TEST", 128, 147], ["fecal virus shedding", "PROBLEM", 169, 189], ["fecal virus", "ANATOMY", 169, 180]]], ["Clarification of such information, however, is of practical importance, since especially high intensity shedders are a concern in environments where many cats are housed together in a limited space.", [["cats", "ORGANISM", 154, 158], ["high intensity shedders", "PROBLEM", 89, 112], ["high intensity", "OBSERVATION_MODIFIER", 89, 103]]], ["These cats shedding large amounts of FCoV pose a high risk of transmission to non-infected cats, and in order to reduce infection pressure in multi-cat environments, the contact of non-infected cats to litter trays of high intensity shedders must be avoided [33, 44] .", [["FCoV", "CHEMICAL", 37, 41], ["infection", "DISEASE", 120, 129], ["cats", "ORGANISM", 6, 10], ["FCoV", "GENE_OR_GENE_PRODUCT", 37, 41], ["cats", "ORGANISM", 91, 95], ["cats", "ORGANISM", 194, 198], ["cats", "SPECIES", 6, 10], ["cats", "SPECIES", 91, 95], ["cats", "SPECIES", 194, 198], ["FCoV", "PROBLEM", 37, 41], ["non-infected cats", "TREATMENT", 78, 95], ["infection pressure in multi-cat environments", "PROBLEM", 120, 164], ["non-infected cats", "TREATMENT", 181, 198], ["large", "OBSERVATION_MODIFIER", 20, 25], ["amounts", "OBSERVATION_MODIFIER", 26, 33], ["FCoV", "OBSERVATION", 37, 41], ["infection", "OBSERVATION", 120, 129], ["high intensity", "OBSERVATION_MODIFIER", 218, 232]]], ["However, the routine practice of testing four sequential fecal samples or rectal swabs taken one week to one month apart for FCoV by RT-qPCR, while increasing the likelihood of correctly identifying non-shedders, leads to a prolonged period of time, in which the shedding status of cats in the multi-cat environment is unknown [31, 41] .", [["fecal samples", "ANATOMY", 57, 70], ["rectal swabs", "ANATOMY", 74, 86], ["fecal samples", "ORGANISM_SUBSTANCE", 57, 70], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 74, 86], ["cats", "ORGANISM", 282, 286], ["cats", "SPECIES", 282, 286], ["FCoV", "SPECIES", 125, 129], ["testing four sequential fecal samples", "TEST", 33, 70], ["rectal swabs", "TEST", 74, 86], ["FCoV", "PROBLEM", 125, 129], ["rectal", "ANATOMY", 74, 80]]], ["This is especially problematic in rescue shelters, where new cats with unknown FCoV status are to be introduced.", [["cats", "ORGANISM", 61, 65], ["FCoV", "CANCER", 79, 83], ["FCoV", "OBSERVATION", 79, 83]]], ["Antibody titers (for which only one blood sample is necessary), in contrast, are available much faster and therefore could help to distinguish high intensity from low intensity shedders or cats not shedding FCoV.", [["blood sample", "ANATOMY", 36, 48], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["cats", "ORGANISM", 189, 193], ["Antibody titers", "TEST", 0, 15], ["blood sample", "TEST", 36, 48], ["high intensity from low intensity shedders", "PROBLEM", 143, 185], ["low intensity", "OBSERVATION_MODIFIER", 163, 176]]], ["The results of the present study indicate that the risk of shedding large amounts of FCoV will increase with the level of a cat's antibody titer, and a cat without antibodies most likely will not shed large amounts of FCoV.", [["FCoV", "CHEMICAL", 85, 89], ["FCoV", "GENE_OR_GENE_PRODUCT", 85, 89], ["cat", "ORGANISM", 124, 127], ["cat", "ORGANISM", 152, 155], ["FCoV", "GENE_OR_GENE_PRODUCT", 218, 222], ["FCoV", "PROTEIN", 85, 89], ["antibodies", "PROTEIN", 164, 174], ["FCoV", "PROTEIN", 218, 222], ["cat", "SPECIES", 124, 127], ["the present study", "TEST", 15, 32], ["shedding large amounts of FCoV", "PROBLEM", 59, 89], ["a cat's antibody titer", "TEST", 122, 144], ["a cat without antibodies", "PROBLEM", 150, 174], ["FCoV", "OBSERVATION", 85, 89], ["FCoV", "OBSERVATION", 218, 222]]], ["This understanding might help to at least estimate whether strict quarantine measures are indispensable or not for each individual cat.", [["cat", "ORGANISM", 131, 134], ["strict quarantine measures", "TREATMENT", 59, 85]]], ["The practice of separating high intensity shedders, low intensity shedders and non-shedders in a cat population in order to eliminate FCoV infection is being proposed, but not without controversy [44, 45] .", [["infection", "DISEASE", 139, 148], ["cat", "ORGANISM", 97, 100], ["FCoV", "GENE_OR_GENE_PRODUCT", 134, 138], ["FCoV", "SPECIES", 134, 138], ["separating high intensity shedders", "TREATMENT", 16, 50], ["low intensity shedders", "PROBLEM", 52, 74], ["a cat population", "TREATMENT", 95, 111], ["FCoV infection", "PROBLEM", 134, 148], ["high intensity", "OBSERVATION_MODIFIER", 27, 41], ["low intensity", "OBSERVATION_MODIFIER", 52, 65], ["FCoV", "OBSERVATION_MODIFIER", 134, 138], ["infection", "OBSERVATION", 139, 148]]], ["It has been suggested that antibody measurement might be of importance in breeding catteries, in which kittens might be initially protected from infection by maternally-derived antibodies (MDA), that are transferred by nursing from antibody-positive queens, but can become infected as soon as MDA wane.", [["infection", "DISEASE", 145, 154], ["MDA", "CHEMICAL", 293, 296], ["MDA", "CHEMICAL", 293, 296], ["kittens", "ORGANISM", 103, 110], ["maternally-derived antibodies", "GENE_OR_GENE_PRODUCT", 158, 187], ["MDA", "SIMPLE_CHEMICAL", 189, 192], ["MDA", "SIMPLE_CHEMICAL", 293, 296], ["MDA", "PROTEIN", 189, 192], ["antibody measurement", "TEST", 27, 47], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 145, 154], ["infected", "OBSERVATION", 273, 281]]], ["Isolation of pregnant queens before birth and early weaning of kittens at an age of five to six weeks, before the loss of MDA, has been proposed [30, 33] .", [["MDA", "CHEMICAL", 122, 125], ["MDA", "CHEMICAL", 122, 125], ["kittens", "ORGANISM", 63, 70], ["MDA", "SIMPLE_CHEMICAL", 122, 125], ["the loss of MDA", "PROBLEM", 110, 125]]], ["However, this protocol has been questioned, since the adequate socialization of isolated kittens is a concern and FCoV infection can occur as early as two weeks of age [46] .DiscussionAfter fecal-oral FCoV infection, three possible shedding patterns have been observed.", [["oral", "ANATOMY", 196, 200], ["infection", "DISEASE", 119, 128], ["infection", "DISEASE", 206, 215], ["kittens", "ORGANISM", 89, 96], ["FCoV", "GENE_OR_GENE_PRODUCT", 114, 118], ["fecal", "ORGANISM_SUBSTANCE", 190, 195], ["oral", "ORGANISM_SUBDIVISION", 196, 200], ["this protocol", "TREATMENT", 9, 22], ["isolated kittens", "PROBLEM", 80, 96], ["FCoV infection", "PROBLEM", 114, 128], ["fecal-oral FCoV infection", "PROBLEM", 190, 215], ["shedding patterns", "PROBLEM", 232, 249], ["infection", "OBSERVATION", 119, 128], ["oral", "ANATOMY", 196, 200], ["FCoV infection", "OBSERVATION", 201, 215]]], ["Cats can shed FCoV intermittently [3, 22, 23, 31, 32, 47] .", [["Cats", "ORGANISM", 0, 4]]], ["Most likely, this is only partially caused by intermittent fecal excretion, but also by re-infection with either the same or a different FCoV strain throughout their lives [22] .", [["fecal", "ANATOMY", 59, 64], ["fecal", "ORGANISM_SUBSTANCE", 59, 64], ["intermittent fecal excretion", "PROBLEM", 46, 74], ["re-infection", "PROBLEM", 88, 100], ["a different FCoV strain", "PROBLEM", 125, 148], ["intermittent", "OBSERVATION_MODIFIER", 46, 58], ["fecal excretion", "OBSERVATION", 59, 74], ["FCoV", "OBSERVATION", 137, 141]]], ["Some cats will shed FCoV for weeks or months and eventually cease fecal shedding.", [["fecal", "ANATOMY", 66, 71], ["FCoV", "CHEMICAL", 20, 24], ["cats", "ORGANISM", 5, 9], ["FCoV", "CANCER", 20, 24], ["fecal", "ORGANISM_SUBSTANCE", 66, 71], ["cats", "SPECIES", 5, 9], ["fecal shedding", "PROBLEM", 66, 80]]], ["Up to 13% of cats will shed FCoV persistently for a prolonged period of time and sometimes even lifelong [3, 22, 31, 32, 47] .", [["cats", "ORGANISM", 13, 17], ["cats", "SPECIES", 13, 17], ["FCoV", "OBSERVATION", 28, 32]]], ["The exact percentage of cats following each pattern is unknown and likely varies depending on the epidemiological situation and virulence of the infecting FCoV strain.", [["cats", "ORGANISM", 24, 28], ["FCoV strain", "ORGANISM", 155, 166], ["cats", "SPECIES", 24, 28], ["FCoV", "SPECIES", 155, 159], ["the infecting FCoV strain", "PROBLEM", 141, 166], ["infecting FCoV strain", "OBSERVATION", 145, 166]]], ["In order to correctly characterize a FCoV-shedding cat for eradication purposes, sequential fecal samples must be obtained and four fecal samples, collected 5-30 days apart, were obtained from each cat in this study.", [["fecal samples", "ANATOMY", 92, 105], ["fecal samples", "ANATOMY", 132, 145], ["FCoV", "CHEMICAL", 37, 41], ["FCoV", "SIMPLE_CHEMICAL", 37, 41], ["cat", "ORGANISM", 51, 54], ["fecal samples", "ORGANISM_SUBSTANCE", 92, 105], ["fecal samples", "ORGANISM_SUBSTANCE", 132, 145], ["cat", "ORGANISM", 198, 201], ["cat", "SPECIES", 51, 54], ["a FCoV-shedding cat", "TREATMENT", 35, 54], ["eradication purposes", "TREATMENT", 59, 79], ["sequential fecal samples", "TEST", 81, 105], ["four fecal samples", "TEST", 127, 145], ["this study", "TEST", 205, 215], ["FCoV", "OBSERVATION", 37, 41]]], ["Results indicate that cats had significantly higher antibody titers if they shed FCoV more frequently.", [["cats", "ORGANISM", 22, 26], ["FCoV", "GENE_OR_GENE_PRODUCT", 81, 85], ["cats", "SPECIES", 22, 26], ["significantly higher antibody titers", "PROBLEM", 31, 67]]], ["When considering the results of the individual cats, it becomes apparent that most cats (71%) that did not shed FCoV in any fecal sample either did not have antibodies (9/24) or only had a low antibody titer of 1:25 (8/24), whereas most cats with a high antibody titer of 1:400 (8/10; 80%) shed FCoV in all four samples.", [["fecal sample", "ANATOMY", 124, 136], ["samples", "ANATOMY", 312, 319], ["FCoV", "CHEMICAL", 112, 116], ["cats", "ORGANISM", 47, 51], ["cats", "ORGANISM", 83, 87], ["FCoV", "GENE_OR_GENE_PRODUCT", 112, 116], ["fecal", "ORGANISM_SUBSTANCE", 124, 129], ["cats", "ORGANISM", 237, 241], ["FCoV", "CANCER", 295, 299], ["antibodies", "PROTEIN", 157, 167], ["FCoV", "PROTEIN", 295, 299], ["cats", "SPECIES", 83, 87], ["cats", "SPECIES", 237, 241], ["any fecal sample", "TEST", 120, 136], ["antibodies", "TEST", 157, 167], ["a low antibody titer", "PROBLEM", 187, 207], ["a high antibody titer", "TEST", 247, 268], ["FCoV", "OBSERVATION", 112, 116]]], ["Nevertheless, although there was a tendency for cats shedding FCoV more frequently (possibly due to continuous re-infection) to have higher antibody titers, again there was some overlap, and the correlation was only significant for cats shedding in all four fecal samples compared to non-shedders.DiscussionIt was also determined whether cats shedding FCoV in all four samples had higher antibody titers than cats shedding FCoV in only one, two, or three fecal samples.", [["fecal samples", "ANATOMY", 258, 271], ["samples", "ANATOMY", 369, 376], ["fecal samples", "ANATOMY", 455, 468], ["FCoV", "CHEMICAL", 423, 427], ["cats", "ORGANISM", 48, 52], ["cats", "ORGANISM", 232, 236], ["cats", "ORGANISM", 338, 342], ["FCoV", "GENE_OR_GENE_PRODUCT", 352, 356], ["cats", "ORGANISM", 409, 413], ["cats", "SPECIES", 232, 236], ["cats", "SPECIES", 338, 342], ["cats", "SPECIES", 409, 413], ["FCoV", "SPECIES", 62, 66], ["FCoV", "SPECIES", 423, 427], ["cats shedding FCoV", "PROBLEM", 48, 66], ["continuous re-infection", "PROBLEM", 100, 123], ["higher antibody titers", "PROBLEM", 133, 155], ["cats shedding", "PROBLEM", 232, 245], ["cats shedding FCoV", "PROBLEM", 338, 356], ["all four samples", "TEST", 360, 376], ["higher antibody titers", "PROBLEM", 381, 403], ["re-infection", "OBSERVATION", 111, 123]]], ["The latter cats probably eliminated the infection at some point, shed intermittently or became re-infected.", [["infection", "DISEASE", 40, 49], ["cats", "ORGANISM", 11, 15], ["the infection", "PROBLEM", 36, 49], ["infection", "OBSERVATION", 40, 49]]], ["In this context, it is of special interest to evaluate whether measurement of the antibody titer can indicate if a cat likely is continuously shedding FCoV, and thus, poses a permanent risk of infection to other cats.", [["infection", "DISEASE", 193, 202], ["cat", "ORGANISM", 115, 118], ["FCoV", "GENE_OR_GENE_PRODUCT", 151, 155], ["cats", "ORGANISM", 212, 216], ["cats", "SPECIES", 212, 216], ["the antibody titer", "TEST", 78, 96], ["continuously shedding FCoV", "PROBLEM", 129, 155], ["infection", "PROBLEM", 193, 202], ["infection", "OBSERVATION", 193, 202]]], ["It could be shown that, in this population, cats that were RT-qPCR-positive in all four samples had significantly Pathogens 2020, 9, 598 8 of 13 higher antibody titers than cats, that were RT-qPCR-positive only intermittently in one, two, or three fecal samples.", [["samples", "ANATOMY", 88, 95], ["fecal samples", "ANATOMY", 248, 261], ["cats", "ORGANISM", 44, 48], ["cats", "ORGANISM", 173, 177], ["cats", "SPECIES", 44, 48], ["cats", "SPECIES", 173, 177], ["cats", "TEST", 44, 48], ["RT-qPCR", "TEST", 59, 66], ["Pathogens", "TEST", 114, 123], ["higher antibody titers", "TEST", 145, 167], ["cats", "TEST", 173, 177], ["RT", "TEST", 189, 191], ["qPCR", "TEST", 192, 196]]], ["Additionally, cats shedding FCoV in all four samples also had significantly higher mean fecal virus loads than cats shedding only intermittently.", [["samples", "ANATOMY", 45, 52], ["cats", "ORGANISM", 14, 18], ["FCoV", "GENE_OR_GENE_PRODUCT", 28, 32], ["fecal virus", "ORGANISM", 88, 99], ["cats", "ORGANISM", 111, 115], ["cats", "SPECIES", 14, 18], ["cats", "SPECIES", 111, 115], ["cats shedding FCoV", "PROBLEM", 14, 32], ["all four samples", "TEST", 36, 52], ["significantly higher mean fecal virus loads", "PROBLEM", 62, 105], ["fecal virus loads", "OBSERVATION", 88, 105]]], ["This confirms the results of one study performed as part of a doctoral thesis, which followed 77 FCoV-infected cats over a period of 24 weeks, and could demonstrate that the amount of FCoV RNA shed was significantly higher with higher shedding frequency (defined as % of RT-qPCR-positive fecal samples) [36] .DiscussionTwenty-four cats were RT-qPCR-negative in all four fecal samples, indicating that they persistently did not shed FCoV.", [["fecal samples", "ANATOMY", 288, 301], ["fecal samples", "ANATOMY", 370, 383], ["cats", "ORGANISM", 111, 115], ["FCoV", "GENE_OR_GENE_PRODUCT", 184, 188], ["cats", "ORGANISM", 331, 335], ["FCoV", "GENE_OR_GENE_PRODUCT", 432, 436], ["FCoV RNA", "RNA", 184, 192], ["FCoV", "PROTEIN", 432, 436], ["cats", "SPECIES", 111, 115], ["one study", "TEST", 29, 38], ["FCoV RNA", "TEST", 184, 192], ["higher shedding frequency", "PROBLEM", 228, 253], ["RT", "TEST", 271, 273], ["qPCR", "TEST", 274, 278], ["RT-qPCR", "TEST", 341, 348], ["amount", "OBSERVATION_MODIFIER", 174, 180], ["FCoV RNA", "OBSERVATION", 184, 192], ["higher", "OBSERVATION_MODIFIER", 216, 222], ["FCoV", "OBSERVATION", 432, 436]]], ["These cats either did not have contact to FCoV, which seems rather unlikely given the fact that all of the included catteries harbored at least one FCoV-shedding cat and the virus is highly contagious [7, 23, 33] .", [["cats", "ORGANISM", 6, 10], ["FCoV", "GENE_OR_GENE_PRODUCT", 148, 152], ["cat", "ORGANISM", 162, 165], ["cats", "SPECIES", 6, 10], ["FCoV", "PROBLEM", 42, 46], ["the virus", "PROBLEM", 170, 179], ["FCoV", "OBSERVATION", 42, 46], ["highly", "OBSERVATION_MODIFIER", 183, 189], ["contagious", "OBSERVATION_MODIFIER", 190, 200]]], ["Alternatively, these cats could have been resistant to FCoV.", [["FCoV", "CHEMICAL", 55, 59], ["FCoV", "CHEMICAL", 55, 59], ["cats", "ORGANISM", 21, 25], ["FCoV", "SIMPLE_CHEMICAL", 55, 59], ["FCoV", "PROTEIN", 55, 59], ["cats", "SPECIES", 21, 25], ["FCoV", "OBSERVATION", 55, 59]]], ["Resistant cats never shed FCoV and do not develop FCoV antibodies or only very low titers [31] .", [["cats", "ORGANISM", 10, 14], ["FCoV", "CANCER", 26, 30], ["FCoV antibodies", "GENE_OR_GENE_PRODUCT", 50, 65], ["FCoV antibodies", "PROTEIN", 50, 65], ["cats", "SPECIES", 10, 14], ["FCoV", "SPECIES", 50, 54], ["Resistant cats", "PROBLEM", 0, 14], ["FCoV antibodies", "TEST", 50, 65], ["very low titers", "PROBLEM", 74, 89]]], ["Interestingly, however, 15 of the 24 non-shedders in this study did have antibodies.", [["antibodies", "PROTEIN", 73, 83], ["this study", "TEST", 53, 63], ["antibodies", "PROBLEM", 73, 83]]], ["Mostly, these cats had low antibody titers.", [["cats", "ORGANISM", 14, 18], ["cats", "SPECIES", 14, 18], ["these cats", "TEST", 8, 18], ["low antibody titers", "PROBLEM", 23, 42]]], ["A possible explanation for this could be that the cats had been infected previously, but ceased shedding before the beginning of the study and antibodies persisted for a longer period of time.", [["cats", "ORGANISM", 50, 54], ["antibodies", "PROTEIN", 143, 153], ["cats", "SPECIES", 50, 54], ["the study", "TEST", 129, 138], ["antibodies", "TREATMENT", 143, 153], ["possible explanation for", "UNCERTAINTY", 2, 26], ["infected", "OBSERVATION", 64, 72]]], ["The longest period documented in the literature for which a cat remained antibody-positive after it stopped FCoV shedding was 25 months and decreasing antibody titers were demonstrated in studies following cats ceasing to shed FCoV over time [31] .", [["cat", "ORGANISM", 60, 63], ["FCoV", "SIMPLE_CHEMICAL", 108, 112], ["cats", "ORGANISM", 206, 210], ["a cat remained antibody", "TEST", 58, 81], ["FCoV shedding", "PROBLEM", 108, 121], ["decreasing antibody titers", "PROBLEM", 140, 166], ["cats", "TREATMENT", 206, 210]]], ["It is possible that antibody titers were in the process of declining in the cats in the present study as well.DiscussionThis study had some limitations.", [["cats", "ORGANISM", 76, 80], ["antibody titers", "PROBLEM", 20, 35], ["the present study", "TEST", 84, 101], ["This study", "TEST", 120, 130], ["possible", "UNCERTAINTY", 6, 14], ["antibody titers", "OBSERVATION", 20, 35], ["declining", "OBSERVATION_MODIFIER", 59, 68]]], ["First, blood samples were obtained from each cat at only one time point.", [["blood samples", "ANATOMY", 7, 20], ["blood samples", "ORGANISM_SUBSTANCE", 7, 20], ["cat", "ORGANISM", 45, 48], ["blood samples", "TEST", 7, 20]]], ["Therefore, it was impossible to follow the cats and the development of their antibody titers over time.", [["cats", "ORGANISM", 43, 47], ["cats", "SPECIES", 43, 47], ["their antibody titers", "PROBLEM", 71, 92]]], ["This would have been especially interesting in cats that ceased to shed virus or in persistent viral shedders.", [["cats", "ORGANISM", 47, 51], ["cats", "SPECIES", 47, 51], ["shed virus", "PROBLEM", 67, 77], ["persistent viral shedders", "PROBLEM", 84, 109], ["persistent", "OBSERVATION_MODIFIER", 84, 94], ["viral shedders", "OBSERVATION", 95, 109]]], ["A second limitation is the fact that most cats were housed very closely, and each cattery housed at least one cat that shed FCoV.", [["cats", "ORGANISM", 42, 46], ["cat", "ORGANISM", 110, 113], ["FCoV", "CANCER", 124, 128], ["cats", "SPECIES", 42, 46], ["FCoV", "OBSERVATION", 124, 128]]], ["Thus, cross-contamination between the individual cats cannot fully be excluded, even though cat breeders acted with great caution to separate fecal samples.", [["fecal samples", "ANATOMY", 142, 155], ["cats", "ORGANISM", 49, 53], ["cat", "ORGANISM", 92, 95], ["fecal samples", "ORGANISM_SUBSTANCE", 142, 155], ["cats", "SPECIES", 49, 53], ["cat", "SPECIES", 92, 95], ["cross-contamination between the individual cats", "PROBLEM", 6, 53], ["cat breeders", "TREATMENT", 92, 104]]], ["Thirdly, in the past, the term chronic FCoV carrier has been used for cats shedding FCoV for at least nine months [31] .", [["FCoV", "CHEMICAL", 39, 43], ["FCoV", "CANCER", 39, 43], ["cats", "ORGANISM", 70, 74], ["FCoV", "CANCER", 84, 88], ["the term chronic FCoV carrier", "TREATMENT", 22, 51], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["FCoV", "OBSERVATION", 39, 43]]], ["Therefore, it is not known whether cats shedding FCoV in all four fecal samples were true FCoV carriers or might have ceased shedding after the end of the study period.Materials and MethodsThe study was performed prospectively and included 82 cats originating from 19 German catteries.", [["fecal samples", "ANATOMY", 66, 79], ["FCoV", "CHEMICAL", 49, 53], ["cats", "ORGANISM", 35, 39], ["FCoV", "GENE_OR_GENE_PRODUCT", 49, 53], ["fecal samples", "ORGANISM_SUBSTANCE", 66, 79], ["FCoV", "GENE_OR_GENE_PRODUCT", 90, 94], ["cats", "ORGANISM", 243, 247], ["cats", "SPECIES", 35, 39], ["cats", "SPECIES", 243, 247], ["cats shedding FCoV", "PROBLEM", 35, 53], ["Methods", "TREATMENT", 182, 189], ["The study", "TEST", 189, 198], ["not known", "UNCERTAINTY", 17, 26]]], ["Catteries were distributed all over Germany.", [["distributed", "OBSERVATION_MODIFIER", 15, 26], ["all", "OBSERVATION_MODIFIER", 27, 30]]], ["A cattery was defined as a cat household with at least five cats and at least one intact queen for breeding.", [["cat", "ORGANISM", 27, 30], ["cats", "ORGANISM", 60, 64], ["cats", "SPECIES", 60, 64], ["A cattery", "TREATMENT", 0, 9], ["intact", "OBSERVATION", 82, 88]]], ["Breeders collected samples from a variable non-predefined number of cats in their cattery.", [["samples", "ANATOMY", 19, 26], ["cats", "ORGANISM", 68, 72], ["cats", "SPECIES", 68, 72], ["variable", "OBSERVATION_MODIFIER", 34, 42]]], ["Breeds included British Shorthair (n = 24), Bengal (n = 19), Birman (n = 15), Maine Coon (n = 7), Scottish Fold (n = 7), Norwegian Forest (n = 5), Turkish Van (n = 3), and Turkish Angora (n = 2).", [["Bengal (n", "TEST", 44, 53], ["Birman", "TEST", 61, 67], ["Maine Coon", "TEST", 78, 88], ["Scottish Fold", "TEST", 98, 111]]], ["The study protocol was approved by the responsible veterinary authority (Regierung von Oberbayern; reference number 55.2-1-54-2532.", [["The study protocol", "TEST", 0, 18]]], ["2-14-13) .Materials and MethodsCat breeders collected four fecal samples from the cats, at varying time intervals from 5-30 days between collections.", [["fecal samples", "ANATOMY", 59, 72], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 59, 72], ["cats", "ORGANISM", 82, 86], ["cats", "SPECIES", 82, 86], ["Materials", "TREATMENT", 10, 19], ["MethodsCat breeders", "TREATMENT", 24, 43]]], ["Samples were frozen at \u221220\u00b0C until examination.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["examination", "TEST", 35, 46]]], ["All fecal samples were examined for FCoV load per g of feces by RT-qPCR.", [["fecal samples", "ANATOMY", 4, 17], ["feces", "ANATOMY", 55, 60], ["fecal samples", "ORGANISM_SUBSTANCE", 4, 17], ["FCoV", "SIMPLE_CHEMICAL", 36, 40], ["feces", "ORGANISM_SUBSTANCE", 55, 60], ["FCoV", "PROTEIN", 36, 40], ["All fecal samples", "TEST", 0, 17], ["FCoV load", "TEST", 36, 45], ["fecal", "ANATOMY", 4, 9]]], ["A mean fecal virus load was calculated for each cat from all RT-qPCR-positive samples.", [["samples", "ANATOMY", 78, 85], ["fecal virus", "ORGANISM", 7, 18], ["cat", "ORGANISM", 48, 51], ["cat", "SPECIES", 48, 51], ["A mean fecal virus load", "TEST", 0, 23], ["each cat", "TEST", 43, 51], ["all RT", "TEST", 57, 63], ["qPCR", "TEST", 64, 68], ["virus load", "OBSERVATION", 13, 23]]], ["For RT-qPCR, total nucleic acid was extracted from fecal samples by QIAamp DNA Blood BioRobot MDx Kit on an automated Qiagen platform (QIAGEN GmbH, Hilden, Germany) according to the manufacturer instructions, with slight modifications.", [["fecal samples", "ANATOMY", 51, 64], ["nucleic acid", "CHEMICAL", 19, 31], ["fecal samples", "ORGANISM_SUBSTANCE", 51, 64], ["RT-qPCR", "TEST", 4, 11], ["total nucleic acid", "TREATMENT", 13, 31], ["fecal samples", "TEST", 51, 64], ["slight modifications", "TREATMENT", 214, 234], ["slight modifications", "OBSERVATION", 214, 234]]], ["The RT-qPCR and total nucleic acid extraction procedures were adapted from previously published protocols [24, 48] .", [["nucleic acid", "CHEMICAL", 22, 34], ["The RT-qPCR", "TEST", 0, 11], ["total nucleic acid extraction procedures", "TREATMENT", 16, 56]]], ["A quantitative real-time PCR based on the 7b gene [48] was performed as a singleplex reaction at a commercial reference laboratory (IDEXX Laboratories, Ludwigsburg, Germany).", [["A quantitative real-time PCR", "TEST", 0, 28], ["a singleplex reaction", "PROBLEM", 72, 93]]], ["Real-time PCR was run with six quality controls, including: (1) PCR-positive controls (quantitatively;), using synthetic DNA covering the real-time PCR target region (Integrated DNA Technologies IDT, Coralville, IA, USA), (2) PCR-negative controls (PCR-grade nuclease free water), (3) negative extraction controls (extraction positions filled with lysis solution and PCR-grade nuclease free water only), (4) RNA pre-analytical internal sample control targeting feline ssr rRNA (18S rRNA) gene complex, (5) a swab-based environmental contamination monitoring control, and (6) spike-in internal positive control (using lambda phage DNA).", [["DNA", "CELLULAR_COMPONENT", 121, 124], ["DNA", "CELLULAR_COMPONENT", 178, 181], ["feline", "ORGANISM", 461, 467], ["ssr rRNA", "GENE_OR_GENE_PRODUCT", 468, 476], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 478, 486], ["DNA", "CELLULAR_COMPONENT", 630, 633], ["synthetic DNA", "DNA", 111, 124], ["PCR target region", "DNA", 148, 165], ["feline ssr rRNA", "DNA", 461, 476], ["18S rRNA) gene complex", "DNA", 478, 500], ["lambda phage DNA", "DNA", 617, 633], ["Real-time PCR", "TEST", 0, 13], ["PCR", "TEST", 64, 67], ["synthetic DNA", "TREATMENT", 111, 124], ["IDT", "TEST", 195, 198], ["PCR", "TEST", 226, 229], ["PCR", "TEST", 249, 252], ["extraction controls (extraction positions", "TREATMENT", 294, 335], ["lysis solution", "TREATMENT", 348, 362], ["PCR", "TEST", 367, 370], ["RNA pre-analytical internal sample control", "TREATMENT", 408, 450], ["targeting feline ssr rRNA (18S rRNA) gene complex", "PROBLEM", 451, 500], ["a swab", "TEST", 506, 512], ["environmental contamination monitoring control", "TREATMENT", 519, 565], ["spike", "PROBLEM", 575, 580], ["internal positive control", "TREATMENT", 584, 609], ["lambda phage DNA", "TREATMENT", 617, 633]]], ["These controls assessed the functionality of the PCR test protocols (1) for the absence of contamination in the reagents (2) and laboratory (5), the absence of cross-contamination during the extraction process (3), quality and integrity of the RNA as a measure of sample quality (4), reverse transcription protocol (5 and 6), and the absence of PCR-inhibitory substances as a carryover from the sample matrix (6) .Materials and MethodsThe interpretation of RT-qPCR results is demonstrated in Table 4 .", [["sample", "ANATOMY", 264, 270], ["the PCR test protocols", "TEST", 45, 67], ["contamination", "PROBLEM", 91, 104], ["cross-contamination", "PROBLEM", 160, 179], ["the extraction process", "TREATMENT", 187, 209], ["reverse transcription protocol", "TREATMENT", 284, 314], ["PCR", "TEST", 345, 348], ["RT-qPCR results", "TEST", 457, 472]]], ["If RT-qPCR was initially weak positive (threshold cycle (Ct) > 40), RT-qPCR was repeated in duplicate.", [["RT-qPCR", "TEST", 3, 10], ["weak positive", "PROBLEM", 25, 38], ["threshold cycle", "TEST", 40, 55], ["Ct)", "TEST", 57, 60], ["RT-qPCR", "TEST", 68, 75]]], ["Depending on the results of this duplicate repetitive analysis, results were then categorized (Table 4 ).", [["this duplicate repetitive analysis", "TEST", 28, 62]]], ["Questionable RT-qPCR results occurred in four cats.", [["cats", "ORGANISM", 46, 50], ["cats", "SPECIES", 46, 50], ["RT-qPCR", "TEST", 13, 20]]], ["The first cat had one fecal sample that was weak positive by RT-qPCR (low concentrations of FCoV RNA were detected but viral load was below the limit of quantification); the other three fecal samples of this cat were RT-qPCR-negative.", [["fecal sample", "ANATOMY", 22, 34], ["fecal samples", "ANATOMY", 186, 199], ["cat", "ORGANISM", 10, 13], ["fecal", "ORGANISM_SUBSTANCE", 22, 27], ["cat", "ORGANISM", 208, 211], ["FCoV RNA", "RNA", 92, 100], ["one fecal sample", "TEST", 18, 34], ["weak positive", "PROBLEM", 44, 57], ["RT", "TEST", 61, 63], ["qPCR", "TEST", 64, 68], ["low concentrations of FCoV RNA", "PROBLEM", 70, 100], ["viral load", "TEST", 119, 129], ["this cat", "TEST", 203, 211], ["RT-qPCR", "TEST", 217, 224], ["negative", "OBSERVATION", 225, 233]]], ["The second cat had two RT-qPCR-negative, one RT-qPCR-positive and one weak positive fecal sample.", [["fecal sample", "ANATOMY", 84, 96], ["cat", "ORGANISM", 11, 14], ["The second cat", "TEST", 0, 14], ["two RT-qPCR", "TEST", 19, 30], ["one RT-qPCR", "TEST", 41, 52], ["one weak positive fecal sample", "PROBLEM", 66, 96], ["positive", "OBSERVATION", 53, 61], ["fecal sample", "OBSERVATION", 84, 96]]], ["The third cat had three RT-qPCR-positive and one fecal sample below the limit of quantification.", [["fecal sample", "ANATOMY", 49, 61], ["cat", "ORGANISM", 10, 13], ["three RT-qPCR", "TEST", 18, 31], ["one fecal sample", "TEST", 45, 61]]], ["The fourth cat had three RT-qPCR-negative and one fecal sample below the limit of quantification.", [["fecal sample", "ANATOMY", 50, 62], ["cat", "ORGANISM", 11, 14], ["three RT-qPCR", "TEST", 19, 32], ["one fecal sample", "TEST", 46, 62]]], ["Weak positive samples were considered positive for further analysis.", [["samples", "ANATOMY", 14, 21], ["Weak positive samples", "PROBLEM", 0, 21], ["further analysis", "TEST", 51, 67]]], ["Samples below the limit of quantification were considered negative for further analysis.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["further analysis", "TEST", 71, 87]]], ["The two cats with only one weak RT-qPCR-positive or one below the limit of quantification and three RT-qPCR-negative fecal samples each were excluded from all analyses involving fecal virus load, since mean fecal virus load could not be determined.", [["fecal samples", "ANATOMY", 117, 130], ["cats", "ORGANISM", 8, 12], ["fecal virus", "ORGANISM", 178, 189], ["fecal virus", "ORGANISM", 207, 218], ["cats", "SPECIES", 8, 12], ["qPCR", "TEST", 35, 39], ["quantification", "TEST", 75, 89], ["three RT-qPCR", "TEST", 94, 107], ["all analyses", "TEST", 155, 167], ["fecal virus load", "PROBLEM", 178, 194], ["mean fecal virus load", "TEST", 202, 223], ["fecal virus", "OBSERVATION", 178, 189]]], ["Additionally, one serum and/or plasma sample was obtained from each of the 82 cats, around the time of collection of the last fecal sample of each cat.", [["serum", "ANATOMY", 18, 23], ["plasma sample", "ANATOMY", 31, 44], ["fecal sample", "ANATOMY", 126, 138], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["plasma sample", "ORGANISM_SUBSTANCE", 31, 44], ["cats", "ORGANISM", 78, 82], ["cat", "ORGANISM", 147, 150], ["cats", "SPECIES", 78, 82], ["cat", "SPECIES", 147, 150], ["one serum", "TEST", 14, 23], ["plasma sample", "TEST", 31, 44]]], ["Only a serum sample was available from 68 cats, only a plasma sample was available from 10 cats, and both a serum and a plasma sample were available from four cats.", [["serum sample", "ANATOMY", 7, 19], ["plasma sample", "ANATOMY", 55, 68], ["serum", "ANATOMY", 108, 113], ["plasma sample", "ANATOMY", 120, 133], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["cats", "ORGANISM", 42, 46], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["cats", "ORGANISM", 91, 95], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["plasma", "ORGANISM_SUBSTANCE", 120, 126], ["cats", "ORGANISM", 159, 163], ["cats", "SPECIES", 42, 46], ["a serum sample", "TEST", 5, 19], ["a plasma sample", "TEST", 53, 68], ["a serum", "TEST", 106, 113], ["a plasma sample", "TEST", 118, 133]]], ["Serum and/or plasma antibody titers were determined by an indirect immunofluorescence assay as previously described [49, 50] , using PD-5 cells (swine origin) infected with transmissible gastroenteritis virus (Perdue strain).", [["Serum", "ANATOMY", 0, 5], ["plasma", "ANATOMY", 13, 19], ["PD-5 cells", "ANATOMY", 133, 143], ["transmissible gastroenteritis", "DISEASE", 173, 202], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["PD-5 cells", "CELL", 133, 143], ["swine", "ORGANISM", 145, 150], ["transmissible gastroenteritis virus", "ORGANISM", 173, 208], ["swine", "SPECIES", 145, 150], ["transmissible gastroenteritis virus", "SPECIES", 173, 208], ["transmissible gastroenteritis virus", "SPECIES", 173, 208], ["Serum", "TEST", 0, 5], ["plasma antibody titers", "TEST", 13, 35], ["an indirect immunofluorescence assay", "TEST", 55, 91], ["PD-5 cells", "TREATMENT", 133, 143], ["transmissible gastroenteritis virus", "PROBLEM", 173, 208], ["transmissible", "OBSERVATION_MODIFIER", 173, 186], ["gastroenteritis", "OBSERVATION", 187, 202]]], ["Infected cells were mixed with uninfected cells; the latter served as internal negative control.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 42, 47], ["cells", "CELL", 9, 14], ["cells", "CELL", 42, 47], ["uninfected cells", "CELL_TYPE", 31, 47], ["Infected cells", "PROBLEM", 0, 14], ["uninfected cells", "PROBLEM", 31, 47], ["mixed", "OBSERVATION_MODIFIER", 20, 25], ["uninfected cells", "OBSERVATION", 31, 47]]], ["Cat samples were tested at dilutions of 1:25, 1:100, 1:400 and 1:1600.", [["samples", "ANATOMY", 4, 11], ["Cat", "ORGANISM", 0, 3], ["Cat samples", "TEST", 0, 11]]], ["The fluorescein isothiocyanate (FITC) conjugated secondary antibody (rabbit anti cat IgG (H + L), Nordic-MUbio, Sustern, Netherlands; LuBio Sience GmBH, Luzern, Switzerland) was diluted at 1:40.", [["fluorescein isothiocyanate", "CHEMICAL", 4, 30], ["fluorescein isothiocyanate", "CHEMICAL", 4, 30], ["FITC", "CHEMICAL", 32, 36], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 4, 30], ["FITC", "SIMPLE_CHEMICAL", 32, 36], ["rabbit", "ORGANISM", 69, 75], ["fluorescein isothiocyanate (FITC) conjugated secondary antibody", "PROTEIN", 4, 67], ["rabbit anti cat IgG", "PROTEIN", 69, 88], ["rabbit", "SPECIES", 69, 75], ["rabbit", "SPECIES", 69, 75], ["The fluorescein isothiocyanate (FITC) conjugated", "TEST", 0, 48], ["antibody", "TEST", 59, 67], ["rabbit anti cat IgG", "TEST", 69, 88]]], ["The serum samples and the conjugate were each incubated at 37 \u2022 C for 1 h in a humid chamber, followed by three phosphate buffered saline (PBS) wash steps, and drying of the slide surface with absorbing paper, preventing the wells from drying out.", [["serum samples", "ANATOMY", 4, 17], ["surface", "ANATOMY", 180, 187], ["phosphate", "CHEMICAL", 112, 121], ["phosphate", "CHEMICAL", 112, 121], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 112, 137], ["The serum samples", "TEST", 0, 17], ["a humid chamber", "TREATMENT", 77, 92], ["three phosphate buffered saline (PBS", "TREATMENT", 106, 142], ["the slide surface", "TREATMENT", 170, 187]]], ["A positive control (aliquoted serum sample of a FCoV-antibody-positive field cat) and a negative control (aliquoted serum from a specified pathogen free FCoV-antibody-negative cat) were run with each slide.", [["serum sample", "ANATOMY", 30, 42], ["serum", "ANATOMY", 116, 121], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["FCoV", "GENE_OR_GENE_PRODUCT", 48, 52], ["cat", "ORGANISM", 77, 80], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["FCoV", "GENE_OR_GENE_PRODUCT", 153, 157], ["cat", "ORGANISM", 176, 179], ["FCoV", "PROTEIN", 48, 52], ["antibody", "PROTEIN", 53, 61], ["FCoV", "PROTEIN", 153, 157], ["antibody", "PROTEIN", 158, 166], ["A positive control (aliquoted serum sample", "PROBLEM", 0, 42], ["a FCoV-antibody", "TEST", 46, 61], ["aliquoted serum", "TEST", 106, 121], ["a specified pathogen free FCoV", "TEST", 127, 157], ["antibody", "TEST", 158, 166]]], ["The slides were covered with a cover slide, fixed with a few drops of drops of PBS-Glycerol (1:3) and read using a fluorescence microscope (Leica DMLB, Leica Microsystems, Heerbrugg, Switzerland).", [["PBS-Glycerol", "CHEMICAL", 79, 91], ["Glycerol", "CHEMICAL", 83, 91], ["PBS-Glycerol", "SIMPLE_CHEMICAL", 79, 91], ["a cover slide", "TREATMENT", 29, 42], ["a few drops of drops of PBS-Glycerol", "TREATMENT", 55, 91], ["a fluorescence microscope", "TEST", 113, 138]]], ["The antigen preparations used to prepare the slides were tested for the absence of contaminating viruses by RT-PCR and PCR, as previously described [51] .Materials and MethodsThe correlation between level of antibody titer and mean fecal virus load was determined by Spearman's correlation.", [["fecal virus", "ORGANISM", 232, 243], ["The antigen preparations", "TREATMENT", 0, 24], ["the slides", "TEST", 41, 51], ["contaminating viruses", "PROBLEM", 83, 104], ["RT-PCR", "TEST", 108, 114], ["PCR", "TEST", 119, 122], ["level of antibody titer", "TEST", 199, 222], ["mean fecal virus load", "TEST", 227, 248], ["Spearman's correlation", "TEST", 267, 289]]], ["Kruskal-Wallis test including Dunn's post-test was performed in order to determine a possible correlation between antibody titer and the frequency of virus shedding in an individual cat.", [["cat", "ORGANISM", 182, 185], ["cat", "SPECIES", 182, 185], ["Kruskal-Wallis test", "TEST", 0, 19], ["Dunn's post-test", "TEST", 30, 46], ["antibody titer", "TEST", 114, 128], ["virus shedding", "PROBLEM", 150, 164]]], ["Kruskal-Wallis test was also performed to evaluate a possible correlation between frequency and amount of fecal virus shedding.", [["fecal virus", "ORGANISM", 106, 117], ["Kruskal-Wallis test", "TEST", 0, 19], ["fecal virus shedding", "PROBLEM", 106, 126], ["fecal virus", "OBSERVATION", 106, 117]]], ["Mann-Whitney U test was applied when comparing cats shedding in all four fecal samples collected and cats shedding in only one to three fecal samples, in order to determine a possible correlation between the frequency of FCoV shedding and antibody titer and between the frequency of FCoV shedding and mean fecal virus load.", [["fecal samples", "ANATOMY", 73, 86], ["fecal samples", "ANATOMY", 136, 149], ["cats", "ORGANISM", 47, 51], ["cats", "ORGANISM", 101, 105], ["FCoV", "GENE_OR_GENE_PRODUCT", 221, 225], ["FCoV", "GENE_OR_GENE_PRODUCT", 283, 287], ["fecal virus", "ORGANISM", 306, 317], ["cats", "SPECIES", 47, 51], ["cats", "SPECIES", 101, 105], ["FCoV", "SPECIES", 221, 225], ["FCoV", "SPECIES", 283, 287], ["Whitney U test", "TEST", 5, 19], ["all four fecal samples", "TEST", 64, 86], ["FCoV shedding", "PROBLEM", 221, 234], ["antibody titer", "TEST", 239, 253], ["FCoV shedding", "PROBLEM", 283, 296], ["mean fecal virus load", "PROBLEM", 301, 322], ["FCoV", "OBSERVATION", 221, 225], ["FCoV", "OBSERVATION", 283, 287]]], ["Statistical analysis was performed using Graph Pad Prism version 5.04 (GraphPad Software, San Diego, CA, USA).ConclusionsIn this study, cats with antibodies and especially cats with higher antibody titers were more likely to shed FCoV; additionally, they shed FCoV significantly more frequently throughout the study period and had significantly higher mean fecal virus loads than cats with lower antibody titers or without antibodies.", [["cats", "ORGANISM", 136, 140], ["cats", "ORGANISM", 172, 176], ["FCoV", "CANCER", 230, 234], ["FCoV", "GENE_OR_GENE_PRODUCT", 260, 264], ["fecal virus", "ORGANISM", 357, 368], ["cats", "ORGANISM", 380, 384], ["antibodies", "PROTEIN", 146, 156], ["antibodies", "PROTEIN", 423, 433], ["cats", "SPECIES", 136, 140], ["cats", "SPECIES", 172, 176], ["cats", "SPECIES", 380, 384], ["Statistical analysis", "TEST", 0, 20], ["Graph Pad Prism version", "TEST", 41, 64], ["this study", "TEST", 124, 134], ["antibodies", "TEST", 146, 156], ["higher antibody titers", "PROBLEM", 182, 204], ["the study", "TEST", 306, 315], ["significantly higher mean fecal virus loads", "PROBLEM", 331, 374], ["lower antibody titers", "PROBLEM", 390, 411], ["antibodies", "PROBLEM", 423, 433], ["FCoV", "OBSERVATION", 230, 234], ["FCoV", "OBSERVATION", 260, 264], ["virus loads", "OBSERVATION", 363, 374], ["without", "UNCERTAINTY", 415, 422]]], ["Cats shedding FCoV in all four fecal samples collected had significantly higher antibody titers and significantly higher mean fecal virus loads than cats shedding FCoV intermittently.", [["fecal samples", "ANATOMY", 31, 44], ["FCoV", "CHEMICAL", 14, 18], ["Cats", "ORGANISM", 0, 4], ["FCoV", "GENE_OR_GENE_PRODUCT", 14, 18], ["fecal virus", "ORGANISM", 126, 137], ["cats", "ORGANISM", 149, 153], ["cats", "SPECIES", 149, 153], ["FCoV", "SPECIES", 163, 167], ["Cats shedding FCoV", "PROBLEM", 0, 18], ["all four fecal samples", "TEST", 22, 44], ["significantly higher antibody titers", "PROBLEM", 59, 95], ["significantly higher mean fecal virus loads", "PROBLEM", 100, 143], ["FCoV", "OBSERVATION", 14, 18], ["virus loads", "OBSERVATION", 132, 143]]], ["However, it is important to note that even antibody-negative cats shed FCoV, and only 77% of the antibody-positive cats shed FCoV with their feces.", [["FCoV", "ANATOMY", 71, 75], ["feces", "ANATOMY", 141, 146], ["cats", "ORGANISM", 61, 65], ["FCoV", "CANCER", 71, 75], ["cats", "ORGANISM", 115, 119], ["FCoV", "CANCER", 125, 129], ["feces", "ORGANISM_SUBSTANCE", 141, 146], ["antibody", "PROTEIN", 97, 105], ["cats", "SPECIES", 61, 65], ["cats", "SPECIES", 115, 119], ["antibody", "TEST", 43, 51], ["the antibody", "TEST", 93, 105]]], ["Therefore, the measurement of the antibody titer can help in managing FCoV infection in catteries or multi-cat households, but cannot replace the examination of fecal samples by RT-qPCR.", [["fecal samples", "ANATOMY", 161, 174], ["infection", "DISEASE", 75, 84], ["FCoV", "CANCER", 70, 74], ["cat", "ORGANISM", 107, 110], ["fecal samples", "ORGANISM_SUBSTANCE", 161, 174], ["FCoV", "SPECIES", 70, 74], ["the antibody titer", "TREATMENT", 30, 48], ["FCoV infection in catteries", "PROBLEM", 70, 97], ["the examination", "TEST", 142, 157], ["fecal samples", "TEST", 161, 174], ["infection", "OBSERVATION", 75, 84]]], ["RT-qPCR and antibody titer taken together can give a more reliable picture of the status of an individual cat than each test alone.", [["cat", "ORGANISM", 106, 109], ["RT-qPCR", "TEST", 0, 7], ["antibody titer", "TEST", 12, 26]]]], "PMC7319630": [["IntroductionPatients with coronavirus disease (COVID-19) have an increased incidence of cardiovascular comorbidities compared to the general population1.", [["cardiovascular", "ANATOMY", 88, 102], ["coronavirus disease", "DISEASE", 26, 45], ["cardiovascular comorbidities", "DISEASE", 88, 116], ["cardiovascular", "ANATOMICAL_SYSTEM", 88, 102], ["coronavirus disease", "PROBLEM", 26, 45], ["COVID", "TEST", 47, 52], ["cardiovascular comorbidities", "PROBLEM", 88, 116], ["coronavirus disease", "OBSERVATION", 26, 45], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["cardiovascular", "ANATOMY", 88, 102], ["comorbidities", "OBSERVATION", 103, 116]]], ["They can present with an acute cardiovascular event or an exacerbation of a preexisting cardiac condition.", [["cardiovascular", "ANATOMY", 31, 45], ["cardiac", "ANATOMY", 88, 95], ["cardiac condition", "DISEASE", 88, 105], ["cardiac", "ORGAN", 88, 95], ["an acute cardiovascular event", "PROBLEM", 22, 51], ["a preexisting cardiac condition", "PROBLEM", 74, 105], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["exacerbation", "OBSERVATION", 58, 70], ["cardiac", "ANATOMY", 88, 95], ["condition", "OBSERVATION", 96, 105]]], ["A wide spectrum of cardiovascular manifestations has been documented in patients suffering from COVID-19 such as thrombo-embolic events, acute coronary syndrome, heart failure and cardiogenic shock1 and they are associated with poor prognosis.", [["cardiovascular", "ANATOMY", 19, 33], ["coronary", "ANATOMY", 143, 151], ["heart", "ANATOMY", 162, 167], ["cardiovascular manifestations", "DISEASE", 19, 48], ["thrombo-embolic events", "DISEASE", 113, 135], ["acute coronary syndrome", "DISEASE", 137, 160], ["heart failure", "DISEASE", 162, 175], ["cardiogenic shock1", "DISEASE", 180, 198], ["cardiovascular", "ANATOMICAL_SYSTEM", 19, 33], ["patients", "ORGANISM", 72, 80], ["heart", "ORGAN", 162, 167], ["patients", "SPECIES", 72, 80], ["cardiovascular manifestations", "PROBLEM", 19, 48], ["COVID", "TEST", 96, 101], ["thrombo-embolic events", "PROBLEM", 113, 135], ["acute coronary syndrome", "PROBLEM", 137, 160], ["heart failure", "PROBLEM", 162, 175], ["cardiogenic shock1", "PROBLEM", 180, 198], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["cardiovascular manifestations", "OBSERVATION", 19, 48], ["thrombo-embolic", "OBSERVATION", 113, 128], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["coronary", "ANATOMY", 143, 151], ["syndrome", "OBSERVATION", 152, 160], ["heart", "ANATOMY", 162, 167], ["failure", "OBSERVATION", 168, 175], ["cardiogenic shock1", "OBSERVATION", 180, 198]]], ["We describe a patient with COVID-19 who presented with subacute myocardial infarction and bilateral pulmonary emboli associated with biventricular thrombi.Case presentationA 63-year-old woman, active smoker with a known medical history of emphysema presented with a 2 weeks history of worsening of dyspnea, non-productive cough and chills.", [["myocardial", "ANATOMY", 64, 74], ["pulmonary emboli", "ANATOMY", 100, 116], ["biventricular thrombi", "ANATOMY", 133, 154], ["myocardial infarction", "DISEASE", 64, 85], ["pulmonary emboli", "DISEASE", 100, 116], ["biventricular thrombi", "DISEASE", 133, 154], ["emphysema", "DISEASE", 239, 248], ["dyspnea", "DISEASE", 298, 305], ["cough", "DISEASE", 322, 327], ["chills", "DISEASE", 332, 338], ["patient", "ORGANISM", 14, 21], ["myocardial", "MULTI-TISSUE_STRUCTURE", 64, 74], ["pulmonary", "ORGAN", 100, 109], ["woman", "ORGANISM", 186, 191], ["patient", "SPECIES", 14, 21], ["woman", "SPECIES", 186, 191], ["subacute myocardial infarction", "PROBLEM", 55, 85], ["bilateral pulmonary emboli", "PROBLEM", 90, 116], ["biventricular thrombi", "PROBLEM", 133, 154], ["emphysema", "PROBLEM", 239, 248], ["dyspnea", "PROBLEM", 298, 305], ["non-productive cough", "PROBLEM", 307, 327], ["chills", "PROBLEM", 332, 338], ["subacute", "OBSERVATION_MODIFIER", 55, 63], ["myocardial", "ANATOMY", 64, 74], ["infarction", "OBSERVATION", 75, 85], ["bilateral", "ANATOMY_MODIFIER", 90, 99], ["pulmonary", "ANATOMY", 100, 109], ["emboli", "OBSERVATION", 110, 116], ["biventricular", "ANATOMY", 133, 146], ["thrombi", "OBSERVATION", 147, 154], ["active", "OBSERVATION_MODIFIER", 193, 199], ["smoker", "OBSERVATION", 200, 206], ["emphysema", "OBSERVATION", 239, 248], ["worsening", "OBSERVATION_MODIFIER", 285, 294], ["dyspnea", "OBSERVATION", 298, 305], ["non-productive", "OBSERVATION_MODIFIER", 307, 321], ["cough", "OBSERVATION", 322, 327], ["chills", "OBSERVATION", 332, 338]]], ["She had chest pain for 24 hours, which resolved the day prior to admission.", [["chest", "ANATOMY", 8, 13], ["chest pain", "DISEASE", 8, 18], ["chest", "ORGANISM_SUBDIVISION", 8, 13], ["chest pain", "PROBLEM", 8, 18], ["chest", "ANATOMY", 8, 13]]], ["Due to the delayed presentation and the resolution of her chest pain, she was managed conservatively with aspirin, clopidogrel and enoxaparin.", [["chest", "ANATOMY", 58, 63], ["chest pain", "DISEASE", 58, 68], ["aspirin", "CHEMICAL", 106, 113], ["clopidogrel", "CHEMICAL", 115, 126], ["enoxaparin", "CHEMICAL", 131, 141], ["aspirin", "CHEMICAL", 106, 113], ["clopidogrel", "CHEMICAL", 115, 126], ["enoxaparin", "CHEMICAL", 131, 141], ["chest", "ORGANISM_SUBDIVISION", 58, 63], ["aspirin", "SIMPLE_CHEMICAL", 106, 113], ["clopidogrel", "SIMPLE_CHEMICAL", 115, 126], ["enoxaparin", "SIMPLE_CHEMICAL", 131, 141], ["her chest pain", "PROBLEM", 54, 68], ["aspirin", "TREATMENT", 106, 113], ["clopidogrel", "TREATMENT", 115, 126], ["enoxaparin", "TREATMENT", 131, 141], ["chest", "ANATOMY", 58, 63]]], ["A few hours later, she went into cardiac arrest with an underlying rhythm of monomorphic ventricular tachycardia.", [["cardiac", "ANATOMY", 33, 40], ["ventricular", "ANATOMY", 89, 100], ["cardiac arrest", "DISEASE", 33, 47], ["ventricular tachycardia", "DISEASE", 89, 112], ["ventricular", "ORGAN", 89, 100], ["cardiac arrest", "PROBLEM", 33, 47], ["monomorphic ventricular tachycardia", "PROBLEM", 77, 112], ["cardiac", "ANATOMY", 33, 40], ["arrest", "OBSERVATION", 41, 47], ["tachycardia", "OBSERVATION", 101, 112]]], ["After successful cardiorespiratory resuscitation, she was transferred to our tertiary care academic center.Case presentationOn presentation, the patient was tachypneic with a respiratory rate of 35 breaths/minute.", [["respiratory", "ANATOMY", 175, 186], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["successful cardiorespiratory resuscitation", "TREATMENT", 6, 48], ["tachypneic", "PROBLEM", 157, 167], ["a respiratory rate", "TEST", 173, 191]]], ["Her oxygen saturation was 93% on 2L/min of oxygen via nasal prongs before cardiac arrest.", [["nasal", "ANATOMY", 54, 59], ["cardiac", "ANATOMY", 74, 81], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 43, 49], ["cardiac arrest", "DISEASE", 74, 88], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["Her oxygen saturation", "TEST", 0, 21], ["oxygen", "TREATMENT", 43, 49], ["nasal prongs", "TREATMENT", 54, 66], ["cardiac arrest", "PROBLEM", 74, 88], ["cardiac", "ANATOMY", 74, 81], ["arrest", "OBSERVATION", 82, 88]]], ["She was intubated during cardiorespiratory reanimation.", [["She", "ORGANISM", 0, 3], ["intubated", "TREATMENT", 8, 17], ["cardiorespiratory reanimation", "TREATMENT", 25, 54]]], ["Blood pressure and heart rate were within normal range.", [["Blood", "ANATOMY", 0, 5], ["heart", "ANATOMY", 19, 24], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["heart", "ORGAN", 19, 24], ["Blood pressure", "TEST", 0, 14], ["heart rate", "TEST", 19, 29], ["pressure", "OBSERVATION_MODIFIER", 6, 14], ["heart", "ANATOMY", 19, 24], ["normal range", "OBSERVATION", 42, 54]]], ["Physical examination showed jugular vein distension, bibasilar crackles and lower extremity edema.", [["jugular vein", "ANATOMY", 28, 40], ["bibasilar", "ANATOMY", 53, 62], ["lower extremity edema", "ANATOMY", 76, 97], ["jugular vein distension", "DISEASE", 28, 51], ["lower extremity edema", "DISEASE", 76, 97], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 28, 40], ["lower extremity", "ORGANISM_SUBDIVISION", 76, 91], ["edema", "PATHOLOGICAL_FORMATION", 92, 97], ["Physical examination", "TEST", 0, 20], ["jugular vein distension", "PROBLEM", 28, 51], ["bibasilar crackles", "PROBLEM", 53, 71], ["lower extremity edema", "PROBLEM", 76, 97], ["jugular vein", "ANATOMY", 28, 40], ["distension", "OBSERVATION", 41, 51], ["bibasilar", "ANATOMY_MODIFIER", 53, 62], ["crackles", "OBSERVATION", 63, 71], ["lower", "ANATOMY_MODIFIER", 76, 81], ["extremity", "ANATOMY", 82, 91], ["edema", "OBSERVATION", 92, 97]]], ["Laboratory work-up revealed mild lymphopenia of 1,3 x 109/L (normal range: 1,5-3,5).", [["lymphopenia", "DISEASE", 33, 44], ["Laboratory work", "TEST", 0, 15], ["mild lymphopenia", "PROBLEM", 28, 44], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["lymphopenia", "OBSERVATION", 33, 44]]], ["Platelet count, coagulation parameters and fibrinogen were normal.", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 43, 53], ["fibrinogen", "PROTEIN", 43, 53], ["Platelet count", "TEST", 0, 14], ["coagulation parameters", "TEST", 16, 38], ["fibrinogen", "TEST", 43, 53], ["normal", "OBSERVATION", 59, 65]]], ["Troponin I (0,937 \u03bcg/L, normal value < 0,300), creatinine kinase (457 U/L, normal range: 30-185) and lactate (4,2 mmol/L, normal range: 0,6-2,4) were elevated.", [["creatinine", "CHEMICAL", 47, 57], ["lactate", "CHEMICAL", 101, 108], ["creatinine", "CHEMICAL", 47, 57], ["lactate", "CHEMICAL", 101, 108], ["Troponin I", "GENE_OR_GENE_PRODUCT", 0, 10], ["creatinine kinase", "GENE_OR_GENE_PRODUCT", 47, 64], ["lactate", "SIMPLE_CHEMICAL", 101, 108], ["Troponin I", "PROTEIN", 0, 10], ["creatinine kinase", "PROTEIN", 47, 64], ["Troponin I", "TEST", 0, 10], ["creatinine kinase", "TEST", 47, 64], ["U/L", "TEST", 70, 73], ["lactate", "TEST", 101, 108], ["elevated", "PROBLEM", 150, 158]]], ["Lupus anticoagulant, anti-beta-2-glycoprotein and anticardiolipin antibodies were negative.", [["anti-beta-2-glycoprotein", "GENE_OR_GENE_PRODUCT", 21, 45], ["anticardiolipin antibodies", "GENE_OR_GENE_PRODUCT", 50, 76], ["anti-beta-2-glycoprotein", "PROTEIN", 21, 45], ["anticardiolipin antibodies", "PROTEIN", 50, 76], ["Lupus anticoagulant", "TEST", 0, 19], ["anti-beta", "TEST", 21, 30], ["anticardiolipin antibodies", "TEST", 50, 76]]], ["PCR for SARS-CoV-2 was positive.Case presentationElectrocardiogram revealed sinus rhythm with ST-segment elevation, T-wave inversion and pathological Q waves in leads V1 to V6, I and aVL, consistent with subacute anterolateral ST-elevation myocardial infarction.", [["sinus", "ANATOMY", 76, 81], ["aVL", "ANATOMY", 183, 186], ["myocardial", "ANATOMY", 240, 250], ["myocardial infarction", "DISEASE", 240, 261], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 18], ["aVL", "CANCER", 183, 186], ["myocardial", "MULTI-TISSUE_STRUCTURE", 240, 250], ["SARS-CoV", "SPECIES", 8, 16], ["PCR", "TEST", 0, 3], ["SARS", "TEST", 8, 12], ["CoV", "TEST", 13, 16], ["Electrocardiogram", "TEST", 49, 66], ["sinus rhythm", "PROBLEM", 76, 88], ["ST-segment elevation", "PROBLEM", 94, 114], ["T-wave inversion", "PROBLEM", 116, 132], ["pathological Q waves in leads V1 to V6", "PROBLEM", 137, 175], ["subacute anterolateral ST-elevation myocardial infarction", "PROBLEM", 204, 261], ["sinus rhythm", "ANATOMY", 76, 88], ["segment", "ANATOMY_MODIFIER", 97, 104], ["elevation", "OBSERVATION", 105, 114], ["wave inversion", "OBSERVATION", 118, 132], ["Q waves", "OBSERVATION", 150, 157], ["V1", "ANATOMY_MODIFIER", 167, 169], ["aVL", "ANATOMY", 183, 186], ["consistent with", "UNCERTAINTY", 188, 203], ["subacute", "OBSERVATION_MODIFIER", 204, 212], ["anterolateral", "ANATOMY_MODIFIER", 213, 226], ["elevation", "OBSERVATION_MODIFIER", 230, 239], ["myocardial", "ANATOMY", 240, 250], ["infarction", "OBSERVATION", 251, 261]]], ["Cardiomegaly with mild interstitial edema were demonstrated on chest X-ray.", [["interstitial edema", "ANATOMY", 23, 41], ["Cardiomegaly", "DISEASE", 0, 12], ["interstitial edema", "DISEASE", 23, 41], ["interstitial edema", "PATHOLOGICAL_FORMATION", 23, 41], ["Cardiomegaly", "PROBLEM", 0, 12], ["mild interstitial edema", "PROBLEM", 18, 41], ["chest X-ray", "TEST", 63, 74], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["interstitial", "ANATOMY_MODIFIER", 23, 35], ["edema", "OBSERVATION", 36, 41], ["chest", "ANATOMY", 63, 68]]], ["Coronary angiogram showed 99% stenosis of the proximal left anterior descending coronary artery (LAD) with organized thrombi and TIMI-1 blood flow (Fig.1a).", [["Coronary", "ANATOMY", 0, 8], ["left anterior descending coronary artery", "ANATOMY", 55, 95], ["LAD", "ANATOMY", 97, 100], ["thrombi", "ANATOMY", 117, 124], ["blood", "ANATOMY", 136, 141], ["stenosis", "DISEASE", 30, 38], ["thrombi", "DISEASE", 117, 124], ["Coronary", "MULTI-TISSUE_STRUCTURE", 0, 8], ["anterior descending coronary artery", "MULTI-TISSUE_STRUCTURE", 60, 95], ["LAD", "MULTI-TISSUE_STRUCTURE", 97, 100], ["thrombi", "MULTI-TISSUE_STRUCTURE", 117, 124], ["TIMI-1", "GENE_OR_GENE_PRODUCT", 129, 135], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["Coronary angiogram", "TEST", 0, 18], ["99% stenosis of the proximal left anterior descending coronary artery", "PROBLEM", 26, 95], ["organized thrombi", "PROBLEM", 107, 124], ["TIMI", "TEST", 129, 133], ["stenosis", "OBSERVATION", 30, 38], ["proximal", "ANATOMY_MODIFIER", 46, 54], ["left anterior descending coronary artery", "ANATOMY", 55, 95], ["LAD", "ANATOMY", 97, 100], ["organized", "OBSERVATION_MODIFIER", 107, 116], ["thrombi", "OBSERVATION", 117, 124]]], ["The circumflex and right coronary arteries had non-significant stenoses.", [["circumflex", "ANATOMY", 4, 14], ["right coronary arteries", "ANATOMY", 19, 42], ["stenoses", "DISEASE", 63, 71], ["circumflex", "MULTI-TISSUE_STRUCTURE", 4, 14], ["right coronary arteries", "MULTI-TISSUE_STRUCTURE", 19, 42], ["non-significant stenoses", "PROBLEM", 47, 71], ["circumflex", "ANATOMY", 4, 14], ["right coronary arteries", "ANATOMY", 19, 42], ["non-significant", "OBSERVATION_MODIFIER", 47, 62], ["stenoses", "OBSERVATION", 63, 71]]], ["Left ventriculography revealed severe ventricular dysfunction with extended anterolateral akinesis, apical aneurysm and thrombus (Fig. 1b).Case presentationCardiac tomography done to eliminate a pseudoaneurysm demonstrated severe systolic dysfunction with a left ventricular ejection fraction of 17% and complete akinesis of the LAD territory.", [["ventricular", "ANATOMY", 38, 49], ["apical aneurysm", "ANATOMY", 100, 115], ["thrombus", "ANATOMY", 120, 128], ["Cardiac", "ANATOMY", 156, 163], ["pseudoaneurysm", "ANATOMY", 195, 209], ["left ventricular", "ANATOMY", 258, 274], ["LAD", "ANATOMY", 329, 332], ["ventricular dysfunction", "DISEASE", 38, 61], ["aneurysm", "DISEASE", 107, 115], ["thrombus", "DISEASE", 120, 128], ["pseudoaneurysm", "DISEASE", 195, 209], ["systolic dysfunction", "DISEASE", 230, 250], ["ventricular", "MULTI-TISSUE_STRUCTURE", 38, 49], ["thrombus", "PATHOLOGICAL_FORMATION", 120, 128], ["pseudoaneurysm", "PATHOLOGICAL_FORMATION", 195, 209], ["ventricular", "MULTI-TISSUE_STRUCTURE", 263, 274], ["LAD", "MULTI-TISSUE_STRUCTURE", 329, 332], ["Left ventriculography", "TEST", 0, 21], ["severe ventricular dysfunction", "PROBLEM", 31, 61], ["extended anterolateral akinesis", "PROBLEM", 67, 98], ["apical aneurysm", "PROBLEM", 100, 115], ["thrombus", "PROBLEM", 120, 128], ["Cardiac tomography", "TEST", 156, 174], ["a pseudoaneurysm", "PROBLEM", 193, 209], ["severe systolic dysfunction", "PROBLEM", 223, 250], ["a left ventricular ejection fraction", "TEST", 256, 292], ["complete akinesis of the LAD territory", "PROBLEM", 304, 342], ["severe", "OBSERVATION", 31, 37], ["ventricular", "ANATOMY", 38, 49], ["dysfunction", "OBSERVATION", 50, 61], ["anterolateral", "OBSERVATION_MODIFIER", 76, 89], ["akinesis", "OBSERVATION", 90, 98], ["apical", "ANATOMY_MODIFIER", 100, 106], ["aneurysm", "OBSERVATION", 107, 115], ["thrombus", "OBSERVATION", 120, 128], ["pseudoaneurysm", "OBSERVATION", 195, 209], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["systolic", "OBSERVATION_MODIFIER", 230, 238], ["dysfunction", "OBSERVATION", 239, 250], ["left ventricular", "ANATOMY", 258, 274], ["ejection fraction", "OBSERVATION", 275, 292], ["akinesis", "OBSERVATION", 313, 321], ["LAD", "ANATOMY", 329, 332], ["territory", "ANATOMY_MODIFIER", 333, 342]]], ["An apical aneurysm measuring 5 cm in diameter and a left ventricular thrombus (LVT) measuring 12 mm thick extending over a 6 cm perimeter were found.", [["apical aneurysm", "ANATOMY", 3, 18], ["left ventricular thrombus", "ANATOMY", 52, 77], ["LVT", "ANATOMY", 79, 82], ["aneurysm", "DISEASE", 10, 18], ["left ventricular thrombus", "DISEASE", 52, 77], ["apical aneurysm", "MULTI-TISSUE_STRUCTURE", 3, 18], ["ventricular thrombus", "PATHOLOGICAL_FORMATION", 57, 77], ["An apical aneurysm", "PROBLEM", 0, 18], ["a left ventricular thrombus", "PROBLEM", 50, 77], ["apical", "ANATOMY_MODIFIER", 3, 9], ["aneurysm", "OBSERVATION", 10, 18], ["5 cm", "OBSERVATION_MODIFIER", 29, 33], ["diameter", "OBSERVATION_MODIFIER", 37, 45], ["left ventricular", "ANATOMY", 52, 68], ["thrombus", "OBSERVATION", 69, 77], ["LVT", "OBSERVATION", 79, 82], ["12 mm", "OBSERVATION_MODIFIER", 94, 99], ["thick", "OBSERVATION_MODIFIER", 100, 105], ["6 cm", "OBSERVATION_MODIFIER", 123, 127]]], ["Unexpectedly, a moderate right ventricular hypokinesis with a small right ventricular thrombus measuring 4 mm by 10 mm and multiple bilateral pulmonary emboli were also noted (Fig. 2).Case presentationGiven the presence of multiple thrombi in the heart and lungs, therapeutic anticoagulation with IV heparin and warfarin was initiated.", [["right ventricular", "ANATOMY", 25, 42], ["right ventricular thrombus", "ANATOMY", 68, 94], ["pulmonary emboli", "ANATOMY", 142, 158], ["thrombi", "ANATOMY", 232, 239], ["heart", "ANATOMY", 247, 252], ["lungs", "ANATOMY", 257, 262], ["ventricular hypokinesis", "DISEASE", 31, 54], ["ventricular thrombus", "DISEASE", 74, 94], ["pulmonary emboli", "DISEASE", 142, 158], ["thrombi", "DISEASE", 232, 239], ["heparin", "CHEMICAL", 300, 307], ["warfarin", "CHEMICAL", 312, 320], ["warfarin", "CHEMICAL", 312, 320], ["ventricular", "MULTI-TISSUE_STRUCTURE", 31, 42], ["ventricular thrombus", "PATHOLOGICAL_FORMATION", 74, 94], ["pulmonary", "ORGAN", 142, 151], ["thrombi", "PATHOLOGICAL_FORMATION", 232, 239], ["heart", "ORGAN", 247, 252], ["lungs", "ORGAN", 257, 262], ["IV heparin", "SIMPLE_CHEMICAL", 297, 307], ["warfarin", "SIMPLE_CHEMICAL", 312, 320], ["a moderate right ventricular hypokinesis", "PROBLEM", 14, 54], ["a small right ventricular thrombus", "PROBLEM", 60, 94], ["multiple bilateral pulmonary emboli", "PROBLEM", 123, 158], ["multiple thrombi in the heart and lungs", "PROBLEM", 223, 262], ["therapeutic anticoagulation", "TREATMENT", 264, 291], ["IV heparin", "TREATMENT", 297, 307], ["warfarin", "TREATMENT", 312, 320], ["moderate", "OBSERVATION_MODIFIER", 16, 24], ["right ventricular", "ANATOMY", 25, 42], ["hypokinesis", "OBSERVATION", 43, 54], ["small", "OBSERVATION_MODIFIER", 62, 67], ["right ventricular", "ANATOMY", 68, 85], ["thrombus", "OBSERVATION", 86, 94], ["4 mm", "OBSERVATION_MODIFIER", 105, 109], ["10 mm", "OBSERVATION_MODIFIER", 113, 118], ["multiple", "OBSERVATION_MODIFIER", 123, 131], ["bilateral", "ANATOMY_MODIFIER", 132, 141], ["pulmonary", "ANATOMY", 142, 151], ["emboli", "OBSERVATION", 152, 158], ["multiple", "OBSERVATION_MODIFIER", 223, 231], ["thrombi", "OBSERVATION", 232, 239], ["heart", "ANATOMY", 247, 252], ["lungs", "ANATOMY", 257, 262]]], ["The patient later deteriorated and required systemic support with vasopressors and inotropic agents.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["systemic support", "TREATMENT", 44, 60], ["vasopressors", "TREATMENT", 66, 78], ["inotropic agents", "TREATMENT", 83, 99]]], ["Despite treatment, she died from cardiogenic and pulmonary septic shock.DiscussionThis COVID-19 patient had an extensive anterior myocardial infarction with severe systolic dysfunction.", [["pulmonary", "ANATOMY", 49, 58], ["myocardial", "ANATOMY", 130, 140], ["cardiogenic and pulmonary septic shock", "DISEASE", 33, 71], ["anterior myocardial infarction", "DISEASE", 121, 151], ["systolic dysfunction", "DISEASE", 164, 184], ["pulmonary", "ORGAN", 49, 58], ["patient", "ORGANISM", 96, 103], ["myocardial", "MULTI-TISSUE_STRUCTURE", 130, 140], ["patient", "SPECIES", 96, 103], ["treatment", "TREATMENT", 8, 17], ["cardiogenic", "PROBLEM", 33, 44], ["pulmonary septic shock", "PROBLEM", 49, 71], ["an extensive anterior myocardial infarction", "PROBLEM", 108, 151], ["severe systolic dysfunction", "PROBLEM", 157, 184], ["cardiogenic", "OBSERVATION_MODIFIER", 33, 44], ["pulmonary", "ANATOMY", 49, 58], ["septic shock", "OBSERVATION", 59, 71], ["anterior", "ANATOMY_MODIFIER", 121, 129], ["myocardial", "ANATOMY", 130, 140], ["infarction", "OBSERVATION", 141, 151], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["systolic dysfunction", "OBSERVATION", 164, 184]]], ["The proposed mechanisms for cardiovascular injury in COVID-19 include the release of proinflammatory cytokines leading to plaque instability, myocardial inflammation, hypercoagulable state and myocardial depression1.DiscussionLVT can occur as a complication of acute myocardial infarction with ejection fraction below 35% or non-ischemic cardiomyopathy2.", [["cardiovascular", "ANATOMY", 28, 42], ["plaque", "ANATOMY", 122, 128], ["myocardial", "ANATOMY", 142, 152], ["myocardial", "ANATOMY", 193, 203], ["myocardial", "ANATOMY", 267, 277], ["cardiovascular injury", "DISEASE", 28, 49], ["COVID-19", "CHEMICAL", 53, 61], ["plaque instability", "DISEASE", 122, 140], ["myocardial inflammation", "DISEASE", 142, 165], ["myocardial depression1", "DISEASE", 193, 215], ["DiscussionLVT", "DISEASE", 216, 229], ["acute myocardial infarction", "DISEASE", 261, 288], ["COVID-19", "CHEMICAL", 53, 61], ["cardiovascular", "ANATOMICAL_SYSTEM", 28, 42], ["plaque", "PATHOLOGICAL_FORMATION", 122, 128], ["myocardial", "MULTI-TISSUE_STRUCTURE", 142, 152], ["myocardial", "MULTI-TISSUE_STRUCTURE", 193, 203], ["myocardial", "MULTI-TISSUE_STRUCTURE", 267, 277], ["proinflammatory cytokines", "PROTEIN", 85, 110], ["cardiovascular injury", "PROBLEM", 28, 49], ["COVID", "TEST", 53, 58], ["proinflammatory cytokines", "PROBLEM", 85, 110], ["plaque instability", "PROBLEM", 122, 140], ["myocardial inflammation", "PROBLEM", 142, 165], ["hypercoagulable state", "PROBLEM", 167, 188], ["myocardial depression1", "PROBLEM", 193, 215], ["acute myocardial infarction", "PROBLEM", 261, 288], ["ejection fraction", "TEST", 294, 311], ["non-ischemic cardiomyopathy2", "PROBLEM", 325, 353], ["proinflammatory cytokines", "OBSERVATION", 85, 110], ["plaque", "OBSERVATION", 122, 128], ["myocardial", "ANATOMY", 142, 152], ["inflammation", "OBSERVATION", 153, 165], ["hypercoagulable state", "OBSERVATION", 167, 188], ["myocardial", "ANATOMY", 193, 203], ["depression1", "OBSERVATION", 204, 215], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["myocardial", "ANATOMY", 267, 277], ["infarction", "OBSERVATION", 278, 288], ["non-ischemic cardiomyopathy2", "OBSERVATION", 325, 353]]], ["It mostly occurs with anterior myocardial infarction when there is an aneurysm or apical akinesis2.", [["myocardial", "ANATOMY", 31, 41], ["aneurysm", "ANATOMY", 70, 78], ["apical akinesis2", "ANATOMY", 82, 98], ["anterior myocardial infarction", "DISEASE", 22, 52], ["aneurysm", "DISEASE", 70, 78], ["anterior myocardial", "MULTI-TISSUE_STRUCTURE", 22, 41], ["anterior myocardial infarction", "PROBLEM", 22, 52], ["an aneurysm", "PROBLEM", 67, 78], ["apical akinesis2", "PROBLEM", 82, 98], ["anterior", "ANATOMY_MODIFIER", 22, 30], ["myocardial", "ANATOMY", 31, 41], ["infarction", "OBSERVATION", 42, 52], ["aneurysm", "OBSERVATION", 70, 78], ["apical", "ANATOMY_MODIFIER", 82, 88], ["akinesis2", "OBSERVATION", 89, 98]]], ["The damage to the endocardial tissue, the hypercoagulable state and the loss of regional contractile function lead to blood stasis and thrombus formation3.", [["endocardial tissue", "ANATOMY", 18, 36], ["contractile", "ANATOMY", 89, 100], ["blood", "ANATOMY", 118, 123], ["thrombus", "ANATOMY", 135, 143], ["blood stasis", "DISEASE", 118, 130], ["thrombus", "DISEASE", 135, 143], ["endocardial tissue", "TISSUE", 18, 36], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["thrombus", "PATHOLOGICAL_FORMATION", 135, 143], ["The damage to the endocardial tissue", "PROBLEM", 0, 36], ["the hypercoagulable state", "PROBLEM", 38, 63], ["the loss of regional contractile function", "PROBLEM", 68, 109], ["blood stasis", "PROBLEM", 118, 130], ["thrombus formation3", "PROBLEM", 135, 154], ["damage", "OBSERVATION", 4, 10], ["endocardial tissue", "ANATOMY", 18, 36], ["hypercoagulable state", "OBSERVATION", 42, 63], ["loss", "OBSERVATION_MODIFIER", 72, 76], ["regional contractile function", "OBSERVATION", 80, 109], ["blood stasis", "OBSERVATION", 118, 130], ["thrombus", "OBSERVATION", 135, 143]]], ["With effective reperfusion, the incidence of LVT after myocardial infarction has decreased in the PCI era from 33% to 10%3.", [["myocardial", "ANATOMY", 55, 65], ["LVT", "DISEASE", 45, 48], ["myocardial infarction", "DISEASE", 55, 76], ["myocardial", "MULTI-TISSUE_STRUCTURE", 55, 65], ["effective reperfusion", "TREATMENT", 5, 26], ["LVT", "PROBLEM", 45, 48], ["myocardial infarction", "PROBLEM", 55, 76], ["effective", "OBSERVATION_MODIFIER", 5, 14], ["reperfusion", "OBSERVATION", 15, 26], ["myocardial", "ANATOMY", 55, 65], ["infarction", "OBSERVATION", 66, 76], ["decreased", "OBSERVATION_MODIFIER", 81, 90]]], ["However, in patients presenting more than 12 hours after the onset of symptoms, a study showed that thrombus formation was 48% higher than in the early presentation group4.", [["thrombus", "ANATOMY", 100, 108], ["thrombus", "DISEASE", 100, 108], ["patients", "ORGANISM", 12, 20], ["thrombus", "PATHOLOGICAL_FORMATION", 100, 108], ["patients", "SPECIES", 12, 20], ["symptoms", "PROBLEM", 70, 78], ["a study", "TEST", 80, 87], ["thrombus formation", "PROBLEM", 100, 118], ["thrombus", "OBSERVATION", 100, 108], ["higher", "OBSERVATION_MODIFIER", 127, 133]]], ["In contrast, the formation of biventricular thrombi following acute myocardial infarction, first reported in 1986, is even rarer.", [["biventricular thrombi", "ANATOMY", 30, 51], ["myocardial", "ANATOMY", 68, 78], ["biventricular thrombi", "DISEASE", 30, 51], ["acute myocardial infarction", "DISEASE", 62, 89], ["myocardial", "MULTI-TISSUE_STRUCTURE", 68, 78], ["biventricular thrombi", "PROBLEM", 30, 51], ["acute myocardial infarction", "PROBLEM", 62, 89], ["biventricular", "ANATOMY", 30, 43], ["thrombi", "OBSERVATION", 44, 51], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["myocardial", "ANATOMY", 68, 78], ["infarction", "OBSERVATION", 79, 89]]], ["The majority of the cases subsequently reported were associated with an underlying prothrombotic condition such as nephrotic syndrome, hypereosinophilic syndrome, heparin-induced thrombocytopenia, anti-phospholipid syndrome and other coagulopathies.", [["nephrotic syndrome", "DISEASE", 115, 133], ["hypereosinophilic syndrome", "DISEASE", 135, 161], ["heparin", "CHEMICAL", 163, 170], ["thrombocytopenia", "DISEASE", 179, 195], ["anti-phospholipid syndrome", "DISEASE", 197, 223], ["coagulopathies", "DISEASE", 234, 248], ["heparin", "SIMPLE_CHEMICAL", 163, 170], ["an underlying prothrombotic condition", "PROBLEM", 69, 106], ["nephrotic syndrome", "PROBLEM", 115, 133], ["hypereosinophilic syndrome", "PROBLEM", 135, 161], ["heparin", "TREATMENT", 163, 170], ["thrombocytopenia", "PROBLEM", 179, 195], ["anti-phospholipid syndrome", "PROBLEM", 197, 223], ["other coagulopathies", "PROBLEM", 228, 248], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["prothrombotic", "OBSERVATION", 83, 96], ["nephrotic syndrome", "OBSERVATION", 115, 133], ["hypereosinophilic syndrome", "OBSERVATION", 135, 161], ["thrombocytopenia", "OBSERVATION", 179, 195], ["anti-phospholipid syndrome", "OBSERVATION", 197, 223], ["coagulopathies", "OBSERVATION", 234, 248]]], ["The presence of antiphospholipid antibodies has been associated with COVID-19 but was negative in our patient.", [["antiphospholipid antibodies", "DISEASE", 16, 43], ["antiphospholipid antibodies", "GENE_OR_GENE_PRODUCT", 16, 43], ["patient", "ORGANISM", 102, 109], ["antiphospholipid antibodies", "PROTEIN", 16, 43], ["patient", "SPECIES", 102, 109], ["antiphospholipid antibodies", "PROBLEM", 16, 43], ["COVID", "TEST", 69, 74], ["antiphospholipid antibodies", "OBSERVATION", 16, 43]]], ["To our knowledge, this is the first reported case of biventricular thrombi after myocardial infarction in a patient with COVID-19.", [["biventricular thrombi", "ANATOMY", 53, 74], ["myocardial", "ANATOMY", 81, 91], ["biventricular thrombi", "DISEASE", 53, 74], ["myocardial infarction", "DISEASE", 81, 102], ["biventricular thrombi", "PATHOLOGICAL_FORMATION", 53, 74], ["myocardial", "MULTI-TISSUE_STRUCTURE", 81, 91], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["biventricular thrombi", "PROBLEM", 53, 74], ["myocardial infarction", "PROBLEM", 81, 102], ["COVID", "TEST", 121, 126], ["biventricular", "ANATOMY", 53, 66], ["thrombi", "OBSERVATION", 67, 74], ["myocardial", "ANATOMY", 81, 91], ["infarction", "OBSERVATION", 92, 102]]], ["Our hypothesis is that the combination of an extensive anterior myocardial infarction with delayed presentation and COVID-19 caused an important inflammatory cascade that led to thrombi formations.Uncited reference", [["anterior myocardial", "ANATOMY", 55, 74], ["thrombi", "ANATOMY", 178, 185], ["myocardial infarction", "DISEASE", 64, 85], ["COVID-19", "CHEMICAL", 116, 124], ["thrombi", "DISEASE", 178, 185], ["COVID-19", "CHEMICAL", 116, 124], ["anterior myocardial", "MULTI-TISSUE_STRUCTURE", 55, 74], ["thrombi", "PATHOLOGICAL_FORMATION", 178, 185], ["an extensive anterior myocardial infarction", "PROBLEM", 42, 85], ["COVID", "TEST", 116, 121], ["an important inflammatory cascade", "PROBLEM", 132, 165], ["thrombi formations", "PROBLEM", 178, 196], ["extensive", "OBSERVATION_MODIFIER", 45, 54], ["anterior", "ANATOMY_MODIFIER", 55, 63], ["myocardial", "ANATOMY", 64, 74], ["infarction", "OBSERVATION", 75, 85], ["inflammatory cascade", "OBSERVATION", 145, 165], ["thrombi", "OBSERVATION", 178, 185]]]], "PMC4591909": [["INTRODUCTIONMiddle East Respiratory Syndrome (MERS) was first detected in South Korea (hereafter Korea) in May 2015, and resulted in a death toll of 36, with 186 confirmed cases between May 11 and July 4, the symptom onset dates of the first and last cases, respectively [1].", [["Respiratory Syndrome", "DISEASE", 24, 44], ["MERS", "DISEASE", 46, 50], ["death", "DISEASE", 135, 140], ["East Respiratory Syndrome", "PROBLEM", 19, 44], ["Respiratory Syndrome", "OBSERVATION", 24, 44]]], ["MERS is caused by a recombinant coronavirus strain (MERS-CoV) that was first identified in 2012; accumulating evidence points to dromedary camels as the likely major reservoir.", [["MERS", "DISEASE", 0, 4], ["recombinant coronavirus strain", "ORGANISM", 20, 50], ["MERS-CoV", "ORGANISM", 52, 60], ["MERS-CoV", "SPECIES", 52, 60], ["a recombinant coronavirus strain", "PROBLEM", 18, 50], ["likely", "UNCERTAINTY", 153, 159], ["major", "OBSERVATION_MODIFIER", 160, 165], ["reservoir", "OBSERVATION_MODIFIER", 166, 175]]], ["While camel-to-human infection and subsequent human-to-human infection have been confirmed, the exact modes of transmission of MERS-CoV have yet to be clarified [2].", [["infection", "DISEASE", 21, 30], ["human-to-human infection", "DISEASE", 46, 70], ["camel", "ORGANISM", 6, 11], ["human", "ORGANISM", 15, 20], ["human", "ORGANISM", 46, 51], ["human", "ORGANISM", 55, 60], ["MERS-CoV", "ORGANISM", 127, 135], ["camel", "SPECIES", 6, 11], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 55, 60], ["MERS-CoV", "SPECIES", 127, 135], ["human infection", "PROBLEM", 15, 30], ["human infection", "PROBLEM", 55, 70], ["infection", "OBSERVATION", 21, 30]]], ["The origin of the outbreak in Korea was the arrival of the first case in May 2015 from Saudi Arabia, experiencing a high incidence of MERS.", [["MERS", "DISEASE", 134, 138], ["a high incidence of MERS", "PROBLEM", 114, 138], ["origin", "OBSERVATION_MODIFIER", 4, 10], ["outbreak", "OBSERVATION_MODIFIER", 18, 26]]], ["Most infections have been confirmed to occur in hospital settings [3].", [["infections", "DISEASE", 5, 15], ["Most infections", "PROBLEM", 0, 15]]], ["However, some cases have unclear routes or symptom onset dates, necessitating an in-depth investigation.", [["an in-depth investigation", "TEST", 78, 103]]], ["While it is difficult to clearly trace back all cases in a large-scale outbreak, an exclusion-based rapid investigation after mapping of all possibilities is indispensable to control outbreak.INTRODUCTIONThe present study relates to an in-depth investigation performCorrespondenceon the 178th case with confirmed MERS (hereafter referred to as #178) who was infected during the 2015 outbreak in Korea. #178 was followed starting from June 23, the date of confirmed diagnosis, and measures were taken to prevent further spread, with concerted efforts by an epidemiological investigation team of the Korea Centers for Disease Control and Prevention (KCDC) and civil professionals.MATERIALS AND METHODSThis survey was performed using elimination methods after mapping all possible routes.", [["MERS", "DISEASE", 313, 317], ["a large-scale outbreak", "PROBLEM", 57, 79], ["an exclusion", "TEST", 81, 93], ["rapid investigation", "TEST", 100, 119], ["The present study", "TEST", 204, 221], ["Disease Control", "TREATMENT", 616, 631], ["METHODSThis survey", "TEST", 692, 710], ["elimination methods", "TREATMENT", 731, 750], ["mapping", "TEST", 757, 764], ["large", "OBSERVATION_MODIFIER", 59, 64]]], ["As #178 did not have direct contact with MERS patients, we investigated the possibilities for exposure from the 2-week incubation period (June 2-16) to the date of symptom onset. #178 frequently visited his father during the latter\u2019s treatment in Pyeongtaek St. Mary\u2019s Hospital (PSMH) from May 18-29, and Pyeongtaek Good Samaritan Bagae Hospital (GSBH) from May 29 through June 6.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["symptom onset", "PROBLEM", 164, 177]]], ["We reviewed the investigation data of these hospitals and performed additional surveys on patients and related persons with whom #178 may have come into contact.", [["patients", "ORGANISM", 90, 98], ["persons", "ORGANISM", 111, 118], ["patients", "SPECIES", 90, 98], ["persons", "SPECIES", 111, 118]]], ["All persons with whom #178 may have had contact during the 2-week incubation period, e.g., his family, and colleagues, were asked in person or by phone whether they had MERS-related symptoms or visited a hospital for similar symptoms.", [["persons", "ORGANISM", 4, 11], ["persons", "SPECIES", 4, 11], ["person", "SPECIES", 133, 139], ["related symptoms", "PROBLEM", 174, 190], ["similar symptoms", "PROBLEM", 217, 233]]], ["Moreover, initial symptoms onset of #178 were reexamined by checking his hospital visit and medical records.", [["initial symptoms", "PROBLEM", 10, 26]]], ["The KCDC performed polymerase chain reaction (PCR) assays on sputum samples and serum antibody detection tests on individuals with whom #178 had direct contact, to screen for positive individuals with a confirmatory test.MATERIALS AND METHODSBecause this study was conducted as an outbreak investigation, institutional review board approval was not necessary.Clinical course ::: RESULTS#178 is a 29-year-old man living in Pyeongtaek, Gyeonggi-do, Korea, where the initial outbreak occurred.", [["sputum samples", "ANATOMY", 61, 75], ["serum", "ANATOMY", 80, 85], ["sputum samples", "ORGANISM_SUBSTANCE", 61, 75], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["man", "ORGANISM", 408, 411], ["serum antibody", "PROTEIN", 80, 94], ["man", "SPECIES", 408, 411], ["The KCDC", "TEST", 0, 8], ["polymerase chain reaction", "PROBLEM", 19, 44], ["PCR", "TEST", 46, 49], ["sputum samples", "TEST", 61, 75], ["serum antibody detection tests", "TEST", 80, 110], ["a confirmatory test", "TEST", 201, 220], ["this study", "TEST", 250, 260], ["an outbreak investigation", "TEST", 278, 303]]], ["He was a smoker and had social alcohol drinking, and was in good health without medication.", [["alcohol", "CHEMICAL", 31, 38], ["alcohol", "CHEMICAL", 31, 38], ["He", "ORGANISM", 0, 2], ["medication", "TREATMENT", 80, 90]]], ["He first noticed a febrile sensation, chills, and myalgia on June 16, and presented to Asan Saewoori Clinic on June 17, where he was prescribed medicine for an upper respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 160, 183], ["febrile sensation", "DISEASE", 19, 36], ["chills", "DISEASE", 38, 44], ["myalgia", "DISEASE", 50, 57], ["respiratory tract infection", "DISEASE", 166, 193], ["upper respiratory", "ORGANISM_SUBDIVISION", 160, 177], ["tract", "ORGANISM_SUBDIVISION", 178, 183], ["a febrile sensation", "PROBLEM", 17, 36], ["chills", "PROBLEM", 38, 44], ["myalgia", "PROBLEM", 50, 57], ["medicine", "TREATMENT", 144, 152], ["an upper respiratory tract infection", "PROBLEM", 157, 193], ["febrile", "OBSERVATION_MODIFIER", 19, 26], ["chills", "OBSERVATION", 38, 44], ["upper", "ANATOMY_MODIFIER", 160, 165], ["respiratory tract", "ANATOMY", 166, 183], ["infection", "OBSERVATION", 184, 193]]], ["On June 18, he was administered intravenous fluids for fever (38.5\u00b0C) and myalgia in GSBH, again received outpatient treatment at Saewoori Clinic on June 19, and was again administered intravenous fluids on June 20 at GSBH.", [["intravenous", "ANATOMY", 32, 43], ["intravenous", "ANATOMY", 185, 196], ["fever", "DISEASE", 55, 60], ["myalgia", "DISEASE", 74, 81], ["intravenous fluids", "TREATMENT", 32, 50], ["fever", "PROBLEM", 55, 60], ["myalgia", "PROBLEM", 74, 81], ["outpatient treatment", "TREATMENT", 106, 126], ["intravenous fluids", "TREATMENT", 185, 203]]], ["On June 21, owing to ongoing symptoms, he was admitted to an isolation room in Pyeongtaek Good Morning Hospital, on referral from GSBH.", [["ongoing symptoms", "PROBLEM", 21, 37]]], ["Upon confirmatory diagnosis of MERS on June 23, he was then referred to Gyeonggi Provincial Medical Center Suwon Hospital.Clinical course ::: RESULTSThe chest radiography taken on June 21 revealed that pneumonia had developed over a few days, and he was treated primarily for pneumonia.", [["chest", "ANATOMY", 153, 158], ["MERS", "DISEASE", 31, 35], ["pneumonia", "DISEASE", 202, 211], ["pneumonia", "DISEASE", 276, 285], ["RESULTSThe chest radiography", "TEST", 142, 170], ["pneumonia", "PROBLEM", 202, 211], ["pneumonia", "PROBLEM", 276, 285], ["chest", "ANATOMY", 153, 158], ["pneumonia", "OBSERVATION", 202, 211], ["pneumonia", "OBSERVATION", 276, 285]]], ["With negative results from two sputum tests and complete disappearance of symptoms, he was discharged on July 2 (Figure 1).#178\u2019s father ::: Suspected exposure events and transmission routes ::: RESULTS#178\u2019s father (a resident of Jeollanam-do) was receiving postoperative pain management and chemotherapy.", [["postoperative pain", "DISEASE", 259, 277], ["two sputum tests", "TEST", 27, 43], ["symptoms", "PROBLEM", 74, 82], ["postoperative pain management", "TREATMENT", 259, 288], ["chemotherapy", "TREATMENT", 293, 305]]], ["He had a history of liver cancer operation in Chonnam National University Hospital in 2008, and hepatic artery embolization for recurrent liver cancer and lung metastasis in Seoul Asan Medical Center in June 2014.", [["liver cancer", "ANATOMY", 20, 32], ["hepatic artery", "ANATOMY", 96, 110], ["liver cancer", "ANATOMY", 138, 150], ["lung", "ANATOMY", 155, 159], ["liver cancer", "DISEASE", 20, 32], ["hepatic artery embolization", "DISEASE", 96, 123], ["liver cancer", "DISEASE", 138, 150], ["liver cancer", "CANCER", 20, 32], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 96, 110], ["liver cancer", "CANCER", 138, 150], ["lung", "ORGAN", 155, 159], ["liver cancer", "PROBLEM", 20, 32], ["hepatic artery embolization", "TREATMENT", 96, 123], ["recurrent liver cancer", "PROBLEM", 128, 150], ["lung metastasis", "PROBLEM", 155, 170], ["liver", "ANATOMY", 20, 25], ["cancer", "OBSERVATION", 26, 32], ["hepatic artery", "ANATOMY", 96, 110], ["embolization", "OBSERVATION", 111, 123], ["liver", "ANATOMY", 138, 143], ["cancer", "OBSERVATION", 144, 150], ["lung", "ANATOMY", 155, 159], ["metastasis", "OBSERVATION", 160, 170]]], ["He was hospitalized in PSMH from May 18-29, 2015 because of poor general condition.", [["poor general condition", "PROBLEM", 60, 82]]], ["He was referred to GSBH on May 29 and died there on June 6.", [["He", "ORGANISM", 0, 2]]], ["He was tested twice for MERS-CoV (sputum on May 29 and endotracheal aspiration on June 1) before his death, with negative results, and chest radiography (May 29) did not yield clear pneumonia findings.", [["death", "DISEASE", 101, 106], ["pneumonia", "DISEASE", 182, 191], ["He", "ORGANISM", 0, 2], ["MERS-CoV", "SPECIES", 24, 32], ["MERS", "PROBLEM", 24, 28], ["CoV (sputum", "PROBLEM", 29, 40], ["endotracheal aspiration", "PROBLEM", 55, 78], ["chest radiography", "TEST", 135, 152], ["clear pneumonia findings", "PROBLEM", 176, 200], ["chest", "ANATOMY", 135, 140], ["pneumonia", "OBSERVATION", 182, 191]]], ["However, he developed fever on June 2 and the chest radiography taken on June 4 showed findings suspicious pneumonia.", [["chest", "ANATOMY", 46, 51], ["fever", "DISEASE", 22, 27], ["pneumonia", "DISEASE", 107, 116], ["fever", "PROBLEM", 22, 27], ["the chest radiography", "TEST", 42, 63], ["pneumonia", "PROBLEM", 107, 116], ["fever", "OBSERVATION", 22, 27], ["chest", "ANATOMY", 46, 51], ["suspicious", "OBSERVATION_MODIFIER", 96, 106], ["pneumonia", "OBSERVATION", 107, 116]]], ["And no additional MERS test was performed after then.", [["additional MERS test", "TEST", 7, 27]]], ["He was completely bed-ridden throughout hospitalization.", [["He", "ORGANISM", 0, 2]]], ["He was admitted to Room 8104 in PSMH the day after discharge of #1 from the same room.", [["He", "ORGANISM", 0, 2]]], ["There was no MERS patient in Room 7110, where he stayed for the next 8 days (Tables 1 and 2, Figures 2 and 3).Pyeongtaek St. Mary\u2019s Hospital ::: Suspected exposure events and transmission routes ::: RESULTSDuring the time when #178 visited his father in PSMH (May 18-29), he might be exposed to MERS patients (#6, #9, #11, #12, #13, #14, #21, #28, #29, #32, #42, #43, and #53).", [["MERS", "DISEASE", 295, 299], ["patient", "ORGANISM", 18, 25], ["patients", "ORGANISM", 300, 308], ["patient", "SPECIES", 18, 25], ["patients", "SPECIES", 300, 308], ["no", "UNCERTAINTY", 10, 12], ["MERS", "OBSERVATION", 13, 17]]], ["If #178 was infected in PSMH by May 29, the incubation period had exceeded 2 weeks due to showing the symptoms on Jun 16 (Tables 1 and 2, Figures 2 and 3).Pyeongtaek Good Samaritan Bagae Hospital ::: Suspected exposure events and transmission routes ::: RESULTSThe possibility that #178 was infected by other MERS patients in GSBH during the period he visited his father (May 29-June 6) was investigated.", [["PSMH", "CANCER", 24, 28], ["patients", "ORGANISM", 314, 322], ["GSBH", "CANCER", 326, 330], ["patients", "SPECIES", 314, 322], ["the symptoms", "PROBLEM", 98, 110], ["Jun", "TEST", 114, 117], ["infected", "OBSERVATION", 12, 20]]], ["However, #22 did not leave the room, and there was no contact between #22 and #178 (Tables 1 and 2, Figure 2).#178\u2019s wife and mother ::: Suspected exposure events and transmission routes ::: RESULTSBecause #178\u2019s wife and mother provided care for #178\u2019s father during hospitalization, we evaluated the possibility that they became infected and transmitted MERS-CoV to #178.", [["MERS-CoV", "ORGANISM", 356, 364], ["MERS-CoV", "SPECIES", 356, 364], ["infected", "PROBLEM", 331, 339], ["infected", "OBSERVATION", 331, 339]]], ["In particular, #178\u2019s wife received outpatient treatment for upper respiratory symptoms 4 times (May 25, 27, 30, and June 3), which raised the suspicion that she was a mild case of MERS [4].", [["respiratory", "ANATOMY", 67, 78], ["upper respiratory symptoms", "DISEASE", 61, 87], ["MERS", "DISEASE", 181, 185], ["outpatient treatment", "TREATMENT", 36, 56], ["upper respiratory symptoms", "PROBLEM", 61, 87], ["upper", "ANATOMY_MODIFIER", 61, 66], ["respiratory", "ANATOMY", 67, 78]]], ["However, four sputum samples (June 26-July 2) from her yielded negative results, as did the serum test (June 25).", [["sputum samples", "ANATOMY", 14, 28], ["serum", "ANATOMY", 92, 97], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["four sputum samples", "TEST", 9, 28], ["the serum test", "TEST", 88, 102]]], ["And #178\u2019s mother had no symptoms and showed negative sputum result, without no serum test (Tables 1 and 2, Figure 2).Pyeongtaek community ::: Suspected exposure events and transmission routes ::: RESULTSDuring the incubation period for #178, many MERS patients were in Pyeongtaek.", [["sputum", "ANATOMY", 54, 60], ["serum", "ANATOMY", 80, 85], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["symptoms", "PROBLEM", 25, 33], ["serum test", "TEST", 80, 90], ["Tables", "TEST", 92, 98]]], ["Therefore, the possibility of infection in community was evaluated.", [["infection", "DISEASE", 30, 39], ["infection", "PROBLEM", 30, 39], ["possibility of", "UNCERTAINTY", 15, 29], ["infection", "OBSERVATION", 30, 39]]], ["We investigated the movements of 4 cases (#32, #40, #53, and #119) who were possibly active in the downtown of the same district around June 2-6.", [["possibly", "UNCERTAINTY", 76, 84], ["active", "OBSERVATION_MODIFIER", 85, 91]]], ["We considered the time of symptom onset (June 16) in #178, and compared this with the times of possible exposure.", [["symptom onset", "PROBLEM", 26, 39]]], ["The comparison of movements yielded the following results: while there was no overlapping area with #40, contacts with #32 (June 2), #53 (June 2 and 3), and #119 (June 2 and 4) could not be excluded because they were not isolated, and movement analyses could not clearly prove that they had no overlapping zones (Tables 1 and 2, Figure 2).Preventive measures for those in contact with #178 ::: RESULTSEighty-one individuals who had contact with #178 after symptom onset, including his wife, colleagues, and medical staffs, were quarantined.", [["individuals", "ORGANISM", 412, 423], ["overlapping area", "PROBLEM", 78, 94], ["movement analyses", "TEST", 235, 252]]], ["No additional MERS transmission was observed through the maximum possible incubation period (Figure 1).DISCUSSIONWe performed an in-depth investigation on #178 who had unclear modes of transmission.", [["additional MERS transmission", "PROBLEM", 3, 31], ["MERS", "OBSERVATION", 14, 18]]], ["The results yielded two possibilities: infection during visits to his father who was a suspected false negative patient, and infection from other MERS patients in the hospital under the assumption that the incubation period was exceptionally long (Figure 3).DISCUSSIONIf it is postulated that #178 was infected through his father, three scenarios may be considered for his father\u2019s infection: i) from the contaminated environment during the 2 days in Room 8104; ii) from the other patients during the 2 days in Room 8112; and iii) from repeated exposure to MERS-CoV in other areas within the hospital.", [["infection", "DISEASE", 39, 48], ["infection", "DISEASE", 125, 134], ["MERS", "DISEASE", 146, 150], ["infection", "DISEASE", 382, 391], ["patient", "ORGANISM", 112, 119], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 481, 489], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 557, 565], ["patient", "SPECIES", 112, 119], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 481, 489], ["MERS-CoV", "SPECIES", 557, 565], ["infection", "PROBLEM", 39, 48], ["infection", "PROBLEM", 125, 134], ["infection", "OBSERVATION", 39, 48]]], ["If his father was actually a false negative patient, a plausible scenario would be that #178 was infected from his father during visits, especially around June 6, the date of his father\u2019s death.", [["death", "DISEASE", 188, 193], ["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51]]], ["However, except for vague findings of pneumonia, his father showed no clear MERS symptoms, and the sputum test was negative, as were those of 5 other family members contacted his father.", [["sputum", "ANATOMY", 99, 105], ["pneumonia", "DISEASE", 38, 47], ["pneumonia", "PROBLEM", 38, 47], ["clear MERS symptoms", "PROBLEM", 70, 89], ["the sputum test", "TEST", 95, 110], ["pneumonia", "OBSERVATION", 38, 47], ["no", "UNCERTAINTY", 67, 69]]], ["As his father is dead, it could not be verified whether he was a patient.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72]]], ["A 66-year-old man developed high fever on returning home after meeting his 30-year-old daughter in Qatar, and died 5 days after hospitalization (12 days after symptom onset).", [["fever", "DISEASE", 33, 38], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["high fever", "PROBLEM", 28, 38], ["high", "OBSERVATION_MODIFIER", 28, 32], ["fever", "OBSERVATION", 33, 38]]], ["The MERS PCR test performed the day before his death was negative.", [["death", "DISEASE", 47, 52], ["The MERS PCR test", "TEST", 0, 17], ["his death", "TEST", 43, 52], ["negative", "OBSERVATION", 57, 65]]], ["His 34-year-old son took care of him during his illness, developed MERS symptoms with high fever 3 days after the funeral, and was confirmed.", [["fever", "DISEASE", 91, 96], ["MERS symptoms", "PROBLEM", 67, 80], ["high fever", "PROBLEM", 86, 96]]], ["The son had no foreign travel, and as this was the first MERS case in Tunisia, the only possibility was infection from the father.", [["infection", "DISEASE", 104, 113], ["infection", "PROBLEM", 104, 113], ["foreign travel", "OBSERVATION", 15, 29], ["infection", "OBSERVATION", 104, 113]]], ["The Tunisian public health office sent the father\u2019s serum taken before his death to the US Centers for Disease Control, and it was MERS-positive [4].", [["serum", "ANATOMY", 52, 57], ["death", "DISEASE", 75, 80], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["Disease Control", "TREATMENT", 103, 118]]], ["In Korea, there was also a #119 case in which a negative diagnosis on the first test was corrected to positive with additional tests.", [["the first test", "TEST", 70, 84], ["additional tests", "TEST", 116, 132]]], ["Unlike the Tunisian case, a confirmatory test was not possible because the father\u2019s serum was not stored [5].DISCUSSIONThe second scenario assumes a long incubation period.", [["serum", "ANATOMY", 84, 89], ["father", "ORGANISM", 75, 81], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["a confirmatory test", "TEST", 26, 45]]], ["The estimated incubation period in this scenario is 18 days, which is considerably longer than the known 2-14 days, but is statistically possible.DISCUSSIONOther modes of transmission were evaluated and excluded.", [["The estimated incubation period", "TREATMENT", 0, 31], ["incubation", "OBSERVATION_MODIFIER", 14, 24], ["period", "OBSERVATION_MODIFIER", 25, 31], ["18 days", "OBSERVATION_MODIFIER", 52, 59], ["statistically possible", "UNCERTAINTY", 123, 145]]], ["First, the possibility of being infected from the other 3 MERS patients in GSBH could be excluded by confirming no direct contact.", [["patients", "ORGANISM", 63, 71], ["GSBH", "CANCER", 75, 79], ["patients", "SPECIES", 63, 71], ["possibility of", "UNCERTAINTY", 11, 25], ["infected", "OBSERVATION", 32, 40], ["could be excluded", "UNCERTAINTY", 80, 97]]], ["Community-acquired infection is possible, but it is less plausible than others, more so considering the MERS-specific transmission patterns are in hospital settings and through close contact [6].", [["infection", "DISEASE", 19, 28], ["acquired infection", "PROBLEM", 10, 28], ["infection", "OBSERVATION", 19, 28]]], ["The possibility of error regarding #178\u2019s symptom onset date was also considered; however, we could exclude this revealing that he did not have any symptoms before June 16, and that he did not visit medical facilities before June 16 (Table 2).DISCUSSIONFrom the standpoint of prevention, there are lessons learned.", [["any symptoms", "PROBLEM", 144, 156]]], ["Although #178 and his family were exposed to MERS-CoV in PSMH, and belonged to the subjects for initial quarantine, they were not closely monitored.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 45, 53], ["MERS-CoV", "SPECIES", 45, 53]]], ["Although she received outpatient treatment for respiratory symptoms several times, #178\u2019s wife was not subjected to MERS testing.", [["respiratory", "ANATOMY", 47, 58], ["respiratory symptoms", "DISEASE", 47, 67], ["outpatient treatment", "TREATMENT", 22, 42], ["respiratory symptoms", "PROBLEM", 47, 67], ["MERS testing", "TEST", 116, 128]]], ["His family kept providing care for #178\u2019s father in GSBH without precautionary measures, even after transfer from PSMH.", [["GSBH", "CANCER", 52, 56], ["precautionary measures", "TREATMENT", 65, 87]]], ["No additional MERS testing was undertaken after the sputum-negative for #178\u2019s father.", [["additional MERS testing", "TEST", 3, 26], ["the sputum", "TEST", 48, 58], ["MERS", "OBSERVATION", 14, 18]]], ["The funeral was held without any precautionary measures.", [["any precautionary measures", "TREATMENT", 29, 55]]], ["After #178 returned to Pyeongtaek following the funeral, he came into contact with a large number of individuals after symptom onset.", [["symptom onset", "PROBLEM", 119, 132]]], ["Fortunately, no additional MERS cases occurred among those in contact with #178.", [["additional MERS cases", "PROBLEM", 16, 37], ["no", "UNCERTAINTY", 13, 15]]], ["In addition, those in contact with #178\u2019s father, including relatives, GSBH staffs, and those who transported or shrouded the corpse, did not develop any symptoms.DISCUSSIONIn conclusion, we arrived at two plausible scenarios: intrafamilial spread through the father and a prolonged incubation period from the infection at PSMH.", [["infection", "DISEASE", 310, 319], ["any symptoms", "PROBLEM", 150, 162], ["the infection at PSMH", "PROBLEM", 306, 327], ["infection", "OBSERVATION", 310, 319]]]], "25c010bda0dd4f0e74edde37105e4204f75ccba7": [["The fact that Parkinson's patients get COVID-19 is probably because their main medication was Levodopa and not amantadine.", [["Parkinson", "DISEASE", 14, 23], ["Levodopa", "CHEMICAL", 94, 102], ["amantadine", "CHEMICAL", 111, 121], ["COVID-19", "CHEMICAL", 39, 47], ["Levodopa", "CHEMICAL", 94, 102], ["amantadine", "CHEMICAL", 111, 121], ["patients", "ORGANISM", 26, 34], ["Levodopa", "SIMPLE_CHEMICAL", 94, 102], ["amantadine", "SIMPLE_CHEMICAL", 111, 121], ["patients", "SPECIES", 26, 34], ["Parkinson's", "PROBLEM", 14, 25], ["COVID", "TEST", 39, 44], ["Levodopa", "TREATMENT", 94, 102], ["amantadine", "TREATMENT", 111, 121]]]], "PMC7301834": [["We read with great interest the research letter by Tadolini et al. in which they have published the first cohort of 49 cases of TB and COVID-19 co-infection.", [["TB", "DISEASE", 128, 130], ["infection", "DISEASE", 147, 156], ["COVID-19", "SPECIES", 135, 143], ["TB", "PROBLEM", 128, 130], ["COVID", "TEST", 135, 140], ["co-infection", "PROBLEM", 144, 156], ["infection", "OBSERVATION", 147, 156]]]], "52adcc8bb78ae8b4b0066f73445a9d10cd77810d": [["U N C O R R E C T E D M A N U S C R I P T 2ABSTRACTIn march 2020, a pandemic of respiratory infection due to the SARS-CoV2 is underway, dengue fever epidemics are at the same time present in many regions of the inter-equatorial zone.", [["respiratory infection", "DISEASE", 80, 101], ["SARS", "DISEASE", 113, 117], ["dengue fever", "DISEASE", 136, 148], ["respiratory infection", "PROBLEM", 80, 101], ["the SARS", "PROBLEM", 109, 117], ["dengue fever epidemics", "PROBLEM", 136, 158], ["respiratory", "ANATOMY", 80, 91], ["infection", "OBSERVATION", 92, 101], ["regions", "ANATOMY_MODIFIER", 196, 203], ["inter-equatorial", "ANATOMY_MODIFIER", 211, 227], ["zone", "ANATOMY_MODIFIER", 228, 232]]], ["We report the first cases of covid19-dengue co-infection, which occurred in Mayotte, aABSTRACTFrench island in the Indian Ocean.Highlightreported, mostly DENV1 serotypes.", [["dengue co-infection", "DISEASE", 37, 56], ["covid19", "GENE_OR_GENE_PRODUCT", 29, 36], ["DENV1", "GENE_OR_GENE_PRODUCT", 154, 159], ["covid19-dengue co-infection", "PROBLEM", 29, 56], ["mostly DENV1 serotypes", "PROBLEM", 147, 169], ["co-infection", "OBSERVATION", 44, 56], ["mostly", "OBSERVATION_MODIFIER", 147, 153], ["DENV1 serotypes", "OBSERVATION", 154, 169]]], ["It is therefore likely that the patient acquired dengue upon returning from France, as the incubation time for COVID-19 is 3 to 5 days in general, but can be up to 14 days, as it is 2 to 7 days for dengue fever, being up to 14 days as well.HighlightTo our knowledge, COVID19 and dengue virus co-infection has not been reported yet, In the present case, it was not the biological assessment which challenged the clinicians, but the occurrence of a diffuse exanthema, which prompted the search for dengue fever.", [["dengue", "DISEASE", 49, 55], ["dengue fever", "DISEASE", 198, 210], ["dengue virus co-infection", "DISEASE", 279, 304], ["exanthema", "DISEASE", 455, 464], ["dengue fever", "DISEASE", 496, 508], ["patient", "ORGANISM", 32, 39], ["COVID19", "GENE_OR_GENE_PRODUCT", 267, 274], ["dengue virus", "ORGANISM", 279, 291], ["patient", "SPECIES", 32, 39], ["dengue", "SPECIES", 198, 204], ["dengue virus", "SPECIES", 279, 291], ["dengue", "PROBLEM", 49, 55], ["COVID", "TEST", 111, 116], ["dengue fever", "PROBLEM", 198, 210], ["COVID19", "TEST", 267, 274], ["dengue virus co-infection", "PROBLEM", 279, 304], ["the biological assessment", "TEST", 364, 389], ["a diffuse exanthema", "PROBLEM", 445, 464], ["dengue fever", "PROBLEM", 496, 508], ["therefore likely", "UNCERTAINTY", 6, 22], ["diffuse", "OBSERVATION_MODIFIER", 447, 454], ["exanthema", "OBSERVATION", 455, 464]]], ["InHighlightThailand, at the beginning of the epidemics, a case was reported describing a COVID-19 patient who initially presented with a skin rash, which was initially considered as a dengue infection, before the diagnosis was corrected.", [["skin", "ANATOMY", 137, 141], ["skin rash", "DISEASE", 137, 146], ["dengue infection", "DISEASE", 184, 200], ["patient", "ORGANISM", 98, 105], ["skin", "ORGAN", 137, 141], ["patient", "SPECIES", 98, 105], ["dengue", "SPECIES", 184, 190], ["a skin rash", "PROBLEM", 135, 146], ["a dengue infection", "PROBLEM", 182, 200], ["skin", "ANATOMY", 137, 141], ["rash", "OBSERVATION", 142, 146], ["infection", "OBSERVATION", 191, 200]]], ["5 In Lombardy, Italy, erythematous rash was the most common lesion among 88 patients with proved COVID-19 infection.", [["lesion", "ANATOMY", 60, 66], ["rash", "DISEASE", 35, 39], ["infection", "DISEASE", 106, 115], ["lesion", "CANCER", 60, 66], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["erythematous rash", "PROBLEM", 22, 39], ["COVID-19 infection", "PROBLEM", 97, 115], ["erythematous", "OBSERVATION_MODIFIER", 22, 34], ["rash", "OBSERVATION", 35, 39], ["most common", "OBSERVATION_MODIFIER", 48, 59], ["infection", "OBSERVATION", 106, 115]]], ["Thus, COVID-19 may present with cutaneous manifestations, which could be confused with dengue fever.HighlightTo conclude, COVID1-19 and dengue virus epidemics occur at the same time in tropical areas and lead to 2 major challenges: the misdiagnosis of two infections with similar presentation and the risk of greater severity.", [["cutaneous", "ANATOMY", 32, 41], ["dengue fever", "DISEASE", 87, 99], ["dengue virus epidemics", "DISEASE", 136, 158], ["infections", "DISEASE", 256, 266], ["COVID-19", "GENE_OR_GENE_PRODUCT", 6, 14], ["COVID1-19", "ORGANISM", 122, 131], ["dengue virus", "ORGANISM", 136, 148], ["dengue virus", "SPECIES", 136, 148], ["cutaneous manifestations", "PROBLEM", 32, 56], ["dengue fever", "PROBLEM", 87, 99], ["COVID1", "TEST", 122, 128], ["dengue virus epidemics", "PROBLEM", 136, 158], ["two infections", "PROBLEM", 252, 266], ["greater severity", "PROBLEM", 309, 325], ["infections", "OBSERVATION", 256, 266], ["greater", "OBSERVATION_MODIFIER", 309, 316], ["severity", "OBSERVATION_MODIFIER", 317, 325]]]], "4d9a65086f2f6ba5a9c1d9ba0a69a6bd5fb6e21e": [["IntroductionThe novel coronavirus disease 2019 (COVID-19) pandemic has led to more than 24 million confirmed cases and over 820,000 deaths worldwide as of late August 2020.IntroductionEarly observational studies reported high rates of venous thromboembolism (VTE) in critically ill patients with COVID-19.", [["venous", "ANATOMY", 235, 241], ["coronavirus disease", "DISEASE", 22, 41], ["COVID-19", "CHEMICAL", 48, 56], ["deaths", "DISEASE", 132, 138], ["venous thromboembolism", "DISEASE", 235, 257], ["VTE", "DISEASE", 259, 262], ["critically ill", "DISEASE", 267, 281], ["COVID-19", "CHEMICAL", 296, 304], ["coronavirus", "ORGANISM", 22, 33], ["COVID-19", "ORGANISM", 48, 56], ["venous thromboembolism", "PATHOLOGICAL_FORMATION", 235, 257], ["patients", "ORGANISM", 282, 290], ["patients", "SPECIES", 282, 290], ["coronavirus disease 2019 (COVID-19", "SPECIES", 22, 56], ["The novel coronavirus disease", "PROBLEM", 12, 41], ["COVID", "TEST", 48, 53], ["pandemic", "PROBLEM", 58, 66], ["observational studies", "TEST", 190, 211], ["venous thromboembolism", "PROBLEM", 235, 257], ["COVID", "TEST", 296, 301], ["coronavirus disease", "OBSERVATION", 22, 41], ["venous", "ANATOMY", 235, 241], ["thromboembolism", "OBSERVATION", 242, 257]]], ["1 A recent meta-analysis reported an incidence of 26% for VTE among 3487 patients from 30 studies based on very low-quality evidence due to heterogeneity and risk of bias.", [["VTE", "DISEASE", 58, 61], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["A recent meta-analysis", "TEST", 2, 24], ["VTE", "TEST", 58, 61], ["30 studies", "TEST", 87, 97], ["heterogeneity", "PROBLEM", 140, 153]]], ["2 Furthermore, studies have reported that elevated D-dimer values in COVID-19 are associated with a higher risk of VTE, mechanical ventilation, and mortality.", [["VTE", "DISEASE", 115, 118], ["D-dimer", "GENE_OR_GENE_PRODUCT", 51, 58], ["COVID-19", "GENE_OR_GENE_PRODUCT", 69, 77], ["elevated D-dimer values", "PROBLEM", 42, 65], ["COVID", "TEST", 69, 74], ["VTE", "PROBLEM", 115, 118], ["mechanical ventilation", "TREATMENT", 120, 142], ["elevated", "OBSERVATION_MODIFIER", 42, 50], ["VTE", "OBSERVATION", 115, 118], ["mechanical ventilation", "OBSERVATION", 120, 142]]], ["[3] [4] [5] However, the clinical implications of D-dimer values are unclear.", [["[3] [4", "SIMPLE_CHEMICAL", 0, 6], ["D-dimer", "SIMPLE_CHEMICAL", 50, 57], ["D-dimer values", "TEST", 50, 64]]], ["We report VTE rates and analyze the diagnostic performance and relationship of D-dimer with VTE in a large observational cohort study of hospitalized adults with COVID-19.MethodsWe conducted a retrospective observational cohort study at New York-Presbyterian Hospital/Weill Cornell Medical Center, a quaternary referral center located in the Upper East Side of Manhattan, and New York-Presbyterian/Lower Manhattan Hospital, an affiliated nonteaching hospital.", [["VTE", "DISEASE", 10, 13], ["VTE", "DISEASE", 92, 95], ["D-dimer", "SIMPLE_CHEMICAL", 79, 86], ["D-dimer", "PROTEIN", 79, 86], ["VTE rates", "TEST", 10, 19], ["VTE", "PROBLEM", 92, 95], ["COVID", "TEST", 162, 167], ["Upper", "ANATOMY_MODIFIER", 342, 347]]], ["We included all consecutive adult (age \u226518 years) cases of COVID-19 confirmed by a positive SARS-CoV02 reverse transcriptase-polymerase chain reaction test admitted to our two hospitals between 3 March 2020, the date of the first positive case, and 15 May 2020.", [["CoV02 reverse transcriptase", "PROTEIN", 97, 124], ["COVID", "TEST", 59, 64], ["a positive SARS", "PROBLEM", 81, 96]]], ["For patients who remained hospitalized at the end of the study period, data collection and analysis were complete through 5 June 2020.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the study", "TEST", 53, 62], ["data collection", "TEST", 71, 86], ["analysis", "TEST", 91, 99]]], ["Univariate analysis and multivariable logistic regression analysis were performed to evaluate the association between the initial D-dimer value during hospitalization, clinical characteristics, and the odds of VTE.", [["VTE", "DISEASE", 210, 213], ["D-dimer", "GENE_OR_GENE_PRODUCT", 130, 137], ["Univariate analysis", "TEST", 0, 19], ["multivariable logistic regression analysis", "TEST", 24, 66], ["VTE", "PROBLEM", 210, 213]]], ["Complete case analysis was used for the multivariable logistic regression.", [["Complete case analysis", "TEST", 0, 22], ["the multivariable logistic regression", "PROBLEM", 36, 73]]], ["Clinical characteristics with P values less than 0.05 in the univariate analysis were included in the multivariable logistic regression analysis. significantly changed.", [["P values", "TEST", 30, 38], ["the univariate analysis", "TEST", 57, 80], ["the multivariable logistic regression analysis", "TEST", 98, 144]]], ["We calculated 95% confidence intervals (CIs) for the likelihood ratios at each level (mutually exclusive, all-inclusive ranges for D-dimer values) to demonstrate non-overlapping CIs.ResultsA total of 1739 hospitalized patients with COVID-19 were included in the study.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 131, 138], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["CIs", "TEST", 40, 43], ["the likelihood ratios", "TEST", 49, 70], ["D-dimer values", "TEST", 131, 145], ["non-overlapping CIs", "PROBLEM", 162, 181], ["COVID", "TEST", 232, 237], ["the study", "TEST", 258, 267], ["non-overlapping CIs", "OBSERVATION", 162, 181]]], ["The median age was 66.5 years (IQR 53.7-77.3), 59% were men, and common comorbidities included hypertension (56%), diabetes mellitus (31%) and obesity (30%).", [["hypertension", "DISEASE", 95, 107], ["diabetes mellitus", "DISEASE", 115, 132], ["obesity", "DISEASE", 143, 150], ["men", "ORGANISM", 56, 59], ["men", "SPECIES", 56, 59], ["IQR", "TEST", 31, 34], ["common comorbidities", "PROBLEM", 65, 85], ["hypertension", "PROBLEM", 95, 107], ["diabetes mellitus", "PROBLEM", 115, 132], ["obesity", "PROBLEM", 143, 150], ["hypertension", "OBSERVATION", 95, 107], ["obesity", "OBSERVATION", 143, 150]]], ["Multilevel likelihood ratios significantly changed at the following D-dimer levels: <1000 ng/mL: 0.14 (95% CI, 0.07-0.30); 1000-7500 ng/mL: 1.19 (0.97-1.47); and >7500 ng/mL: 4.10 (2.94-5.71) ( Table 1) .", [["D-dimer", "GENE_OR_GENE_PRODUCT", 68, 75], ["Multilevel likelihood ratios", "PROBLEM", 0, 28], ["D-dimer levels", "TEST", 68, 82], ["CI", "TEST", 107, 109], ["ratios", "OBSERVATION_MODIFIER", 22, 28], ["significantly", "OBSERVATION_MODIFIER", 29, 42]]], ["With an overall prevalence of VTE of 16%, the posttest probabilities of VTE at each level were: 0.03 (95% CI, 0.01-0.05), 0.18 (0.14-0.23), and 0.43 (0.33-0.53), respectively.DiscussionIn our study of a large cohort of hospitalized COVID-19 patients in New York City the prevalence of objectively confirmed VTE was 7%.", [["VTE", "DISEASE", 30, 33], ["VTE", "DISEASE", 72, 75], ["COVID", "DISEASE", 232, 237], ["VTE", "DISEASE", 307, 310], ["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["VTE", "TEST", 30, 33], ["VTE", "TEST", 72, 75], ["CI", "TEST", 106, 108], ["VTE", "TEST", 307, 310]]], ["The rate of VTE in our patients with COVID-19 was lower than what was previously reported in European and Asian studies, J o u r n a l P r e -p r o o f Journal Pre-proof but similar to a recent US study comprising 400 patients (144 critically ill) in which the overall rate VTE and the rate of VTE in critically COVID-19 patients was 4.8% and 7.6%, respectively .", [["VTE", "DISEASE", 12, 15], ["critically ill", "DISEASE", 232, 246], ["VTE", "DISEASE", 274, 277], ["VTE", "DISEASE", 294, 297], ["COVID-19", "CHEMICAL", 37, 45], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 321, 329], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 321, 329], ["VTE", "PROBLEM", 12, 15], ["COVID", "TEST", 37, 42], ["a recent US study", "TEST", 185, 202], ["the overall rate VTE", "PROBLEM", 257, 277], ["the rate", "TEST", 282, 290], ["VTE", "TEST", 294, 297], ["critically COVID", "TEST", 301, 317], ["VTE", "OBSERVATION", 12, 15]]], ["[1] [2] 6 Elevated D-dimer levels were associated with higher probability of VTE, consistent with reports by others.", [["VTE", "DISEASE", 77, 80], ["[1] [2] 6", "SIMPLE_CHEMICAL", 0, 9], ["D-dimer", "SIMPLE_CHEMICAL", 19, 26], ["Elevated D-dimer levels", "TEST", 10, 33], ["VTE", "PROBLEM", 77, 80], ["VTE", "OBSERVATION", 77, 80], ["consistent with", "UNCERTAINTY", 82, 97]]], ["1 Other significant predictors of VTE in our cohort included Black race, need for supplemental oxygen on presentation, higher platelet counts, and prolonged prothrombin time.", [["platelet", "ANATOMY", 126, 134], ["VTE", "DISEASE", 34, 37], ["oxygen", "CHEMICAL", 95, 101], ["oxygen", "CHEMICAL", 95, 101], ["oxygen", "SIMPLE_CHEMICAL", 95, 101], ["platelet", "CELL", 126, 134], ["prothrombin", "GENE_OR_GENE_PRODUCT", 157, 168], ["prothrombin", "PROTEIN", 157, 168], ["VTE", "PROBLEM", 34, 37], ["supplemental oxygen", "TREATMENT", 82, 101], ["higher platelet counts", "TEST", 119, 141], ["prolonged prothrombin time", "PROBLEM", 147, 173], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["VTE", "OBSERVATION", 34, 37]]], ["Higher odds of VTE among Black patients has been reported previously.", [["VTE", "DISEASE", 15, 18], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["VTE", "PROBLEM", 15, 18], ["VTE", "OBSERVATION", 15, 18]]], ["7 A possible explanation for this is that Black patients have a greater prevalence of comorbidities such as obesity, hypertension and diabetes, and may have sickle cell trait.", [["sickle cell", "ANATOMY", 157, 168], ["obesity", "DISEASE", 108, 115], ["hypertension", "DISEASE", 117, 129], ["diabetes", "DISEASE", 134, 142], ["sickle cell trait", "DISEASE", 157, 174], ["patients", "ORGANISM", 48, 56], ["sickle cell", "CELL", 157, 168], ["patients", "SPECIES", 48, 56], ["comorbidities", "PROBLEM", 86, 99], ["obesity", "PROBLEM", 108, 115], ["hypertension", "PROBLEM", 117, 129], ["diabetes", "PROBLEM", 134, 142], ["sickle cell trait", "PROBLEM", 157, 174], ["possible explanation for", "UNCERTAINTY", 4, 28], ["obesity", "OBSERVATION", 108, 115], ["hypertension", "OBSERVATION", 117, 129], ["diabetes", "OBSERVATION", 134, 142], ["sickle cell trait", "OBSERVATION", 157, 174]]], ["8 In our analysis of the diagnostic performance of D-dimer values, we identified three levels of D-dimer that stratified patients into low-probability (<1000 ng/mL), intermediate-probability (1000-7500 ng/mL), and high-probability groups (>7500 ng/mL).", [["D-dimer", "SIMPLE_CHEMICAL", 51, 58], ["D-dimer", "GENE_OR_GENE_PRODUCT", 97, 104], ["patients", "ORGANISM", 121, 129], ["D-dimer", "PROTEIN", 97, 104], ["patients", "SPECIES", 121, 129], ["D-dimer values", "TEST", 51, 65], ["D-dimer", "PROBLEM", 97, 104]]], ["With a VTE prevalence of 16% in our D-dimer analysis, the posttest probabilities of VTE at each level were 3%, 18%, and 43%, respectively.", [["VTE", "DISEASE", 7, 10], ["VTE", "DISEASE", 84, 87], ["a VTE prevalence", "TEST", 5, 21], ["our D-dimer analysis", "TEST", 32, 52], ["VTE", "TEST", 84, 87]]], ["A recent study of D-dimer levels in critically ill patients with COVID-19 on intermediate-dose thromboprophylaxis reported that D-dimers <2000 ng/mL had a 100% negative predictive value for VTE and >8000 ng/mL had a significantly increased likelihood ratio, concluding that cut-off points of 2000 ng/mL and 8000 ng/mL appear useful to identify patients with low and high probability of having developed VTE, respectively.", [["critically ill", "DISEASE", 36, 50], ["VTE", "DISEASE", 190, 193], ["VTE", "DISEASE", 403, 406], ["D-dimer", "SIMPLE_CHEMICAL", 18, 25], ["patients", "ORGANISM", 51, 59], ["D-dimers", "SIMPLE_CHEMICAL", 128, 136], ["patients", "ORGANISM", 344, 352], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 344, 352], ["A recent study of D-dimer levels", "TEST", 0, 32], ["COVID", "TEST", 65, 70], ["intermediate-dose thromboprophylaxis", "TREATMENT", 77, 113], ["D-dimers", "TEST", 128, 136], ["VTE", "TEST", 190, 193], ["a significantly increased likelihood ratio", "PROBLEM", 214, 256], ["VTE", "PROBLEM", 403, 406], ["increased", "OBSERVATION_MODIFIER", 230, 239], ["likelihood ratio", "OBSERVATION", 240, 256]]], ["9 We identified similar cut-off points that appear to be useful for identifying patients at varyingData collectionDemographic, clinical characteristics and radiology reports were manually abstracted from electronic medical records using a quality-controlled protocol in a REDCap database.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["a quality-controlled protocol", "TREATMENT", 237, 266], ["a REDCap database", "TEST", 270, 287], ["similar", "OBSERVATION_MODIFIER", 16, 23], ["cut", "OBSERVATION_MODIFIER", 24, 27]]], ["2 Vital signs and laboratory values were extracted using an algorithm-based automated process from electronic medical records.", [["Vital signs", "TEST", 2, 13], ["laboratory values", "TEST", 18, 35], ["an algorithm", "TEST", 57, 69]]], ["The study was approved by the institutional review board, which granted a waiver of informed consent.Clinical characteristicsWe evaluated age, gender, race, ethnicity, comorbidities including obesity (defined as body mass index >30 kg/m 2 ), hypertension, coronary artery disease, heart failure, diabetes mellitus, and active cancer.", [["body", "ANATOMY", 212, 216], ["coronary artery", "ANATOMY", 256, 271], ["heart", "ANATOMY", 281, 286], ["cancer", "ANATOMY", 326, 332], ["obesity", "DISEASE", 192, 199], ["hypertension", "DISEASE", 242, 254], ["coronary artery disease", "DISEASE", 256, 279], ["heart failure", "DISEASE", 281, 294], ["diabetes mellitus", "DISEASE", 296, 313], ["active cancer", "DISEASE", 319, 332], ["body", "ORGANISM_SUBDIVISION", 212, 216], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 256, 271], ["heart", "ORGAN", 281, 286], ["cancer", "CANCER", 326, 332], ["The study", "TEST", 0, 9], ["comorbidities", "PROBLEM", 168, 181], ["obesity", "PROBLEM", 192, 199], ["body mass index", "PROBLEM", 212, 227], ["hypertension", "PROBLEM", 242, 254], ["coronary artery disease", "PROBLEM", 256, 279], ["heart failure", "PROBLEM", 281, 294], ["diabetes mellitus", "PROBLEM", 296, 313], ["active cancer", "PROBLEM", 319, 332], ["obesity", "OBSERVATION", 192, 199], ["hypertension", "OBSERVATION", 242, 254], ["coronary artery", "ANATOMY", 256, 271], ["disease", "OBSERVATION", 272, 279], ["heart", "ANATOMY", 281, 286], ["failure", "OBSERVATION", 287, 294], ["diabetes mellitus", "OBSERVATION", 296, 313], ["active", "OBSERVATION_MODIFIER", 319, 325], ["cancer", "OBSERVATION", 326, 332]]], ["Presenting signs and symptoms on hospital admission included dyspnea, chest pain, initial heart rate, systolic and diastolic blood pressure, and need for supplemental oxygen at presentation (defined as within three J o u r n a l P r e -p r o o f", [["chest", "ANATOMY", 70, 75], ["heart", "ANATOMY", 90, 95], ["blood", "ANATOMY", 125, 130], ["dyspnea", "DISEASE", 61, 68], ["chest pain", "DISEASE", 70, 80], ["heart rate, systolic and diastolic blood pressure", "DISEASE", 90, 139], ["oxygen", "CHEMICAL", 167, 173], ["oxygen", "CHEMICAL", 167, 173], ["chest", "ORGANISM_SUBDIVISION", 70, 75], ["heart", "ORGAN", 90, 95], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["oxygen", "SIMPLE_CHEMICAL", 167, 173], ["symptoms", "PROBLEM", 21, 29], ["dyspnea", "PROBLEM", 61, 68], ["chest pain", "PROBLEM", 70, 80], ["initial heart rate", "TEST", 82, 100], ["systolic", "TEST", 102, 110], ["diastolic blood pressure", "TEST", 115, 139], ["supplemental oxygen", "TREATMENT", 154, 173], ["chest", "ANATOMY", 70, 75], ["heart", "ANATOMY", 90, 95], ["diastolic", "ANATOMY", 115, 124], ["blood pressure", "OBSERVATION", 125, 139]]]], "65178a50f1ca33617faea97f86a8d9c2d6fb2e68": [["Impact of Model Shape Mismatch on ReconstructionQuality in Electrical Impedance TomographyI.", [["Model Shape Mismatch", "TREATMENT", 10, 30], ["Model", "OBSERVATION_MODIFIER", 10, 15], ["Shape", "OBSERVATION_MODIFIER", 16, 21], ["Mismatch", "OBSERVATION", 22, 30]]], ["INTRODUCTIONE LECTRICAL impedance tomography (EIT) is a promising medical imaging modality for monitoring ventilation distribution in the lung.", [["lung", "ANATOMY", 138, 142], ["lung", "ORGAN", 138, 142], ["medical imaging modality", "TEST", 66, 90], ["lung", "ANATOMY", 138, 142]]], ["In thoracic EIT, imperceptible current injection and voltage measurement through surface electrodes around the thorax are used to reconstruct a conductivity map across a transverse slice of the body.", [["thoracic", "ANATOMY", 3, 11], ["surface", "ANATOMY", 81, 88], ["thorax", "ANATOMY", 111, 117], ["body", "ANATOMY", 194, 198], ["thorax", "ORGAN", 111, 117], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["imperceptible current injection", "TREATMENT", 17, 48], ["voltage measurement through surface electrodes", "TREATMENT", 53, 99], ["a conductivity map", "TEST", 142, 160], ["thoracic", "ANATOMY", 3, 11], ["thorax", "ANATOMY", 111, 117], ["transverse", "OBSERVATION_MODIFIER", 170, 180], ["body", "ANATOMY", 194, 198]]], ["EIT is low-cost, noninvasive, radiation free, and available at the bedside.", [["low", "OBSERVATION_MODIFIER", 7, 10]]], ["One of the most promising applications of EIT is for monitoring and/or guiding mechanical ventilation therapy.", [["monitoring", "TEST", 53, 63], ["mechanical ventilation therapy", "TREATMENT", 79, 109], ["ventilation therapy", "OBSERVATION", 90, 109]]], ["The ability of EIT to measure regional distribution of ventilation has been validated against single photon emission computed tomography (SPECT) [1] , X-ray computed tomography (CT) [2] , [3] , and positron emission tomography (PET) [4] .", [["ventilation", "TREATMENT", 55, 66], ["single photon emission computed tomography", "TEST", 94, 136], ["X-ray computed tomography (CT)", "TEST", 151, 181], ["positron emission tomography", "TEST", 198, 226]]], ["No other currently available technology can provide real-time long term monitoring of the regional functional state of the lungs.", [["lungs", "ANATOMY", 123, 128], ["lungs", "ORGAN", 123, 128], ["lungs", "ANATOMY", 123, 128]]], ["Although such information could be invaluable in preventing ventilator-induced lung injury (VILI), clinical application of EIT is hindered by difficulties in interpreting the resulting images.I. INTRODUCTIONSuch difficulties are often a result of errors in the forward modeling of the electrical fields, a necessary step in reconstructing the conductivity distribution.", [["lung", "ANATOMY", 79, 83], ["ventilator-induced lung injury", "DISEASE", 60, 90], ["VILI", "DISEASE", 92, 96], ["lung", "ORGAN", 79, 83], ["ventilator", "TREATMENT", 60, 70], ["lung injury", "PROBLEM", 79, 90], ["the resulting images", "TEST", 171, 191], ["lung", "ANATOMY", 79, 83], ["injury", "OBSERVATION", 84, 90]]], ["In particular, no 2-D model can fit EIT data obtained from a 3-D domain (body) [5] and, even when a 3-D model of a domain is used, it is generally impossible to accurately fit data from an isotropic conductivity distribution if the boundary shape is wrong [6] .I. INTRODUCTIONBecause in clinical practice the boundary shape is generally unknown and changes with breathing and posture, the problem is often reduced to reconstructing the changes rather than absolute conductivity, which is less sensitive to shape mismatch and easier to solve.", [["EIT data", "TEST", 36, 44], ["a 3-D domain (body)", "TREATMENT", 59, 78], ["an isotropic conductivity distribution", "TREATMENT", 186, 224], ["absolute conductivity", "PROBLEM", 456, 477], ["less sensitive", "OBSERVATION_MODIFIER", 488, 502]]], ["A circular shape has traditionally been used to represent a cross section of the subject's body [7] .", [["body", "ANATOMY", 91, 95], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["A circular shape", "PROBLEM", 0, 16], ["circular", "OBSERVATION_MODIFIER", 2, 10], ["shape", "OBSERVATION_MODIFIER", 11, 16]]], ["This lack of correspondence to the anatomy imposes several limitations on the analysis of EIT images.", [["the analysis", "TEST", 74, 86], ["EIT images", "TEST", 90, 100]]], ["Because expected organ shape and position on circular images is unknown, it is difficult to distinguish some artifacts from correct images.", [["organ", "ANATOMY", 17, 22], ["organ", "ORGAN", 17, 22], ["circular images", "TEST", 45, 60], ["correct images", "TEST", 124, 138], ["shape", "OBSERVATION_MODIFIER", 23, 28], ["position", "OBSERVATION_MODIFIER", 33, 41], ["artifacts", "OBSERVATION", 109, 118]]], ["Images of different patients cannot be directly compared.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["Images", "TEST", 0, 6]]], ["Moreover, the mismatch between the true body shape and the shape used for reconstruction is known to produce image errors [8] , [6] , which to date have not been properly characterized.I. INTRODUCTIONIn a preliminary study of one reconstruction algorithm [9] , we showed that using the correct body shape obtained from a CT scan produces reconstructions qualitatively superior to those produced with a circular shape.", [["body", "ANATOMY", 40, 44], ["body", "ANATOMY", 294, 298], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["body", "ORGANISM_SUBDIVISION", 294, 298], ["the mismatch between the true body shape", "PROBLEM", 10, 50], ["reconstruction", "TREATMENT", 74, 88], ["image errors", "TEST", 109, 121], ["a preliminary study", "TEST", 203, 222], ["one reconstruction algorithm", "TEST", 226, 254], ["the correct body shape", "TEST", 282, 304], ["a CT scan", "TEST", 319, 328], ["reconstructions", "TREATMENT", 338, 353], ["mismatch", "OBSERVATION", 14, 22], ["true body", "OBSERVATION_MODIFIER", 35, 44], ["shape", "OBSERVATION_MODIFIER", 45, 50], ["shape", "OBSERVATION_MODIFIER", 59, 64], ["circular", "OBSERVATION_MODIFIER", 402, 410], ["shape", "OBSERVATION_MODIFIER", 411, 416]]], ["However, for practical reasons, EIT reconstruction cannot depend on the availability of a CT scan of each individual subject.", [["EIT reconstruction", "TREATMENT", 32, 50], ["a CT scan", "TEST", 88, 97]]], ["Patient shape could instead be obtained by means of, for example, wearable sensors or through optical 3-D surface reconstruction (from images obtained with a multi-camera system).", [["Patient", "SPECIES", 0, 7], ["wearable sensors", "TEST", 66, 82], ["optical 3-D surface reconstruction", "TREATMENT", 94, 128], ["images", "TEST", 135, 141]]], ["However, we believe that developing a set of predefined shapes to choose from for each patient based on easy to measure parameters (weight, height, etc.) is the most practical and least expensive approach.", [["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["weight", "TEST", 132, 138]]], ["In order to develop such a set, a deeper understanding of the errors and tolerances of different EIT algorithms with respect to shape mismatch is required.I. INTRODUCTIONIn the present study we, therefore, seek to 1) characterize and quantify the errors resulting from reconstruction shape mismatch for a number of popular EIT reconstruction algorithms and 2) develop recommendations on the tolerated amount of mismatch for each algorithm.", [["different EIT algorithms", "TREATMENT", 87, 111], ["the present study", "TEST", 173, 190], ["the errors", "PROBLEM", 243, 253], ["reconstruction shape mismatch", "TREATMENT", 269, 298], ["popular EIT reconstruction algorithms", "TREATMENT", 315, 352], ["mismatch for each algorithm", "TREATMENT", 411, 438]]], ["A CT slice in the electrode plane is segmented to obtain the boundary shape, the contour of the lungs and the electrode positions.", [["lungs", "ANATOMY", 96, 101], ["lungs", "ORGAN", 96, 101], ["A CT slice", "TEST", 0, 10], ["boundary shape", "OBSERVATION", 61, 75], ["contour", "OBSERVATION_MODIFIER", 81, 88], ["lungs", "ANATOMY", 96, 101], ["electrode positions", "OBSERVATION", 110, 129]]], ["An FEM with a lung contrast conforming to the CT slice is created and used to simulate a number of targets covering the whole body.", [["lung", "ANATOMY", 14, 18], ["body", "ANATOMY", 126, 130], ["lung", "ORGAN", 14, 18], ["body", "ORGANISM_SUBDIVISION", 126, 130], ["a lung contrast", "TEST", 12, 27], ["the CT slice", "TEST", 42, 54], ["FEM", "ANATOMY", 3, 6], ["lung", "ANATOMY", 14, 18], ["contrast", "OBSERVATION", 19, 27], ["targets", "OBSERVATION_MODIFIER", 99, 106], ["whole body", "ANATOMY_MODIFIER", 120, 130]]], ["Several homogeneous models with distorted shape are created and used for reconstruction.", [["reconstruction", "TREATMENT", 73, 87], ["homogeneous", "OBSERVATION_MODIFIER", 8, 19], ["distorted", "OBSERVATION_MODIFIER", 32, 41], ["shape", "OBSERVATION_MODIFIER", 42, 47]]], ["Based on the individual target reconstructions, a map representing performance metric as a function of position is constructed for each model shape.II. METHODSShortly, the external boundary shape of a human and a swine were obtained from sample CT images in the electrode plane.", [["human", "ORGANISM", 201, 206], ["swine", "ORGANISM", 213, 218], ["human", "SPECIES", 201, 206], ["swine", "SPECIES", 213, 218], ["human", "SPECIES", 201, 206], ["swine", "SPECIES", 213, 218], ["a map", "TEST", 48, 53], ["sample CT images", "TEST", 238, 254], ["shape", "OBSERVATION_MODIFIER", 142, 147]]], ["From each so obtained true shape a number of progressively more circular contours were derived.", [["shape", "OBSERVATION_MODIFIER", 27, 32], ["number", "OBSERVATION_MODIFIER", 35, 41], ["progressively", "OBSERVATION_MODIFIER", 45, 58], ["circular contours", "OBSERVATION", 64, 81]]], ["For each contour a 3-D finite element model (FEM) was built by extrusion along the long axis of the body.", [["body", "ANATOMY", 100, 104], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["a 3-D finite element model (FEM)", "TREATMENT", 17, 49], ["contour", "OBSERVATION_MODIFIER", 9, 16], ["FEM", "ANATOMY", 45, 48], ["extrusion", "OBSERVATION", 63, 72], ["long axis", "ANATOMY_MODIFIER", 83, 92], ["body", "ANATOMY", 100, 104]]], ["The models were used to reconstruct simulated and real data using four EIT reconstruction algorithms.", [["four EIT reconstruction algorithms", "TEST", 66, 100]]], ["The procedure is presented schematically in Fig. 1 .II. METHODSAll calculations have been carried out with Matlab (Mathwarks, Natick, MA) using the EIDORS 1 toolbox [11] , to which all relevant tools developed as part of this project have been contributed and were included in the latest release (3.5).A. Model ShapeTo investigate the impact of mismatch between the actual body shape and that of the FEM used for EIT image reconstruction, a number of progressively more inaccurate shapes were obtained as follows.", [["body", "ANATOMY", 373, 377], ["body", "ORGANISM_SUBDIVISION", 373, 377], ["The procedure", "TREATMENT", 0, 13], ["METHODSAll calculations", "TEST", 56, 79], ["the actual body shape", "TREATMENT", 362, 383], ["the FEM", "TREATMENT", 396, 403], ["EIT image reconstruction", "TREATMENT", 413, 437], ["mismatch", "OBSERVATION", 345, 353], ["FEM", "ANATOMY", 400, 403]]], ["First, the true shape was obtained from a single CT image of the thorax at the electrode plane by manual delineation with a number of points (37 for the human shape and 41 for the swine).", [["thorax", "ANATOMY", 65, 71], ["thorax", "ORGAN", 65, 71], ["human", "ORGANISM", 153, 158], ["swine", "ORGANISM", 180, 185], ["human", "SPECIES", 153, 158], ["swine", "SPECIES", 180, 185], ["human", "SPECIES", 153, 158], ["swine", "SPECIES", 180, 185], ["a single CT image", "TEST", 40, 57], ["manual delineation", "TEST", 98, 116], ["thorax", "ANATOMY", 65, 71]]], ["The original pixel coordinates of the resulting points were rigidly transformed such that the entire shape fitted in a square with side 2 centered at the origin.", [["a square with side 2", "TREATMENT", 117, 137], ["entire", "OBSERVATION_MODIFIER", 94, 100], ["shape", "OBSERVATION_MODIFIER", 101, 106], ["origin", "ANATOMY_MODIFIER", 154, 160]]], ["All subsequents unit-less quantities are reported in this coordinate system.", [["less quantities", "OBSERVATION_MODIFIER", 21, 36]]], ["Second, the points were interpreted in the complex plane (with origin coinciding with the Cartesian coordinates just defined) and a parametric description of the shape was obtained by taking the discrete Fourier transform (DFT) of the resulting complex vector.", [["complex vector", "OBSERVATION", 245, 259]]], ["Third, progressively smoother shapes were obtained by truncating the Fourier series, two components at a time, down to a length of five terms (at 3 the resulting shape was an almost perfect circle but off-center with respect to the other shapes).", [["progressively", "OBSERVATION_MODIFIER", 7, 20], ["smoother", "OBSERVATION_MODIFIER", 21, 29], ["shapes", "OBSERVATION_MODIFIER", 30, 36]]], ["At each series length a new shape of 41-45 equidistant points, the exact number adjusted to allow the creation of a finite element model with Netgen [12] as described below, was obtained by padding the truncated Fourier series with zeros and taking the inverse DFT.", [["41-45 equidistant points", "DNA", 37, 61], ["a finite element model", "TREATMENT", 114, 136], ["zeros", "TREATMENT", 232, 237], ["the inverse DFT", "TREATMENT", 249, 264], ["new", "OBSERVATION_MODIFIER", 24, 27], ["shape", "OBSERVATION_MODIFIER", 28, 33]]], ["All shapes were scaled to have the same area as the original .", [["shapes", "OBSERVATION_MODIFIER", 4, 10]]], ["The last shape was a circle with radius 1.", [["radius", "ANATOMY", 33, 39]]], ["Representative shapes for both animal and human geometries are presented in Fig. 2 .A. Model ShapeThe mismatch between a smooth shape and the original was quantified as the area of symmetric difference (nonoverlapping area) between the two shapes (divided by ), as illustrated in Fig. 2A.", [["human", "ORGANISM", 42, 47], ["2A", "GENE_OR_GENE_PRODUCT", 285, 287], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["The mismatch between a smooth shape", "PROBLEM", 98, 133], ["symmetric difference", "PROBLEM", 181, 201], ["human geometries", "OBSERVATION", 42, 58], ["Shape", "OBSERVATION_MODIFIER", 93, 98], ["mismatch", "OBSERVATION", 102, 110], ["smooth", "OBSERVATION_MODIFIER", 121, 127], ["shape", "OBSERVATION_MODIFIER", 128, 133], ["area", "OBSERVATION_MODIFIER", 173, 177], ["symmetric", "OBSERVATION_MODIFIER", 181, 190], ["difference", "OBSERVATION_MODIFIER", 191, 201], ["nonoverlapping", "OBSERVATION_MODIFIER", 203, 217], ["area", "OBSERVATION_MODIFIER", 218, 222], ["two", "OBSERVATION_MODIFIER", 236, 239], ["shapes", "OBSERVATION_MODIFIER", 240, 246], ["Fig", "OBSERVATION_MODIFIER", 280, 283]]], ["Model Shapeas a function of the number of Fourier coefficients retained (assuming 1 for the circular model).A. Model ShapeIn order to create 3-D models from thus defined contours, we extended the EIDORS interface to Netgen [12] to support extrusion.", [["3-D models", "TREATMENT", 141, 151], ["extrusion", "PROBLEM", 239, 248], ["function", "OBSERVATION_MODIFIER", 16, 24]]], ["Sixteen circular electrodes were placed equidistantly around the perimeter of the model at a height of 0.5.", [["Sixteen circular electrodes", "TREATMENT", 0, 27], ["circular", "OBSERVATION_MODIFIER", 8, 16], ["electrodes", "OBSERVATION_MODIFIER", 17, 27], ["perimeter", "OBSERVATION_MODIFIER", 65, 74]]], ["The mesh was refined locally around the electrodes.", [["The mesh", "TREATMENT", 0, 8], ["mesh", "OBSERVATION", 4, 8]]], ["Occasionally the locations of the electrodes and the outline points interacted in ways that prevented Netgen from successfully meshing the geometry.", [["the electrodes", "TREATMENT", 30, 44]]], ["In such cases, the number of points describing a shape was increased, as mentioned earlier.", [["shape", "OBSERVATION_MODIFIER", 49, 54], ["increased", "OBSERVATION_MODIFIER", 59, 68]]], ["Sample meshes are presented in Fig. 1 .B. Reconstruction AlgorithmsThe reconstruction of conductivity values inside a body based on surface voltage measurements is a severely ill-posed nonlinear inverse problem.", [["body", "ANATOMY", 118, 122], ["surface", "ANATOMY", 132, 139], ["Sample meshes", "TREATMENT", 0, 13], ["The reconstruction of conductivity values", "TEST", 67, 108], ["surface voltage measurements", "TEST", 132, 160], ["a severely ill-posed nonlinear inverse problem", "PROBLEM", 164, 210], ["meshes", "OBSERVATION", 7, 13], ["Fig", "OBSERVATION_MODIFIER", 31, 34], ["body", "ANATOMY_MODIFIER", 118, 122], ["severely", "OBSERVATION_MODIFIER", 166, 174], ["ill", "OBSERVATION_MODIFIER", 175, 178]]], ["However, because of the large uncertainties about measurement noise, domain shape and electrode impedance present in clinical and experimental EIT data alike, various linearized approximations to solving difference data have proven useful.", [["measurement noise", "PROBLEM", 50, 67], ["domain shape", "PROBLEM", 69, 81], ["electrode impedance", "TEST", 86, 105], ["solving difference data", "TEST", 196, 219], ["large", "OBSERVATION_MODIFIER", 24, 29], ["uncertainties", "OBSERVATION", 30, 43], ["shape", "OBSERVATION_MODIFIER", 76, 81], ["electrode impedance", "OBSERVATION", 86, 105]]], ["In difference EIT, a vector of conductivity change between the current conductivity and the reference is reconstructed from measurements of the corresponding change in recorded voltage.", [["conductivity change", "PROBLEM", 31, 50], ["difference EIT", "OBSERVATION", 3, 17]]], ["Often, both differences are element-wise normalized (such that , as is also the case in the present study.", [["the present study", "TEST", 88, 105]]], ["For sufficiently small changes, the relationship between and can be approximated by the linear relationship (1) where is the Jacobian or sensitivity matrix calculated for each element of the FEM as and represents the measurement noise (assumed to be uncorrelated white Gaussian).", [["sufficiently small changes", "PROBLEM", 4, 30], ["the measurement noise", "PROBLEM", 213, 234], ["small", "OBSERVATION_MODIFIER", 17, 22], ["changes", "OBSERVATION", 23, 30], ["FEM", "ANATOMY", 191, 194]]], ["Because the number of conductivity elements is much greater than the number of measurements, is longer than , and is not square and therefore does not have an inverse.", [["number", "OBSERVATION_MODIFIER", 12, 18], ["conductivity elements", "OBSERVATION", 22, 43], ["much", "OBSERVATION_MODIFIER", 47, 51], ["greater", "OBSERVATION_MODIFIER", 52, 59], ["inverse", "OBSERVATION", 159, 166]]], ["Instead, a linear reconstruction algorithm calculates an estimate of (2) using a reconstruction matrix .", [["a linear reconstruction algorithm", "TEST", 9, 42], ["a reconstruction matrix", "TREATMENT", 79, 102]]], ["Many algorithms to derive have been proposed, four of which are used in this study: TSVD (truncated singular value decomposition [13] , [14] ), GREIT (Graz consensus Reconstruction algorithm for EIT [10] ), and two variants of the one-step Gauss-Newton (GN) method.B. Reconstruction AlgorithmsIn the TSVD algorithm, is the truncated pseudoinverse (3) of , where is the singular value decomposition of and is obtained asB.", [["asB", "PROTEIN", 417, 420], ["this study", "TEST", 72, 82], ["Newton (GN) method", "TREATMENT", 246, 264], ["the TSVD algorithm", "TEST", 296, 314]]], ["Reconstruction AlgorithmsAs the threshold is increased less components of are retained, which means that only the more significant singular values are used, thus increasing the amount of regularization.B. Reconstruction AlgorithmsThe GREIT reconstruction matrix is calculated from simulated measurements and the corresponding desired solutions as (5) where and are matrixes obtained by horizontal concatenation of desired solution or simulated measurement vectors, respectively, while and represent the noise and image covariance matrixes [10] .", [["GREIT", "DNA", 234, 239], ["The GREIT reconstruction matrix", "TREATMENT", 230, 261], ["horizontal concatenation of desired solution", "TREATMENT", 386, 430], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["less components", "OBSERVATION_MODIFIER", 55, 70], ["more", "OBSERVATION_MODIFIER", 114, 118], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["singular values", "OBSERVATION", 131, 146], ["increasing", "OBSERVATION_MODIFIER", 162, 172], ["amount", "OBSERVATION_MODIFIER", 177, 183], ["regularization", "OBSERVATION", 187, 201]]], ["The trade-off between the different performance measures is embedded in the desired solutions while the hyperparameter controls the amount of regularization.", [["amount", "OBSERVATION_MODIFIER", 132, 138]]], ["We extended the original implementation of the GREIT algorithm, previously only defined for cylinders, to arbitrary shapes [9] .", [["GREIT algorithm", "DNA", 47, 62], ["the GREIT algorithm", "TEST", 43, 62]]], ["For the GN algorithms, can be expressed as (6) where is a regularization prior matrix and is again a hyperparameter controlling the amount of regularization.", [["the GN algorithms", "TEST", 4, 21], ["a regularization prior matrix", "TREATMENT", 56, 85], ["a hyperparameter", "TREATMENT", 99, 115]]], ["We test the NOSER [15] and discrete Laplace filter [16] priors.", [["discrete Laplace filter", "TREATMENT", 27, 50]]], ["We use the normalized difference imaging approach, whereby conductivity differences are not reconstructed as absolute values but as unit-less ratios to the reference background conductivity, defined as an expiration or target-less simulation measurement for clinical and simulation data, respectively.B. Reconstruction AlgorithmsAll tested algorithms employ the dual model approach whereby the Jacobian is calculated on a 3-D forward model obtained as detailed above, but values are only reconstructed on a 2-D rectangular grid in the electrode plane.", [["the normalized difference imaging approach", "TEST", 7, 49], ["absolute values", "TEST", 109, 124], ["clinical and simulation data", "TEST", 258, 286], ["a 2-D rectangular grid in the electrode plane", "TREATMENT", 505, 550]]], ["After [10] , we adjusted the hyperparameter value for each model and algorithm such as to achieve noise amplification (as defined by the Noise Figure parameter in [17] ) of 0.5 in the center of the image.", [["the hyperparameter value", "TEST", 25, 49]]], ["This method of choosing the regularization parameter is configuration-independent and has been shown to consistently produce good reconstructions [18] .C. Evaluation CriteriaFor each shape, each reconstruction algorithm was evaluated using the performance figures of merit defined in [10] .", [["Evaluation", "TEST", 155, 165], ["each reconstruction algorithm", "TEST", 190, 219]]], ["Briefly, these are: amplitude response (AR), resolution (RES), shape deformation (SD), position error (PE), ringing (RNG), and position error (PE).", [["shape deformation (SD), position error (PE", "PROBLEM", 63, 105], ["ringing (RNG), and position error (PE", "PROBLEM", 108, 145], ["shape", "OBSERVATION_MODIFIER", 63, 68], ["deformation", "OBSERVATION_MODIFIER", 69, 80], ["PE", "OBSERVATION", 103, 105], ["PE", "OBSERVATION", 143, 145]]], ["Each figure of merit is measured empirically on a reconstructed image of a small simulated target, as illustrated in Fig. 3 .C. Evaluation CriteriaTo evaluate the spatial variability of each algorithm with respect to the performance measures, calculations were carried out for a large set of regularly spaced small targets in the electrode plane.", [["Evaluation", "TEST", 128, 138], ["calculations", "TEST", 243, 255], ["a large set of regularly spaced small targets in the electrode plane", "TREATMENT", 277, 345], ["small", "OBSERVATION_MODIFIER", 75, 80], ["large", "OBSERVATION_MODIFIER", 279, 284], ["small", "OBSERVATION_MODIFIER", 309, 314], ["targets", "OBSERVATION", 315, 322]]], ["Thus, for each shape and figure of merit, the performance of the algorithm is represented as an image with each pixel corresponding to one simulated target and its value reflecting the respective figure of merit obtained by reconstructing that single simulated target.", [["an image", "TEST", 93, 101]]], ["The mean of values within each such image and the ratio of standard deviation to the mean are analyzed as a function of the shape deformation .D. SimulationSimulated measurements were obtained through the FEM method using a mesh with the true thorax shape (obtained as described above) and a conductivity contrast in the lung region segmented from the corresponding CT image.", [["thorax", "ANATOMY", 243, 249], ["lung", "ANATOMY", 321, 325], ["thorax", "ORGAN", 243, 249], ["lung", "ORGAN", 321, 325], ["the FEM method", "TREATMENT", 201, 215], ["a mesh", "TREATMENT", 222, 228], ["a conductivity contrast", "TEST", 290, 313], ["the corresponding CT image", "TEST", 348, 374], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["standard deviation", "OBSERVATION", 59, 77], ["shape", "OBSERVATION_MODIFIER", 124, 129], ["FEM", "ANATOMY", 205, 208], ["mesh", "OBSERVATION", 224, 228], ["thorax", "ANATOMY", 243, 249], ["lung", "ANATOMY", 321, 325], ["region", "ANATOMY_MODIFIER", 326, 332]]], ["The lung to other tissue conductivity ratio was 0.1875 (as the average of the expiration and inspiration values assumed in [8] and in agreement with the ranges observed by Gabriel et al. [19] for 100 kHz current frequency).", [["lung", "ANATOMY", 4, 8], ["tissue", "ANATOMY", 18, 24], ["lung", "ORGAN", 4, 8], ["tissue", "TISSUE", 18, 24], ["other tissue conductivity ratio", "TEST", 12, 43], ["the expiration", "TEST", 74, 88], ["inspiration values", "TEST", 93, 111], ["lung", "ANATOMY", 4, 8]]], ["This simulation setup represents well the practical use of EIT where measurements obtained on a heterogeneous body are reconstructed using a homogeneous model.", [["body", "ANATOMY", 110, 114], ["body", "ORGANISM_SUBDIVISION", 110, 114], ["This simulation setup", "TREATMENT", 0, 21]]], ["The meshes of the human and pig chest contained and first-order tetrahedral elements, respectively.E. DataThe animal data used in this study were obtained at the University of Mainz, Germany, under appropriate ethical approval (license no. 1.5 177-07/041-75, Landesuntersuchungsamt Rheinland-Pfalz, 56028 Koblenz, Germany).", [["chest", "ANATOMY", 32, 37], ["human", "ORGANISM", 18, 23], ["pig", "ORGANISM", 28, 31], ["chest", "ORGANISM_SUBDIVISION", 32, 37], ["human", "SPECIES", 18, 23], ["pig", "SPECIES", 28, 31], ["human", "SPECIES", 18, 23], ["pig", "SPECIES", 28, 31], ["The meshes of the human and pig chest", "TREATMENT", 0, 37], ["this study", "TEST", 130, 140], ["meshes", "OBSERVATION", 4, 10], ["human", "ANATOMY", 18, 23], ["pig", "ANATOMY_MODIFIER", 28, 31], ["chest", "ANATOMY", 32, 37], ["tetrahedral elements", "OBSERVATION", 64, 84]]], ["CT data were acquired during a period of apnea in a healthy 23 kg swine.", [["apnea", "DISEASE", 41, 46], ["swine", "SPECIES", 66, 71], ["swine", "SPECIES", 66, 71], ["CT data", "TEST", 0, 7], ["apnea", "PROBLEM", 41, 46]]], ["EIT data were recorded during conventional mechanical ventilation in the same animal.E. DataThe human CT used in this study originates from a diagnostic scan of a male volunteer (54 year old, BMI 25.4, healthy lung and heart) taken to investigate a nonthoracic condition and donated by the subject to the EIDORS project for scientific purposes.E. DataIII.", [["lung", "ANATOMY", 210, 214], ["heart", "ANATOMY", 219, 224], ["human", "ORGANISM", 96, 101], ["lung", "ORGAN", 210, 214], ["heart", "ORGAN", 219, 224], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["EIT data", "TEST", 0, 8], ["conventional mechanical ventilation", "TREATMENT", 30, 65], ["human CT", "TEST", 96, 104], ["this study", "TEST", 113, 123], ["a diagnostic scan", "TEST", 140, 157], ["BMI", "TEST", 192, 195], ["a nonthoracic condition", "PROBLEM", 247, 270], ["mechanical ventilation", "OBSERVATION", 43, 65], ["lung", "ANATOMY", 210, 214], ["heart", "ANATOMY", 219, 224]]], ["Animal Experiment DataSample reconstructed images of animal data using all four algorithms are presented in Fig. 4 .", [["animal data", "TEST", 53, 64]]], ["For all algorithms, the more circular the model shape is, the more distorted the lung shape appears.", [["lung", "ANATOMY", 81, 85], ["lung", "ORGAN", 81, 85], ["all algorithms", "TEST", 4, 18], ["more circular", "OBSERVATION_MODIFIER", 24, 37], ["model", "OBSERVATION_MODIFIER", 42, 47], ["shape", "OBSERVATION_MODIFIER", 48, 53], ["lung", "ANATOMY", 81, 85], ["shape", "OBSERVATION_MODIFIER", 86, 91]]], ["Features along the longer vertical axis are pushed together and lost, particularly at the ventral side.", [["ventral", "ANATOMY", 90, 97], ["longer", "OBSERVATION_MODIFIER", 19, 25], ["vertical axis", "OBSERVATION", 26, 39], ["lost", "OBSERVATION_MODIFIER", 64, 68], ["ventral", "ANATOMY_MODIFIER", 90, 97]]], ["Qualitatively, images reconstructed with the GREIT algorithm exhibit the least artifacts but also the smoothest boundaries.", [["GREIT algorithm", "DNA", 45, 60], ["images", "TEST", 15, 21], ["the GREIT algorithm", "TEST", 41, 60], ["least", "OBSERVATION_MODIFIER", 73, 78], ["artifacts", "OBSERVATION", 79, 88]]], ["Fig. 5 depicts for both models the mean and standard deviation (normalized to the mean) across the map of each performance measure as a function of the number of Fourier coefficients retained to describe the model shape, while sample performance measure maps of GREIT reconstructions on selected porcine thorax model shapes are presented in Fig. 6 .", [["thorax", "ANATOMY", 304, 310], ["porcine", "ORGANISM", 296, 303], ["thorax", "ORGAN", 304, 310], ["sample performance", "TEST", 227, 245], ["GREIT reconstructions", "TREATMENT", 262, 283], ["selected porcine thorax model shapes", "TREATMENT", 287, 323], ["shape", "OBSERVATION_MODIFIER", 214, 219], ["thorax", "ANATOMY", 304, 310], ["Fig", "OBSERVATION_MODIFIER", 341, 344]]], ["With few exceptions, the performance measures visibly worsen as shapes become smoother, but not until the descriptor is truncated to below 13 coefficients for the porcine thorax % and seven coefficients for the human chest shape % , cf. Fig. 2(d) .", [["thorax", "ANATOMY", 171, 177], ["chest", "ANATOMY", 217, 222], ["porcine", "ORGANISM", 163, 170], ["thorax", "ORGAN", 171, 177], ["human", "ORGANISM", 211, 216], ["chest", "ORGANISM_SUBDIVISION", 217, 222], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["the porcine thorax %", "TREATMENT", 159, 179], ["few", "OBSERVATION_MODIFIER", 5, 8], ["thorax", "ANATOMY", 171, 177], ["chest", "ANATOMY", 217, 222]]], ["This corresponds to approximately 4% difference in model shape (for the porcine shape described by 11 coefficient %).", [["the porcine shape", "TREATMENT", 68, 85], ["approximately", "OBSERVATION_MODIFIER", 20, 33], ["4%", "OBSERVATION_MODIFIER", 34, 36], ["difference", "OBSERVATION_MODIFIER", 37, 47], ["model", "OBSERVATION_MODIFIER", 51, 56], ["shape", "OBSERVATION_MODIFIER", 57, 62]]], ["None of the studied algorithms are immune to the effect.B. Performance Measure AnalysisThe performance of the two GN solvers is very similar.", [["the studied algorithms", "TEST", 8, 30], ["very similar", "OBSERVATION_MODIFIER", 128, 140]]], ["The GREIT algorithm stands out for its higher (i.e., worse) but more uniform resolution (cf. Figs.", [["GREIT algorithm", "DNA", 4, 19], ["The GREIT algorithm", "TEST", 0, 19], ["higher", "OBSERVATION_MODIFIER", 39, 45], ["uniform", "OBSERVATION_MODIFIER", 69, 76], ["resolution", "OBSERVATION_MODIFIER", 77, 87]]], ["7 and 8) , lower ringing and shape deformation.", [["lower ringing and shape deformation", "PROBLEM", 11, 46], ["shape", "OBSERVATION_MODIFIER", 29, 34], ["deformation", "OBSERVATION_MODIFIER", 35, 46]]], ["It also has higher position error close to the boundary than other algorithms, which means that changes close to the boundary are reconstructed more centrally than they ought to.", [["higher", "OBSERVATION_MODIFIER", 12, 18], ["position error", "OBSERVATION", 19, 33]]], ["The TSVD algorithm exhibits low average amplitude response, high shape deformation, high ringing as well as lowest and most variable resolution-low (i.e., good) at the boundary and high in the center.A. Figures of MeritIn [10] a group of domain experts defined the desired characteristics of an EIT reconstruction algorithm as (in order of importance): 1) uniform amplitude response (AR), 2) small and uniform position error (PE), 3) low and uniform ringing (RNG), 4) uniform resolution (RES), 5) small shape deformation (SD), and 6) small RES.", [["SD", "DISEASE", 522, 524], ["RES", "CHEMICAL", 540, 543], ["The TSVD algorithm", "TEST", 0, 18], ["low average amplitude response", "PROBLEM", 28, 58], ["high shape deformation", "PROBLEM", 60, 82], ["an EIT reconstruction algorithm", "TEST", 292, 323], ["small and uniform position error (PE), 3) low and uniform ringing (RNG), 4) uniform resolution (RES), 5) small shape deformation (SD), and 6) small RES", "PROBLEM", 392, 543], ["low average", "OBSERVATION_MODIFIER", 28, 39], ["amplitude response", "OBSERVATION", 40, 58], ["high shape", "OBSERVATION_MODIFIER", 60, 70], ["deformation", "OBSERVATION_MODIFIER", 71, 82], ["high ringing", "OBSERVATION", 84, 96], ["variable", "OBSERVATION_MODIFIER", 124, 132], ["resolution", "OBSERVATION_MODIFIER", 133, 143], ["low", "OBSERVATION_MODIFIER", 144, 147], ["high", "OBSERVATION_MODIFIER", 181, 185], ["small", "OBSERVATION_MODIFIER", 392, 397], ["uniform", "OBSERVATION_MODIFIER", 402, 409], ["position error", "OBSERVATION", 410, 424], ["PE", "OBSERVATION", 426, 428], ["low", "OBSERVATION_MODIFIER", 434, 437], ["uniform", "OBSERVATION_MODIFIER", 442, 449], ["uniform", "OBSERVATION_MODIFIER", 468, 475], ["resolution", "OBSERVATION_MODIFIER", 476, 486], ["small", "OBSERVATION_MODIFIER", 497, 502], ["shape", "OBSERVATION_MODIFIER", 503, 508], ["deformation", "OBSERVATION_MODIFIER", 509, 520], ["small", "OBSERVATION_MODIFIER", 534, 539]]], ["These are discussed below in turn.A. Figures of MeritThe behavior of amplitude response is similar for all tested algorithms.", [["all tested algorithms", "TEST", 103, 124]]], ["In general, AR was not uniform across the image.", [["AR", "GENE_OR_GENE_PRODUCT", 12, 14], ["AR", "PROTEIN", 12, 14]]], ["Higher values were recorded within the lung as compared with the surrounding tissue, as shown on Figs.", [["lung", "ANATOMY", 39, 43], ["tissue", "ANATOMY", 77, 83], ["lung", "ORGAN", 39, 43], ["tissue", "TISSUE", 77, 83], ["lung", "ANATOMY", 39, 43], ["tissue", "OBSERVATION", 77, 83]]], ["1, 7 and 8 .", [["1, 7 and 8", "PROTEIN", 0, 10]]], ["The results suggest that conductivity changes in less conductive tissues (e.g., inflated lung) are overestimated.", [["conductive tissues", "ANATOMY", 54, 72], ["lung", "ANATOMY", 89, 93], ["tissues", "TISSUE", 65, 72], ["lung", "ORGAN", 89, 93], ["conductivity changes in less conductive tissues (e.g., inflated lung)", "PROBLEM", 25, 94], ["conductivity changes", "OBSERVATION", 25, 45], ["less", "OBSERVATION_MODIFIER", 49, 53], ["conductive tissues", "OBSERVATION", 54, 72], ["lung", "ANATOMY", 89, 93]]], ["This effect has potentially far reaching consequences for ventilation monitoring in patients with atelectasis (lung collapse), where EIT could underestimate ventilation in the more conductive collapsed regions of the lung.", [["lung", "ANATOMY", 111, 115], ["lung", "ANATOMY", 217, 221], ["atelectasis", "DISEASE", 98, 109], ["lung collapse", "DISEASE", 111, 124], ["patients", "ORGANISM", 84, 92], ["lung", "ORGAN", 111, 115], ["lung", "ORGAN", 217, 221], ["patients", "SPECIES", 84, 92], ["ventilation monitoring", "TEST", 58, 80], ["atelectasis (lung collapse", "PROBLEM", 98, 124], ["atelectasis", "OBSERVATION", 98, 109], ["lung", "ANATOMY", 111, 115], ["collapse", "OBSERVATION", 116, 124], ["ventilation", "OBSERVATION", 157, 168], ["more", "OBSERVATION_MODIFIER", 176, 180], ["conductive", "OBSERVATION_MODIFIER", 181, 191], ["collapsed", "OBSERVATION", 192, 201], ["regions", "ANATOMY_MODIFIER", 202, 209], ["lung", "ANATOMY", 217, 221]]], ["We also observed that AR is not uniform close to the boundary-it is high in the vicinity of the electrodes and low between them.", [["AR", "GENE_OR_GENE_PRODUCT", 22, 24], ["AR", "PROTEIN", 22, 24], ["AR", "PROBLEM", 22, 24], ["uniform", "OBSERVATION_MODIFIER", 32, 39], ["high", "OBSERVATION_MODIFIER", 68, 72]]], ["This could distort the lung shape in some cases and be one of the sources of boundary artifacts in EIT images.", [["lung", "ANATOMY", 23, 27], ["lung", "ORGAN", 23, 27], ["the lung shape", "PROBLEM", 19, 33], ["boundary artifacts", "PROBLEM", 77, 95], ["EIT images", "TEST", 99, 109], ["lung", "ANATOMY", 23, 27], ["shape", "OBSERVATION_MODIFIER", 28, 33], ["boundary artifacts", "OBSERVATION", 77, 95]]], ["In terms of position error, the GREIT algorithm seems to have the lowest ranking performance.", [["GREIT", "DNA", 32, 37], ["the GREIT algorithm", "TEST", 28, 47], ["position error", "OBSERVATION", 12, 26]]], ["Although in the center of the image its performance is on a par or exceeds those of the other algorithms, objects that are close to the boundary but between electrodes are reconstructed deeper in the body than they ought to be.", [["body", "ANATOMY", 200, 204], ["body", "ORGANISM_SUBDIVISION", 200, 204], ["body", "ANATOMY", 200, 204]]], ["Because in thorax imaging the signals of interest originate primarily deeper within the body, this should not present a clinically significant issue.", [["thorax", "ANATOMY", 11, 17], ["body", "ANATOMY", 88, 92], ["thorax", "ORGAN", 11, 17], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["thorax imaging", "TEST", 11, 25], ["thorax", "ANATOMY", 11, 17], ["body", "ANATOMY", 88, 92]]], ["The TSVD algorithm performs best on this figure of merit.A. Figures of MeritRinging displays high sensitivity to shape mismatch, especially for the GREIT algorithm.", [["TSVD algorithm", "DNA", 4, 18], ["The TSVD algorithm", "TEST", 0, 18], ["high sensitivity to shape mismatch", "PROBLEM", 93, 127], ["the GREIT algorithm", "TEST", 144, 163]]], ["While in general GREIT displays lower RNG than the other algorithms, RNG increases pronouncedly for values in excess of 4%, especially at the boundary between the electrodes.", [["GREIT", "DNA", 17, 22], ["RNG", "PROTEIN", 38, 41], ["RNG", "PROTEIN", 69, 72], ["lower", "ANATOMY_MODIFIER", 32, 37], ["increases", "OBSERVATION_MODIFIER", 73, 82], ["electrodes", "ANATOMY_MODIFIER", 163, 173]]], ["The TSVD algorithm, intuitively similar to a boxcar filter in signal processing, produces the most ringing.A. Figures of MeritA nonuniform resolution could lead to a distorted shape and incorrect position of a reconstructed target.", [["The TSVD algorithm", "TEST", 0, 18], ["a boxcar filter", "TREATMENT", 43, 58], ["a distorted shape", "PROBLEM", 164, 181], ["a reconstructed target", "TREATMENT", 208, 230], ["boxcar filter", "OBSERVATION", 45, 58], ["distorted", "OBSERVATION_MODIFIER", 166, 175], ["shape", "OBSERVATION_MODIFIER", 176, 181], ["incorrect position", "OBSERVATION", 186, 204]]], ["Amongst the evaluated algorithms, GREIT exhibits the most uniform resolution for both models.", [["GREIT", "DNA", 34, 39], ["the evaluated algorithms", "TEST", 8, 32], ["most uniform", "OBSERVATION_MODIFIER", 53, 65]]], ["As the shape mismatch increases, RES becomes less uniform, but the non-uniformities seem to be limited to the boundary (cf. Fig. 6 ), and thus have limited impact on the shape deformation for changes of clinical interest in the chest.A. Figures of MeritPartially as a consequence of its uniform resolution, GREIT also features the least shape deformation.", [["chest", "ANATOMY", 228, 233], ["RES", "CHEMICAL", 33, 36], ["RES", "SIMPLE_CHEMICAL", 33, 36], ["chest", "ORGANISM_SUBDIVISION", 228, 233], ["the shape deformation", "TREATMENT", 166, 187], ["shape", "OBSERVATION_MODIFIER", 7, 12], ["mismatch", "OBSERVATION_MODIFIER", 13, 21], ["increases", "OBSERVATION_MODIFIER", 22, 31], ["less", "OBSERVATION_MODIFIER", 45, 49], ["uniform", "OBSERVATION_MODIFIER", 50, 57], ["chest", "ANATOMY", 228, 233], ["uniform", "OBSERVATION_MODIFIER", 287, 294], ["resolution", "OBSERVATION_MODIFIER", 295, 305], ["least", "OBSERVATION_MODIFIER", 331, 336], ["shape", "OBSERVATION_MODIFIER", 337, 342], ["deformation", "OBSERVATION_MODIFIER", 343, 354]]], ["Although inaccuracies close to the boundary are present in all algorithms, they are least pronounced in GREIT.A. Figures of MeritSmall resolution, i.e., the ability to distinguish nearby targets, is the lowest priority figure of merit in the GREIT framework [10] .", [["GREIT", "DNA", 104, 109], ["least", "OBSERVATION_MODIFIER", 84, 89], ["pronounced", "OBSERVATION_MODIFIER", 90, 100]]], ["It is, therefore, not surprising that GREIT performs worst on this criterion.", [["GREIT", "PROTEIN", 38, 43]]], ["However, the GREIT framework allows for several parameters in the calculation of the reconstruction matrix.", [["matrix", "CELLULAR_COMPONENT", 100, 106], ["GREIT", "DNA", 13, 18], ["the reconstruction matrix", "TREATMENT", 81, 106]]], ["A systematic investigation into those parameters could yield optimal values that improve the resolution.B. RecommendationsOur results demonstrate that shape mismatch has a strong detrimental effect on the quality of EIT reconstructions, including effects that are not apparent as artifacts but nonetheless can influence the analysis of EIT images.", [["A systematic investigation", "TEST", 0, 26], ["shape mismatch", "PROBLEM", 151, 165], ["EIT reconstructions", "TEST", 216, 235], ["the analysis", "TEST", 320, 332], ["EIT images", "TEST", 336, 346], ["resolution", "OBSERVATION_MODIFIER", 93, 103], ["shape", "OBSERVATION_MODIFIER", 151, 156], ["mismatch", "OBSERVATION", 157, 165], ["strong", "OBSERVATION_MODIFIER", 172, 178], ["detrimental", "OBSERVATION_MODIFIER", 179, 190], ["effect", "OBSERVATION_MODIFIER", 191, 197], ["not apparent", "UNCERTAINTY", 264, 276]]], ["Therefore, we recommend that in both clinical and research applications EIT data be reconstructed on models closely resembling the actual shape of the body and reflecting the true positions of the electrodes.", [["body", "ANATOMY", 151, 155], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["EIT data", "TEST", 72, 80], ["body", "ANATOMY", 151, 155], ["true positions", "OBSERVATION", 175, 189]]], ["Our observation that shape mismatch of up to 4% has little impact on the quality of the reconstructions means that the shape does not need to match exactly and hence calculations may be simplified by smoothing over the finer detail.C. Clinical PracticeIn clinical practice, the true shape of the thorax would be best represented by a cross-sectional image obtained by computed tomography (CT) or magnetic resonance imaging (MRI).", [["thorax", "ANATOMY", 296, 302], ["thorax", "ORGAN", 296, 302], ["Our observation", "TEST", 0, 15], ["shape mismatch", "PROBLEM", 21, 35], ["a cross-sectional image", "TEST", 332, 355], ["computed tomography (CT", "TEST", 368, 391], ["magnetic resonance imaging", "TEST", 396, 422], ["MRI", "TEST", 424, 427], ["shape", "OBSERVATION_MODIFIER", 21, 26], ["mismatch", "OBSERVATION_MODIFIER", 27, 35], ["up to 4", "OBSERVATION_MODIFIER", 39, 46], ["thorax", "ANATOMY", 296, 302]]], ["Some patients may have prior imaging of the lungs using CT or MRI.", [["lungs", "ANATOMY", 44, 49], ["patients", "ORGANISM", 5, 13], ["lungs", "ORGAN", 44, 49], ["patients", "SPECIES", 5, 13], ["prior imaging of the lungs", "TEST", 23, 49], ["CT or MRI", "TEST", 56, 65], ["lungs", "ANATOMY", 44, 49]]], ["Even if no prior pulmonary imaging was obtained, often abdominal CT scans contain a few images of the caudal part of the lung and could be utilized.", [["pulmonary", "ANATOMY", 17, 26], ["abdominal", "ANATOMY", 55, 64], ["caudal part", "ANATOMY", 102, 113], ["lung", "ANATOMY", 121, 125], ["pulmonary", "ORGAN", 17, 26], ["caudal part", "MULTI-TISSUE_STRUCTURE", 102, 113], ["lung", "ORGAN", 121, 125], ["prior pulmonary imaging", "TEST", 11, 34], ["often abdominal CT scans", "TEST", 49, 73], ["a few images", "TEST", 82, 94], ["pulmonary", "ANATOMY", 17, 26], ["abdominal", "ANATOMY", 55, 64], ["caudal", "ANATOMY_MODIFIER", 102, 108], ["lung", "ANATOMY", 121, 125]]], ["If no prior imaging is available, the physician could choose the appropriate shape of the thorax from a set of predefined shapes based on measurements of a patient's height, weight, BMI, chest circumference or other easy to measure variables.", [["thorax", "ANATOMY", 90, 96], ["chest", "ANATOMY", 187, 192], ["thorax", "ORGAN", 90, 96], ["patient", "ORGANISM", 156, 163], ["chest", "ORGANISM_SUBDIVISION", 187, 192], ["patient", "SPECIES", 156, 163], ["prior imaging", "TEST", 6, 19], ["a patient's height", "TEST", 154, 172], ["weight", "TEST", 174, 180], ["BMI", "TEST", 182, 185], ["chest circumference", "TEST", 187, 206], ["thorax", "ANATOMY", 90, 96], ["chest", "ANATOMY", 187, 192]]], ["Measurements like chest circumference, as well as 2-D measurements of the anterior-posterior and lateral dimension can be easily obtained at the bedside and can be helpful in determining the approximate shape.", [["chest", "ANATOMY", 18, 23], ["chest", "ORGANISM_SUBDIVISION", 18, 23], ["anterior-posterior", "MULTI-TISSUE_STRUCTURE", 74, 92], ["Measurements like chest circumference", "TEST", 0, 37], ["2-D measurements", "TEST", 50, 66], ["chest", "ANATOMY", 18, 23], ["anterior", "ANATOMY_MODIFIER", 74, 82], ["posterior", "ANATOMY_MODIFIER", 83, 92]]], ["Calculating the patient's body mass index (BMI) can provide the investigator with reliable data on whether the patient is overweight (increased amount of soft tissue and body fat around the thorax), normal in weight or underweight (decreased amount of soft tissue and body fat around the thorax).V. FUTURE RESEARCHIn the course of this study, we identified several issues that merit further investigation.", [["body", "ANATOMY", 26, 30], ["soft tissue", "ANATOMY", 154, 165], ["body fat", "ANATOMY", 170, 178], ["thorax", "ANATOMY", 190, 196], ["soft tissue", "ANATOMY", 252, 263], ["body fat", "ANATOMY", 268, 276], ["thorax", "ANATOMY", 288, 294], ["overweight", "DISEASE", 122, 132], ["underweight", "DISEASE", 219, 230], ["patient", "ORGANISM", 16, 23], ["body", "ORGANISM_SUBDIVISION", 26, 30], ["patient", "ORGANISM", 111, 118], ["soft tissue", "TISSUE", 154, 165], ["body fat", "TISSUE", 170, 178], ["thorax", "ORGAN", 190, 196], ["soft tissue", "TISSUE", 252, 263], ["body fat", "TISSUE", 268, 276], ["thorax", "ORGAN", 288, 294], ["patient", "SPECIES", 16, 23], ["patient", "SPECIES", 111, 118], ["the patient's body mass index", "TEST", 12, 41], ["this study", "TEST", 331, 341], ["further investigation", "TEST", 383, 404], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["amount", "OBSERVATION_MODIFIER", 144, 150], ["soft tissue", "OBSERVATION_MODIFIER", 154, 165], ["thorax", "ANATOMY", 190, 196], ["normal", "OBSERVATION", 199, 205], ["decreased", "OBSERVATION_MODIFIER", 232, 241], ["amount", "OBSERVATION_MODIFIER", 242, 248], ["soft tissue", "OBSERVATION_MODIFIER", 252, 263], ["body fat", "ANATOMY_MODIFIER", 268, 276], ["thorax", "ANATOMY", 288, 294]]], ["First is the observed differential amplification by normalized difference EIT reconstruction algorithms of conductivity changes in the lungs and other tissues.", [["lungs", "ANATOMY", 135, 140], ["tissues", "ANATOMY", 151, 158], ["lungs", "ORGAN", 135, 140], ["tissues", "TISSUE", 151, 158], ["normalized difference EIT reconstruction", "TREATMENT", 52, 92], ["conductivity changes in the lungs and other tissues", "PROBLEM", 107, 158], ["conductivity changes", "OBSERVATION", 107, 127], ["lungs", "ANATOMY", 135, 140], ["other tissues", "ANATOMY", 145, 158]]], ["Future research should seek to uncover the causes of this phenomenon, asses its impact on EIT images and devise strategies to reduce or correct for it.", [["this phenomenon", "PROBLEM", 53, 68], ["EIT images", "TEST", 90, 100]]], ["Second, for safety and practical reasons clinical use of EIT cannot depend on a prior examination with an anatomical modality used to build patient-specific models.", [["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["a prior examination", "TEST", 78, 97]]], ["Instead, efforts should be directed at developing other methods of measuring the patients' shape or identifying easy to measure physiological parameters that could be used to build an approximate FEM model or choose one from a library of ready-made models, and developing the required tools.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["an approximate FEM model", "TREATMENT", 181, 205]]], ["The practicality of the latter approach, which we plan to explore in the near future, will depend largely on the required size of such a model library.", [["a model library", "TREATMENT", 135, 150]]], ["The results of the present study are a first step towards estimating the requisite number of models, but further research into the variability of thorax shape and the number of factors that predict it is also needed.V. FUTURE RESEARCHFurther to using the correct model shape, chest EIT should also account for breathing motion and associated with it changes in body shape and electrode positions, which have been shown to strongly influence the measured signal [8] .", [["thorax", "ANATOMY", 146, 152], ["chest", "ANATOMY", 276, 281], ["body", "ANATOMY", 361, 365], ["thorax", "ORGAN", 146, 152], ["chest", "ORGANISM_SUBDIVISION", 276, 281], ["body", "ORGANISM_SUBDIVISION", 361, 365], ["the present study", "TEST", 15, 32], ["chest EIT", "TREATMENT", 276, 285], ["breathing motion", "PROBLEM", 310, 326], ["it changes in body shape and electrode positions", "PROBLEM", 347, 395], ["thorax", "ANATOMY", 146, 152], ["chest", "ANATOMY", 276, 281], ["breathing motion", "OBSERVATION", 310, 326], ["electrode positions", "OBSERVATION", 376, 395]]], ["Future research should offer a characterization of these errors and investigate the efficacy of measures to compensate for them including, but not limited to, monitoring electrode movement with multiple cameras or recovering it from EIT data itself (e.g., [20] ).A. LimitationsIn the present study, we only investigated model shapes obtained by gradually smoothing the correct anatomical shape until a circle was obtained.", [["these errors", "PROBLEM", 51, 63], ["monitoring electrode movement", "TEST", 159, 188], ["EIT data", "TEST", 233, 241], ["the present study", "TEST", 280, 297], ["anatomical shape", "OBSERVATION", 377, 393]]], ["This allowed us to easily control and quantify the amount of shape mismatch and offered insights into the performance loss caused by using the circular shape in studies on humans and swine.", [["humans", "ORGANISM", 172, 178], ["swine", "ORGANISM", 183, 188], ["humans", "SPECIES", 172, 178], ["swine", "SPECIES", 183, 188], ["humans", "SPECIES", 172, 178], ["swine", "SPECIES", 183, 188], ["shape mismatch", "PROBLEM", 61, 75], ["shape mismatch", "OBSERVATION", 61, 75]]], ["However, we can draw no conclusions about which particular features of a subject's shape are the most important to preserve.", [["a subject's shape", "PROBLEM", 71, 88]]], ["Thus, a shape mismatch below the 4% threshold found in our study should not be interpreted as a sufficient or necessary condition for obtaining quality reconstructions in EIT.A. LimitationsOur study is further limited in that we only analyzed normalized linear difference imaging algorithms.", [["a shape mismatch", "PROBLEM", 6, 22], ["our study", "TEST", 55, 64], ["Our study", "TEST", 189, 198], ["shape", "OBSERVATION_MODIFIER", 8, 13], ["mismatch", "OBSERVATION", 14, 22]]], ["Because these algorithms only reconstruct relative changes in conductivity rather than its absolute value, they are less sensitive to uncertainties in initial conditions such as shape, electrode positions, their size and conductivity.", [["these algorithms", "TEST", 8, 24], ["relative changes in conductivity", "PROBLEM", 42, 74], ["its absolute value", "TEST", 87, 105], ["shape", "OBSERVATION_MODIFIER", 178, 183], ["electrode positions", "OBSERVATION", 185, 204], ["size", "OBSERVATION_MODIFIER", 212, 216], ["conductivity", "OBSERVATION_MODIFIER", 221, 233]]], ["Since changes in conductivity are of primary interest in ventilation monitoring, and due to the mentioned advantages, difference imaging is the most widespread approach to thoracic EIT.VI. CONCLUSIONWe present a systematic study into the effect of reconstructing EIT data using models not reflecting the true shape of the investigated body.", [["thoracic", "ANATOMY", 172, 180], ["body", "ANATOMY", 335, 339], ["VI", "GENE_OR_GENE_PRODUCT", 185, 187], ["body", "ORGANISM_SUBDIVISION", 335, 339], ["ventilation monitoring", "TEST", 57, 79], ["difference imaging", "TEST", 118, 136], ["a systematic study", "TEST", 210, 228], ["reconstructing EIT data", "TEST", 248, 271], ["thoracic", "ANATOMY", 172, 180], ["true shape", "OBSERVATION", 304, 314]]], ["We demonstrated that using a circular model, as is frequently done, has a strong detrimental effect on a number of desired characteristics of difference EIT reconstruction algorithms, impeding analysis of the resultant images and possibly skewing conclusions.", [["a circular model", "TEST", 27, 43], ["EIT reconstruction algorithms", "TEST", 153, 182], ["the resultant images", "TEST", 205, 225], ["strong", "OBSERVATION_MODIFIER", 74, 80], ["detrimental", "OBSERVATION_MODIFIER", 81, 92], ["effect", "OBSERVATION", 93, 99]]], ["However, we found that small shape mismatch is well tolerated by all tested algorithms, allowing the use of approximate rather than exact model shapes.", [["small shape mismatch", "PROBLEM", 23, 43], ["all tested algorithms", "TEST", 65, 86], ["small", "OBSERVATION_MODIFIER", 23, 28], ["shape", "OBSERVATION_MODIFIER", 29, 34], ["mismatch", "OBSERVATION", 35, 43]]], ["Future research and development effort should concentrate on developing the requisite knowledge and methods to allow easy choice of an appropriate model shape for individual patients at the bedside.", [["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182]]]], "3447c7e44f9daf94c25901cc47bc01ace5b9c699": [["With the spread of the Coronavirus, especially among the elderly, and the growing fear and anxiety, the issue of coronavirus stigma with the elderly or those associated with the elderly has become a major social concern.", [["Coronavirus", "DISEASE", 23, 34], ["anxiety", "DISEASE", 91, 98], ["coronavirus stigma", "DISEASE", 113, 131], ["coronavirus", "ORGANISM", 113, 124], ["the Coronavirus", "PROBLEM", 19, 34], ["anxiety", "PROBLEM", 91, 98], ["coronavirus stigma", "PROBLEM", 113, 131], ["Coronavirus", "OBSERVATION", 23, 34]]]], "PMC6901795": [["IntroductionThe innate immune system recognizes pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) as against microbial pathogen invasion (1).", [["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 48, 86], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 98, 127], ["PRRs", "GENE_OR_GENE_PRODUCT", 129, 133], ["pathogen-associated molecular patterns", "PROTEIN", 48, 86], ["PAMPs", "PROTEIN", 88, 93], ["pattern recognition receptors", "PROTEIN", 98, 127], ["PRRs", "PROTEIN", 129, 133], ["pathogen", "PROBLEM", 48, 56], ["microbial pathogen invasion", "PROBLEM", 146, 173]]], ["Retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs), as intracellular PRRs, composed of RIG-I, MDA5, and LGP2, recognize non-self signatures of viral RNAs in the cytosol of cells.", [["intracellular", "ANATOMY", 65, 78], ["cytosol", "ANATOMY", 171, 178], ["cells", "ANATOMY", 182, 187], ["Retinoic acid", "CHEMICAL", 0, 13], ["Retinoic acid", "CHEMICAL", 0, 13], ["Retinoic acid inducible gene-I", "GENE_OR_GENE_PRODUCT", 0, 30], ["RIG-I)-like receptors", "GENE_OR_GENE_PRODUCT", 32, 53], ["RLRs", "GENE_OR_GENE_PRODUCT", 55, 59], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 78], ["RIG-I", "GENE_OR_GENE_PRODUCT", 97, 102], ["MDA5", "GENE_OR_GENE_PRODUCT", 104, 108], ["LGP2", "GENE_OR_GENE_PRODUCT", 114, 118], ["cytosol", "CELLULAR_COMPONENT", 171, 178], ["cells", "CELL", 182, 187], ["Retinoic acid inducible gene-I (RIG-I)-like receptors", "PROTEIN", 0, 53], ["RLRs", "PROTEIN", 55, 59], ["intracellular PRRs", "PROTEIN", 65, 83], ["RIG-I", "DNA", 97, 102], ["MDA5", "DNA", 104, 108], ["LGP2", "DNA", 114, 118], ["viral RNAs", "RNA", 153, 163], ["Retinoic acid inducible gene-I (RIG-I)", "PROBLEM", 0, 38], ["intracellular PRRs", "PROBLEM", 65, 83], ["MDA5", "TEST", 104, 108], ["viral RNAs", "PROBLEM", 153, 163], ["MDA5", "ANATOMY", 104, 108], ["non-self signatures", "OBSERVATION", 130, 149], ["viral RNAs", "OBSERVATION", 153, 163]]], ["After activated by viral RNA, RIG-I and MDA5 recruited the downstream adaptor molecule, MAVS, to their N-terminal caspase-recruitment domains (CARDs).", [["N", "CHEMICAL", 103, 104], ["RIG-I", "GENE_OR_GENE_PRODUCT", 30, 35], ["MDA5", "GENE_OR_GENE_PRODUCT", 40, 44], ["MAVS", "GENE_OR_GENE_PRODUCT", 88, 92], ["caspase", "GENE_OR_GENE_PRODUCT", 114, 121], ["viral RNA", "RNA", 19, 28], ["RIG-I", "PROTEIN", 30, 35], ["MDA5", "PROTEIN", 40, 44], ["downstream adaptor molecule", "PROTEIN", 59, 86], ["MAVS", "PROTEIN", 88, 92], ["N-terminal caspase-recruitment domains", "PROTEIN", 103, 141], ["CARDs", "PROTEIN", 143, 148], ["MDA5", "TREATMENT", 40, 44], ["MAVS", "PROBLEM", 88, 92], ["terminal caspase", "TREATMENT", 105, 121], ["viral RNA", "OBSERVATION", 19, 28]]], ["Then, tumor necrosis factor receptor-associated factors (TRAF) and TANK-binding kinase 1/I\u03ba-B kinase \u03b5 interacted with MAVS, which in turn leads to the phosphorylation and cytoplasm-to-nucleus translocation of interferon (IFN) regulatory factor 3 (IRF3), and the activation of type I IFN.", [["cytoplasm", "ANATOMY", 172, 181], ["nucleus", "ANATOMY", 185, 192], ["tumor", "DISEASE", 6, 11], ["necrosis", "DISEASE", 12, 20], ["tumor necrosis factor receptor-associated factors", "GENE_OR_GENE_PRODUCT", 6, 55], ["TRAF", "GENE_OR_GENE_PRODUCT", 57, 61], ["TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 67, 88], ["I\u03ba-B kinase \u03b5", "GENE_OR_GENE_PRODUCT", 89, 102], ["MAVS", "GENE_OR_GENE_PRODUCT", 119, 123], ["cytoplasm", "ORGANISM_SUBSTANCE", 172, 181], ["nucleus", "CELLULAR_COMPONENT", 185, 192], ["interferon (IFN) regulatory factor 3", "GENE_OR_GENE_PRODUCT", 210, 246], ["IRF3", "GENE_OR_GENE_PRODUCT", 248, 252], ["type I IFN", "GENE_OR_GENE_PRODUCT", 277, 287], ["tumor necrosis factor receptor-associated factors", "PROTEIN", 6, 55], ["TRAF", "PROTEIN", 57, 61], ["TANK-binding kinase 1", "PROTEIN", 67, 88], ["I\u03ba-B kinase \u03b5", "PROTEIN", 89, 102], ["MAVS", "PROTEIN", 119, 123], ["interferon (IFN) regulatory factor 3", "PROTEIN", 210, 246], ["IRF3", "PROTEIN", 248, 252], ["type I IFN", "PROTEIN", 277, 287], ["tumor necrosis", "PROBLEM", 6, 20], ["TRAF", "TEST", 57, 61], ["TANK-binding kinase", "TEST", 67, 86], ["I\u03ba", "TEST", 89, 91], ["MAVS", "PROBLEM", 119, 123], ["interferon (IFN)", "TREATMENT", 210, 226], ["tumor", "OBSERVATION_MODIFIER", 6, 11], ["necrosis", "OBSERVATION", 12, 20]]], ["Subsequent IFNs activated a variety of IFN-stimulated genes (ISGs) to limit the virus replication (2).IntroductionNervous necrosis virus (NNV) is a non-enveloped, single-stranded RNA virus belonging to the family Nodaviridae.", [["Nervous necrosis", "DISEASE", 114, 130], ["IFNs", "GENE_OR_GENE_PRODUCT", 11, 15], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 39, 59], ["Nervous necrosis virus", "ORGANISM", 114, 136], ["Nodaviridae", "GENE_OR_GENE_PRODUCT", 213, 224], ["IFNs", "PROTEIN", 11, 15], ["IFN-stimulated genes", "DNA", 39, 59], ["ISGs", "DNA", 61, 65], ["Nervous necrosis virus", "SPECIES", 114, 136], ["NNV", "SPECIES", 138, 141], ["IFN-stimulated genes (ISGs)", "TREATMENT", 39, 66], ["the virus replication", "TREATMENT", 76, 97], ["IntroductionNervous necrosis virus", "PROBLEM", 102, 136], ["a non-enveloped, single-stranded RNA virus", "PROBLEM", 146, 188], ["Nervous", "ANATOMY", 114, 121], ["necrosis", "OBSERVATION", 122, 130]]], ["Increasing evidence has shown that NNV can infect more than 120 fish species and causes mass mortalities of infected fish worldwide (3).", [["mortalities of infected fish", "DISEASE", 93, 121], ["NNV", "GENE_OR_GENE_PRODUCT", 35, 38], ["fish", "ORGANISM_SUBDIVISION", 117, 121], ["NNV", "PROTEIN", 35, 38], ["NNV", "SPECIES", 35, 38], ["NNV", "PROBLEM", 35, 38], ["mass mortalities", "PROBLEM", 88, 104], ["NNV", "OBSERVATION", 35, 38], ["mass", "OBSERVATION", 88, 92], ["infected fish", "OBSERVATION", 108, 121]]], ["It has been revealed that RLRs respond in vivo or in vitro to the stimulation of NNV and possess capacities in the induction of IFNs and ISGs in a variety of fish species.", [["RLRs", "GENE_OR_GENE_PRODUCT", 26, 30], ["NNV", "GENE_OR_GENE_PRODUCT", 81, 84], ["IFNs", "GENE_OR_GENE_PRODUCT", 128, 132], ["fish", "ORGANISM", 158, 162], ["RLRs", "PROTEIN", 26, 30], ["NNV", "PROTEIN", 81, 84], ["IFNs", "PROTEIN", 128, 132], ["ISGs", "PROTEIN", 137, 141], ["NNV", "PROBLEM", 81, 84], ["possess capacities", "PROBLEM", 89, 107], ["IFNs", "TREATMENT", 128, 132], ["ISGs", "TREATMENT", 137, 141], ["fish species", "PROBLEM", 158, 170]]], ["For example, in ZF4 cells, expression of RLRs was significantly enhanced post-NNV infection and RIG-I knockdown significantly restrained group II type I IFN activation (4).", [["ZF4 cells", "ANATOMY", 16, 25], ["ZF4 cells", "CELL", 16, 25], ["RLRs", "GENE_OR_GENE_PRODUCT", 41, 45], ["RIG-I", "GENE_OR_GENE_PRODUCT", 96, 101], ["type I IFN", "GENE_OR_GENE_PRODUCT", 146, 156], ["ZF4 cells", "CELL_LINE", 16, 25], ["RLRs", "PROTEIN", 41, 45], ["IFN", "PROTEIN", 153, 156], ["NNV", "SPECIES", 78, 81], ["ZF4 cells", "PROBLEM", 16, 25], ["expression of RLRs", "PROBLEM", 27, 45], ["significantly enhanced", "PROBLEM", 50, 72], ["NNV infection", "PROBLEM", 78, 91], ["RIG-I knockdown", "TREATMENT", 96, 111], ["significantly", "OBSERVATION_MODIFIER", 50, 63], ["enhanced", "OBSERVATION_MODIFIER", 64, 72], ["NNV", "OBSERVATION_MODIFIER", 78, 81], ["infection", "OBSERVATION", 82, 91]]], ["Our previous studies also suggested that RLR signaling pathway was activated during red spotted grouper nervous necrosis virus (RGNNV) infection in sea perch and its key components possessed anti-RGNNV activities (5, 6).", [["nervous necrosis", "DISEASE", 104, 120], ["infection", "DISEASE", 135, 144], ["RLR", "GENE_OR_GENE_PRODUCT", 41, 44], ["red spotted grouper nervous necrosis virus", "ORGANISM", 84, 126], ["RGNNV", "ORGANISM", 128, 133], ["sea perch", "ORGANISM", 148, 157], ["anti-RGNNV", "GENE_OR_GENE_PRODUCT", 191, 201], ["RLR", "PROTEIN", 41, 44], ["grouper nervous necrosis virus", "SPECIES", 96, 126], ["red spotted grouper nervous necrosis virus", "SPECIES", 84, 126], ["RGNNV", "SPECIES", 128, 133], ["sea perch", "SPECIES", 148, 157], ["Our previous studies", "TEST", 0, 20], ["RLR signaling pathway", "PROBLEM", 41, 62], ["red spotted grouper nervous necrosis virus (RGNNV) infection in sea perch", "PROBLEM", 84, 157], ["spotted", "OBSERVATION_MODIFIER", 88, 95], ["grouper nervous necrosis", "OBSERVATION", 96, 120], ["infection", "OBSERVATION", 135, 144], ["sea perch", "OBSERVATION_MODIFIER", 148, 157]]], ["However, regulation mechanisms of RLR signaling pathway during RGNNV infection is still unclear.", [["infection", "DISEASE", 69, 78], ["RLR", "GENE_OR_GENE_PRODUCT", 34, 37], ["RGNNV", "GENE_OR_GENE_PRODUCT", 63, 68], ["RLR", "PROTEIN", 34, 37], ["RGNNV infection", "PROBLEM", 63, 78], ["infection", "OBSERVATION", 69, 78]]], ["RLR-mediated antiviral signaling pathway is tightly regulated at multiple steps in the signaling cascade.", [["RLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["RLR", "PROTEIN", 0, 3], ["RLR-mediated antiviral signaling pathway", "TREATMENT", 0, 40], ["antiviral signaling", "OBSERVATION", 13, 32], ["cascade", "OBSERVATION_MODIFIER", 97, 104]]], ["Several studies demonstrated that post-translational modifications, including ubiquitination, ISGylation, and phosphorylation, were important mechanisms that regulated the RLR signaling pathway, of which ubiquitination was a key regulatory mechanism for RLR pathway (2).", [["RLR", "GENE_OR_GENE_PRODUCT", 172, 175], ["RLR", "GENE_OR_GENE_PRODUCT", 254, 257], ["RLR", "PROTEIN", 172, 175], ["RLR", "PROTEIN", 254, 257], ["Several studies", "TEST", 0, 15], ["post-translational modifications", "PROBLEM", 34, 66], ["ubiquitination", "PROBLEM", 78, 92], ["ISGylation", "TREATMENT", 94, 104], ["phosphorylation", "TREATMENT", 110, 125], ["post-translational modifications", "OBSERVATION", 34, 66]]], ["For instance, RNF122 negatively regulated RLR signaling pathway by targeting RIG-I (7).", [["RNF122", "CHEMICAL", 14, 20], ["RNF122", "CHEMICAL", 14, 20], ["RNF122", "GENE_OR_GENE_PRODUCT", 14, 20], ["RLR", "GENE_OR_GENE_PRODUCT", 42, 45], ["RIG-I", "GENE_OR_GENE_PRODUCT", 77, 82], ["RNF122", "PROTEIN", 14, 20], ["RLR", "PROTEIN", 42, 45], ["RIG", "PROTEIN", 77, 80]]], ["MDA5 and MAVS were targeted for K48-linked ubiquitination by TRIM13 and RNF5, respectively, which induced MDA5 and MAVS degradation and RLRs signal termination (8, 9).", [["MDA5", "GENE_OR_GENE_PRODUCT", 0, 4], ["MAVS", "GENE_OR_GENE_PRODUCT", 9, 13], ["K48", "GENE_OR_GENE_PRODUCT", 32, 35], ["TRIM13", "GENE_OR_GENE_PRODUCT", 61, 67], ["RNF5", "GENE_OR_GENE_PRODUCT", 72, 76], ["MDA5", "GENE_OR_GENE_PRODUCT", 106, 110], ["MAVS", "GENE_OR_GENE_PRODUCT", 115, 119], ["MDA5", "PROTEIN", 0, 4], ["MAVS", "PROTEIN", 9, 13], ["K48", "PROTEIN", 32, 35], ["TRIM13", "PROTEIN", 61, 67], ["RNF5", "PROTEIN", 72, 76], ["MDA5", "PROTEIN", 106, 110], ["MAVS", "PROTEIN", 115, 119], ["RLRs", "PROTEIN", 136, 140], ["MDA5", "TREATMENT", 0, 4], ["MAVS", "TREATMENT", 9, 13], ["K48", "TEST", 32, 35], ["MAVS degradation", "PROBLEM", 115, 131], ["MAVS degradation", "OBSERVATION", 115, 131]]], ["TRIM25 E3 ubiquitin ligase induced the K63-linked ubiquitination of RIG-I, which activated RLR signaling pathway to elicit host antiviral innate immunity (10).IntroductionTRIM25, an IFN-inducible E3 ligase, is associated with all kinds of cellular processes, such as the immune response, cancer, and so on (11).", [["cellular", "ANATOMY", 239, 247], ["cancer", "ANATOMY", 288, 294], ["cancer", "DISEASE", 288, 294], ["TRIM25 E3", "GENE_OR_GENE_PRODUCT", 0, 9], ["K63", "GENE_OR_GENE_PRODUCT", 39, 42], ["RIG-I", "GENE_OR_GENE_PRODUCT", 68, 73], ["RLR", "GENE_OR_GENE_PRODUCT", 91, 94], ["IFN", "GENE_OR_GENE_PRODUCT", 182, 185], ["E3", "GENE_OR_GENE_PRODUCT", 196, 198], ["cellular", "CELL", 239, 247], ["cancer", "CANCER", 288, 294], ["TRIM25 E3 ubiquitin ligase", "PROTEIN", 0, 26], ["K63", "PROTEIN", 39, 42], ["RIG-I", "PROTEIN", 68, 73], ["RLR", "PROTEIN", 91, 94], ["IntroductionTRIM25", "PROTEIN", 159, 177], ["IFN", "PROTEIN", 182, 185], ["E3 ligase", "PROTEIN", 196, 205], ["the K63", "TEST", 35, 42], ["IntroductionTRIM25", "TREATMENT", 159, 177], ["an IFN-inducible E3 ligase", "PROBLEM", 179, 205], ["cellular processes", "PROBLEM", 239, 257], ["cancer", "PROBLEM", 288, 294], ["E3 ligase", "OBSERVATION", 196, 205], ["cellular processes", "OBSERVATION", 239, 257], ["cancer", "OBSERVATION", 288, 294]]], ["It is becoming evident that TRIM25 has a dual role in RIG-I regulation, since TRIM25 not only induces K63-linked ubiquitination of RIG-I to positive regulate RLR signaling activation but also negatively regulates RIG-I activation through inhibiting HLA-F adjacent transcription 10 degradation, a negative regulator of RIG-I-mediated inflammatory response (12).IntroductionMultiple fish TRIM25 homologs have been reported, including Rhodeus uyekii (13), Epinephelus coioides (14), and Larimichthys crocea (15).", [["TRIM25", "CHEMICAL", 28, 34], ["TRIM25", "GENE_OR_GENE_PRODUCT", 28, 34], ["RIG-I", "GENE_OR_GENE_PRODUCT", 54, 59], ["TRIM25", "GENE_OR_GENE_PRODUCT", 78, 84], ["K63", "GENE_OR_GENE_PRODUCT", 102, 105], ["RIG-I", "GENE_OR_GENE_PRODUCT", 131, 136], ["RLR", "GENE_OR_GENE_PRODUCT", 158, 161], ["RIG-I", "GENE_OR_GENE_PRODUCT", 213, 218], ["HLA-F adjacent transcription 10", "GENE_OR_GENE_PRODUCT", 249, 280], ["RIG-I", "GENE_OR_GENE_PRODUCT", 318, 323], ["fish", "ORGANISM", 381, 385], ["TRIM25", "GENE_OR_GENE_PRODUCT", 386, 392], ["Rhodeus uyekii", "ORGANISM", 432, 446], ["Epinephelus coioides", "ORGANISM", 453, 473], ["Larimichthys crocea", "ORGANISM", 484, 503], ["TRIM25", "PROTEIN", 28, 34], ["TRIM25", "PROTEIN", 78, 84], ["K63", "PROTEIN", 102, 105], ["RIG-I", "PROTEIN", 131, 136], ["RLR", "PROTEIN", 158, 161], ["RIG-I", "PROTEIN", 213, 218], ["RIG-I", "PROTEIN", 318, 323], ["fish TRIM25 homologs", "PROTEIN", 381, 401], ["Rhodeus uyekii", "SPECIES", 432, 446], ["Epinephelus coioides", "SPECIES", 453, 473], ["Larimichthys crocea", "SPECIES", 484, 503], ["Rhodeus uyekii", "SPECIES", 432, 446], ["Epinephelus coioides", "SPECIES", 453, 473], ["Larimichthys crocea", "SPECIES", 484, 503], ["K63", "TEST", 102, 105], ["inflammatory response", "PROBLEM", 333, 354], ["Epinephelus coioides", "PROBLEM", 453, 473], ["RLR signaling activation", "OBSERVATION", 158, 182], ["inflammatory", "OBSERVATION", 333, 345]]], ["Increasing evidence showed that fish TRIM25 was involved in antiviral immunity and played a pivotal role in RLR antiviral signaling pathway (14).", [["fish", "ORGANISM", 32, 36], ["TRIM25", "GENE_OR_GENE_PRODUCT", 37, 43], ["RLR", "GENE_OR_GENE_PRODUCT", 108, 111], ["TRIM25", "PROTEIN", 37, 43], ["antiviral immunity", "TREATMENT", 60, 78], ["fish TRIM25", "OBSERVATION", 32, 43]]], ["However, the mechanism by which fish TRIM25 regulates RLR signaling pathway has not been explored.", [["fish", "ORGANISM", 32, 36], ["TRIM25", "GENE_OR_GENE_PRODUCT", 37, 43], ["RLR", "GENE_OR_GENE_PRODUCT", 54, 57], ["TRIM25", "PROTEIN", 37, 43], ["RLR", "PROTEIN", 54, 57]]], ["In the present study, zebrafish TRIM25 (zbTRIM25) was involved in RGNNV infection and was identified as a positive mediator of RLR signaling pathway by binding to and ubiquitinating the caspase activation and recruitment domain (2CARD) and repressor domain (RD) regions of RIG-I, which is different with the findings in mammals.", [["infection", "DISEASE", 72, 81], ["zebrafish", "ORGANISM", 22, 31], ["TRIM25", "GENE_OR_GENE_PRODUCT", 32, 38], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 40, 48], ["RGNNV", "GENE_OR_GENE_PRODUCT", 66, 71], ["RLR", "GENE_OR_GENE_PRODUCT", 127, 130], ["caspase", "GENE_OR_GENE_PRODUCT", 186, 193], ["RIG-I", "GENE_OR_GENE_PRODUCT", 273, 278], ["zebrafish TRIM25", "PROTEIN", 22, 38], ["zbTRIM25", "PROTEIN", 40, 48], ["RLR", "PROTEIN", 127, 130], ["caspase activation and recruitment domain", "PROTEIN", 186, 227], ["2CARD", "PROTEIN", 229, 234], ["repressor domain (RD) regions", "PROTEIN", 240, 269], ["RIG-I", "PROTEIN", 273, 278], ["zebrafish", "SPECIES", 22, 31], ["zebrafish", "SPECIES", 22, 31], ["zebrafish TRIM25 (zbTRIM25", "TREATMENT", 22, 48], ["RGNNV infection", "PROBLEM", 66, 81], ["the caspase activation", "TREATMENT", 182, 204], ["recruitment domain (2CARD)", "TREATMENT", 209, 235], ["repressor domain (RD) regions of RIG-I", "PROBLEM", 240, 278], ["infection", "OBSERVATION", 72, 81], ["RIG", "OBSERVATION_MODIFIER", 273, 276], ["I", "ANATOMY_MODIFIER", 277, 278], ["different", "OBSERVATION_MODIFIER", 289, 298]]], ["Our findings reveal a novel mechanism of TRIM25 to activate RLR signaling pathway and will help to develop new treatments for viral nervous necrosis disease.Ethics Statement ::: Materials and MethodsAll procedures with zebrafish were approved by the Ethics Committee of Sun Yat-Sen University and the methods were carried out following the approved guidelines.Fish Strains, Cell Lines, Virus, and Reagents ::: Materials and MethodsZebrafish wild-type AB line was purchased from China Zebrafish Resource Center.", [["nervous", "ANATOMY", 132, 139], ["Cell", "ANATOMY", 374, 378], ["viral nervous necrosis disease", "DISEASE", 126, 156], ["TRIM25", "GENE_OR_GENE_PRODUCT", 41, 47], ["RLR", "GENE_OR_GENE_PRODUCT", 60, 63], ["zebrafish", "ORGANISM", 219, 228], ["Cell Lines", "CELL", 374, 384], ["AB line", "CELL", 451, 458], ["TRIM25", "PROTEIN", 41, 47], ["RLR", "PROTEIN", 60, 63], ["MethodsZebrafish wild-type AB line", "CELL_LINE", 424, 458], ["new treatments", "TREATMENT", 107, 121], ["viral nervous necrosis disease", "PROBLEM", 126, 156], ["Fish Strains", "PROBLEM", 360, 372], ["Materials", "TREATMENT", 410, 419], ["MethodsZebrafish wild-type AB line", "TREATMENT", 424, 458], ["viral nervous", "OBSERVATION", 126, 139], ["necrosis", "OBSERVATION", 140, 148], ["Cell Lines", "OBSERVATION", 374, 384]]], ["Fish were raised with 10 h darkness and 14 h light at 28\u00b0C and were fed with commercial pellets twice a day.", [["commercial pellets", "TREATMENT", 77, 95]]], ["All embryos were obtained by natural spawning and staged as previously reported (16).Fish Strains, Cell Lines, Virus, and Reagents ::: Materials and MethodsZBE3 cells derived from zebrafish embryos were cultured at 28\u00b0C as previously described (17).", [["embryos", "ANATOMY", 4, 11], ["Cell", "ANATOMY", 99, 103], ["MethodsZBE3 cells", "ANATOMY", 149, 166], ["embryos", "ANATOMY", 190, 197], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 4, 11], ["Cell Lines", "CELL", 99, 109], ["MethodsZBE3 cells", "CELL", 149, 166], ["zebrafish", "ORGANISM", 180, 189], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 190, 197], ["C", "GENE_OR_GENE_PRODUCT", 218, 219], ["MethodsZBE3 cells", "CELL_LINE", 149, 166], ["zebrafish", "SPECIES", 180, 189], ["zebrafish", "SPECIES", 180, 189], ["All embryos", "PROBLEM", 0, 11], ["Fish Strains", "PROBLEM", 85, 97], ["MethodsZBE3 cells", "TREATMENT", 149, 166], ["zebrafish embryos", "PROBLEM", 180, 197], ["embryos", "OBSERVATION", 4, 11], ["Cell Lines", "OBSERVATION", 99, 109]]], ["HEK 293T cells were cultured in DMEM (Invitrogen) enriched with 10% FBS (Invitrogen) at 37\u00b0C under a humidified atmosphere of air containing 5% CO2.Fish Strains, Cell Lines, Virus, and Reagents ::: Materials and MethodsRGNNV was propagated in ZBE3 cells and stored at \u221280\u00b0C until use.Fish Strains, Cell Lines, Virus, and Reagents ::: Materials and MethodsAnti-Flag (M20008), anti-Myc (M20002), anti-His (M20001L), and anti-HA antibodies (M20013) were purchased from Abmart.", [["HEK 293T cells", "ANATOMY", 0, 14], ["Cell", "ANATOMY", 162, 166], ["ZBE3 cells", "ANATOMY", 243, 253], ["Cell", "ANATOMY", 298, 302], ["CO2", "CHEMICAL", 144, 147], ["CO2", "CHEMICAL", 144, 147], ["HEK 293T cells", "CELL", 0, 14], ["FBS", "ORGANISM_SUBSTANCE", 68, 71], ["CO2", "SIMPLE_CHEMICAL", 144, 147], ["Cell Lines", "CELL", 162, 172], ["ZBE3 cells", "CELL", 243, 253], ["Cell Lines", "CELL", 298, 308], ["anti-Myc", "GENE_OR_GENE_PRODUCT", 375, 383], ["M20002", "SIMPLE_CHEMICAL", 385, 391], ["anti-His", "GENE_OR_GENE_PRODUCT", 394, 402], ["HEK 293T cells", "CELL_LINE", 0, 14], ["MethodsRGNNV", "DNA", 212, 224], ["ZBE3 cells", "CELL_LINE", 243, 253], ["Flag", "PROTEIN", 360, 364], ["M20008", "PROTEIN", 366, 372], ["anti", "PROTEIN", 375, 379], ["Myc", "PROTEIN", 380, 383], ["M20002", "PROTEIN", 385, 391], ["anti", "PROTEIN", 394, 398], ["His", "PROTEIN", 399, 402], ["M20001L", "PROTEIN", 404, 411], ["anti-HA antibodies", "PROTEIN", 418, 436], ["M20013", "PROTEIN", 438, 444], ["HEK 293T cells", "TEST", 0, 14], ["Invitrogen", "TEST", 38, 48], ["a humidified atmosphere of air", "TREATMENT", 99, 129], ["Fish Strains", "PROBLEM", 148, 160], ["MethodsRGNNV", "TREATMENT", 212, 224], ["Fish Strains", "PROBLEM", 284, 296], ["MethodsAnti-Flag (M20008)", "TREATMENT", 348, 373], ["anti-Myc (M20002)", "TREATMENT", 375, 392], ["anti-His (M20001L)", "TREATMENT", 394, 412], ["anti-HA antibodies", "TREATMENT", 418, 436], ["293T cells", "OBSERVATION", 4, 14], ["Cell Lines", "OBSERVATION", 162, 172], ["Cell Lines", "OBSERVATION", 298, 308]]], ["Anti-\u03b1-tubulin (ab15246) and anti-GFP antibodies (G1544) were purchased from Abcam and Sigma, respectively.", [["Anti-\u03b1-tubulin", "GENE_OR_GENE_PRODUCT", 0, 14], ["ab15246", "GENE_OR_GENE_PRODUCT", 16, 23], ["anti-GFP antibodies", "GENE_OR_GENE_PRODUCT", 29, 48], ["Abcam", "GENE_OR_GENE_PRODUCT", 77, 82], ["Anti-\u03b1-tubulin", "PROTEIN", 0, 14], ["ab15246", "PROTEIN", 16, 23], ["anti-GFP antibodies", "PROTEIN", 29, 48], ["G1544", "PROTEIN", 50, 55], ["Abcam", "PROTEIN", 77, 82], ["Anti-\u03b1-tubulin", "TREATMENT", 0, 14], ["anti-GFP antibodies", "TEST", 29, 48]]], ["Goat anti-rabbit IgG-HRP, goat anti-mouse IgG-HRP, Alexa Fluor 488-labeled goat anti-mouse IgG, and Alexa Fluor 555-labeled goat anti-rabbit IgG secondary antibodies were purchased from Invitrogen.Viral Challenge ::: Materials and MethodsFor in vitro infection, ZBE3 cells were challenged with RGNNV [multiplicity of infection (MOI) = 1] for 6, 12, and 24 h, respectively.", [["ZBE3 cells", "ANATOMY", 262, 272], ["infection", "DISEASE", 251, 260], ["RGNNV", "CHEMICAL", 294, 299], ["infection", "DISEASE", 317, 326], ["Alexa Fluor 488", "CHEMICAL", 51, 66], ["Alexa Fluor 555", "CHEMICAL", 100, 115], ["HRP", "GENE_OR_GENE_PRODUCT", 21, 24], ["HRP", "GENE_OR_GENE_PRODUCT", 46, 49], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 51, 66], ["goat", "ORGANISM", 75, 79], ["Alexa Fluor 555", "SIMPLE_CHEMICAL", 100, 115], ["goat", "ORGANISM", 124, 128], ["ZBE3 cells", "CELL", 262, 272], ["Goat anti-rabbit IgG", "PROTEIN", 0, 20], ["HRP", "PROTEIN", 21, 24], ["goat anti-mouse IgG", "PROTEIN", 26, 45], ["HRP", "PROTEIN", 46, 49], ["Alexa Fluor 488-labeled goat anti-mouse IgG", "PROTEIN", 51, 94], ["Alexa Fluor 555-labeled goat anti-rabbit IgG secondary antibodies", "PROTEIN", 100, 165], ["ZBE3 cells", "CELL_LINE", 262, 272], ["Goat", "SPECIES", 0, 4], ["anti-rabbit", "SPECIES", 5, 16], ["goat", "SPECIES", 26, 30], ["anti-mouse", "SPECIES", 31, 41], ["goat", "SPECIES", 75, 79], ["anti-mouse", "SPECIES", 80, 90], ["goat", "SPECIES", 124, 128], ["anti-rabbit", "SPECIES", 129, 140], ["Goat", "SPECIES", 0, 4], ["goat", "SPECIES", 26, 30], ["goat", "SPECIES", 75, 79], ["Alexa Fluor 555", "SPECIES", 100, 115], ["goat", "SPECIES", 124, 128], ["anti-rabbit", "SPECIES", 129, 140], ["Goat anti-rabbit IgG", "TEST", 0, 20], ["HRP", "TEST", 21, 24], ["goat anti-mouse IgG", "TEST", 26, 45], ["Alexa Fluor", "TEST", 51, 62], ["anti-mouse IgG", "TEST", 80, 94], ["Alexa Fluor", "TEST", 100, 111], ["labeled goat anti-rabbit IgG secondary antibodies", "TREATMENT", 116, 165], ["Materials", "TREATMENT", 217, 226], ["Methods", "TREATMENT", 231, 238], ["vitro infection", "PROBLEM", 245, 260], ["ZBE3 cells", "PROBLEM", 262, 272], ["infection", "PROBLEM", 317, 326], ["infection", "OBSERVATION", 251, 260], ["infection", "OBSERVATION", 317, 326]]], ["Subsequently, RNA from cells was extracted to detect the expression of zbTRIM25 mRNA by quantitative real-time PCR (qRT-PCR).Viral Challenge ::: Materials and MethodsFor in vivo infection, RGNNVs (108 TCID50/ml) were injected into the egg yolk of 50 embryos at the single-cell stage in the experimental group.", [["cells", "ANATOMY", 23, 28], ["egg yolk", "ANATOMY", 235, 243], ["embryos", "ANATOMY", 250, 257], ["cell", "ANATOMY", 272, 276], ["infection", "DISEASE", 178, 187], ["RGNNVs", "CHEMICAL", 189, 195], ["cells", "CELL", 23, 28], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 71, 79], ["egg yolk", "MULTI-TISSUE_STRUCTURE", 235, 243], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 250, 257], ["single-cell", "CELL", 265, 276], ["zbTRIM25 mRNA", "RNA", 71, 84], ["zbTRIM25 mRNA", "PROBLEM", 71, 84], ["PCR", "TEST", 111, 114], ["qRT", "TEST", 116, 119], ["PCR", "TEST", 120, 123], ["Methods", "TREATMENT", 159, 166], ["vivo infection", "PROBLEM", 173, 187], ["RGNNVs", "TEST", 189, 195], ["the egg yolk", "TREATMENT", 231, 243], ["infection", "OBSERVATION", 178, 187]]], ["In the mock group, 50 embryos were injected with DMEM.", [["embryos", "ANATOMY", 22, 29], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 22, 29]]], ["A total of 1 nl of solution was microinjected into each embryo using a microinjector.", [["embryo", "ANATOMY", 56, 62], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 56, 62], ["1 nl of solution", "TREATMENT", 11, 27], ["a microinjector", "TREATMENT", 69, 84]]], ["RNA from zebrafish embryo was extracted to detect the expression of zbTRIM25 mRNA by qRT-PCR at 24 h post-injection.Knockdown of zbTRIM25 by siRNA ::: Materials and MethodszbTRIM25 siRNA (5\u2032-GAATCCAGTTGAAGAGAAA-3\u2032) and control siRNA were synthesized by Ribobio Company (Guangzhou, China).", [["embryo", "ANATOMY", 19, 25], ["zebrafish", "ORGANISM", 9, 18], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 19, 25], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 68, 76], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 129, 137], ["MethodszbTRIM25", "GENE_OR_GENE_PRODUCT", 165, 180], ["RNA", "RNA", 0, 3], ["zbTRIM25 mRNA", "RNA", 68, 81], ["zbTRIM25", "DNA", 129, 137], ["zebrafish", "SPECIES", 9, 18], ["zebrafish", "SPECIES", 9, 18], ["zbTRIM25 mRNA", "TREATMENT", 68, 81], ["PCR", "TEST", 89, 92], ["zbTRIM25", "TREATMENT", 129, 137], ["MethodszbTRIM25 siRNA", "TREATMENT", 165, 186], ["GAATCCAGTTGAAGAGAAA", "TEST", 191, 210], ["control siRNA", "TREATMENT", 219, 232], ["zebrafish embryo", "OBSERVATION", 9, 25]]], ["ZBE3 cells were transfected with zbTRIM25 siRNA or control siRNA according to the manufacturer's protocol using Lipofectamine 3000 as previously described (18).", [["ZBE3 cells", "ANATOMY", 0, 10], ["ZBE3 cells", "CELL", 0, 10], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 33, 41], ["ZBE3 cells", "CELL_LINE", 0, 10], ["ZBE3 cells", "PROBLEM", 0, 10], ["zbTRIM25 siRNA", "TREATMENT", 33, 47], ["control siRNA", "TREATMENT", 51, 64], ["the manufacturer's protocol", "TREATMENT", 78, 105], ["Lipofectamine", "TREATMENT", 112, 125]]], ["Twenty-four hours after transfection, ZBE3 cells were infected with RGNNV (MOI = 1) for 24 h and total RNAs were extracted for qRT-PCR analysis.Plasmid Construction ::: Materials and MethodsThe ORF of zbTRIM25 (GenBank accession no. NM200175.1) was sub-cloned into pCMV-Flag or pCMV-Myc vectors (Invitrogen) to generate recombinant plasmid pCMV-Flag-zbTRIM25 or pCMV-Myc-zbTRIM25, respectively.", [["ZBE3 cells", "ANATOMY", 38, 48], ["plasmid", "ANATOMY", 332, 339], ["NM200175.1", "CHEMICAL", 233, 243], ["ZBE3 cells", "CELL", 38, 48], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 201, 209], ["NM200175.1", "SIMPLE_CHEMICAL", 233, 243], ["pCMV", "ORGANISM", 265, 269], ["Flag", "GENE_OR_GENE_PRODUCT", 270, 274], ["pCMV-Myc", "GENE_OR_GENE_PRODUCT", 278, 286], ["Invitrogen", "ORGANISM", 296, 306], ["pCMV-Flag-zbTRIM25", "GENE_OR_GENE_PRODUCT", 340, 358], ["pCMV-Myc-zbTRIM25", "GENE_OR_GENE_PRODUCT", 362, 379], ["ZBE3 cells", "CELL_LINE", 38, 48], ["ORF", "DNA", 194, 197], ["zbTRIM25", "DNA", 201, 209], ["pCMV-Flag or pCMV-Myc vectors", "DNA", 265, 294], ["pCMV", "PROTEIN", 340, 344], ["Flag-zbTRIM25", "DNA", 345, 358], ["pCMV", "DNA", 362, 366], ["Myc-zbTRIM25", "DNA", 367, 379], ["transfection", "TREATMENT", 24, 36], ["ZBE3 cells", "PROBLEM", 38, 48], ["RGNNV", "TEST", 68, 73], ["MOI", "TEST", 75, 78], ["total RNAs", "TEST", 97, 107], ["qRT", "TEST", 127, 130], ["PCR analysis", "TEST", 131, 143], ["pCMV", "TREATMENT", 278, 282], ["Myc vectors", "TREATMENT", 283, 294], ["recombinant plasmid pCMV", "TREATMENT", 320, 344], ["Flag-zbTRIM25", "TREATMENT", 345, 358], ["pCMV", "TREATMENT", 362, 366]]], ["Full-length zbRIG-I and zbRIG-I deletion mutant cDNAs encoding amino acids 1\u2013187 (zbRIG-I-2CARD), 188\u2013937 (zbRIG-I-\u03942CARD), 812\u2013927 (zbRIG-I-RD), and 188\u2013811 [zbRIG-I-\u0394(2CARD+RD)] were inserted into the pEGFP-N3 vectors.", [["amino acids", "CHEMICAL", 63, 74], ["amino acids", "CHEMICAL", 63, 74], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 12, 19], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 24, 31], ["amino acids", "AMINO_ACID", 63, 74], ["zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 82, 95], ["zbRIG-I-\u03942CARD", "GENE_OR_GENE_PRODUCT", 107, 121], ["zbRIG-I-RD", "GENE_OR_GENE_PRODUCT", 133, 143], ["2CARD+RD)", "GENE_OR_GENE_PRODUCT", 169, 178], ["pEGFP", "GENE_OR_GENE_PRODUCT", 203, 208], ["zbRIG-I and zbRIG-I deletion mutant cDNAs", "DNA", 12, 53], ["amino acids 1\u2013187", "PROTEIN", 63, 80], ["zbRIG", "PROTEIN", 82, 87], ["I", "PROTEIN", 88, 89], ["2CARD", "PROTEIN", 90, 95], ["188\u2013937", "PROTEIN", 98, 105], ["zbRIG", "PROTEIN", 107, 112], ["I", "PROTEIN", 113, 114], ["\u03942CARD", "PROTEIN", 115, 121], ["812\u2013927", "PROTEIN", 124, 131], ["zbRIG", "PROTEIN", 133, 138], ["188\u2013811", "PROTEIN", 150, 157], ["zbRIG", "PROTEIN", 159, 164], ["I", "PROTEIN", 165, 166], ["2CARD", "PROTEIN", 169, 174], ["pEGFP-N3 vectors", "DNA", 203, 219], ["zbRIG", "TEST", 12, 17], ["zbRIG", "TEST", 24, 29], ["amino acids", "TEST", 63, 74], ["zbRIG", "TEST", 82, 87], ["zbRIG", "TEST", 107, 112], ["zbRIG", "TEST", 133, 138], ["zbRIG", "TEST", 159, 164], ["N3 vectors", "OBSERVATION", 209, 219]]], ["Full-length zbRIG-I was inserted into the pET-32a(+) (Clontech) vector to generate recombinant plasmid pET-32a(+)-zbRIG-I. zbTRIM25 deletion mutant zbTRIM25-SPRY and zbTRIM25-\u0394SPRY were generated using the pCMV-Flag-zbTRIM25 plasmid as a template.", [["zbRIG-I", "GENE_OR_GENE_PRODUCT", 12, 19], ["pET-32a", "GENE_OR_GENE_PRODUCT", 42, 49], ["Clontech", "GENE_OR_GENE_PRODUCT", 54, 62], ["pET-32a", "GENE_OR_GENE_PRODUCT", 103, 110], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 123, 131], ["zbTRIM25-SPRY", "GENE_OR_GENE_PRODUCT", 148, 161], ["zbTRIM25-\u0394SPRY", "GENE_OR_GENE_PRODUCT", 166, 180], ["zbRIG-I", "DNA", 12, 19], ["pET-32a(+) (Clontech) vector", "DNA", 42, 70], ["recombinant plasmid pET-32a(+)-zbRIG-I. zbTRIM25 deletion mutant zbTRIM25-SPRY and zbTRIM25-\u0394SPRY", "DNA", 83, 180], ["pCMV-Flag-zbTRIM25 plasmid", "DNA", 206, 232], ["the pET", "TEST", 38, 45], ["recombinant plasmid pET", "TEST", 83, 106], ["zbRIG", "TREATMENT", 114, 119], ["zbTRIM25 deletion mutant zbTRIM25", "TREATMENT", 123, 156], ["zbTRIM25-\u0394SPRY", "TREATMENT", 166, 180], ["the pCMV", "TREATMENT", 202, 210], ["Flag-zbTRIM25 plasmid", "TREATMENT", 211, 232]]], ["Primers used for amplifying these genes are listed in Table S1.Plasmid Construction ::: Materials and MethodsHA-K63Ub plasmid was purchased from Rebio (Shanghai, China).RNA Isolation and qRT-PCR ::: Materials and MethodsRNA extraction and cDNA synthesis were performed using Trizol (Invitrogen) and PrimeScript\u2122 1st Strand cDNA Synthesis Kit (Takara) according to the manufacturer's instructions.", [["MethodsHA", "DNA", 102, 111], ["K63Ub plasmid", "DNA", 112, 125], ["Primers", "TREATMENT", 0, 7], ["MethodsHA", "TREATMENT", 102, 111], ["K63Ub plasmid", "TREATMENT", 112, 125], ["MethodsRNA extraction", "TREATMENT", 213, 234], ["cDNA synthesis", "TEST", 239, 253], ["Trizol (Invitrogen)", "TREATMENT", 275, 294], ["PrimeScript\u2122 1st Strand cDNA Synthesis Kit (Takara)", "TREATMENT", 299, 350]]], ["QRT-PCR analyses of zbTRIM25, zbRIG-I, RNA dependent RNA polymerase (RDRP), RLR signaling pathway related genes (MAVS, TRAF3, IRF3, and IFN 1), and ISG15 were performed as previously described (19).", [["zbTRIM25", "GENE_OR_GENE_PRODUCT", 20, 28], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 30, 37], ["RNA dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 39, 67], ["RDRP", "GENE_OR_GENE_PRODUCT", 69, 73], ["RLR", "GENE_OR_GENE_PRODUCT", 76, 79], ["MAVS", "GENE_OR_GENE_PRODUCT", 113, 117], ["TRAF3", "GENE_OR_GENE_PRODUCT", 119, 124], ["IRF3", "GENE_OR_GENE_PRODUCT", 126, 130], ["IFN 1", "GENE_OR_GENE_PRODUCT", 136, 141], ["ISG15", "GENE_OR_GENE_PRODUCT", 148, 153], ["zbTRIM25", "DNA", 20, 28], ["zbRIG", "DNA", 30, 35], ["RNA dependent RNA polymerase", "PROTEIN", 39, 67], ["RDRP", "PROTEIN", 69, 73], ["RLR", "PROTEIN", 76, 79], ["MAVS", "DNA", 113, 117], ["TRAF3", "DNA", 119, 124], ["IRF3", "DNA", 126, 130], ["IFN 1", "DNA", 136, 141], ["ISG15", "DNA", 148, 153], ["QRT", "TEST", 0, 3], ["PCR analyses", "TEST", 4, 16], ["zbTRIM25", "TEST", 20, 28], ["zbRIG", "TEST", 30, 35], ["RNA dependent RNA polymerase (RDRP)", "PROBLEM", 39, 74], ["RLR signaling pathway related genes", "PROBLEM", 76, 111], ["MAVS", "TEST", 113, 117], ["TRAF3", "TEST", 119, 124], ["IRF3", "TEST", 126, 130], ["IFN", "TEST", 136, 139], ["ISG15", "TEST", 148, 153]]], ["Relative expression levels of target genes were normalized to 18s rRNA using 2\u2212\u0394\u0394Ct methods.", [["target genes", "DNA", 30, 42], ["18s rRNA", "RNA", 62, 70], ["Relative expression levels of target genes", "PROBLEM", 0, 42]]], ["Primers sequences used for qRT-PCR are listed in Table S1.Dual Luciferase Reporter Assay ::: Materials and MethodsHEK 293T cells, pre-seeded in 24-well plates, were transfected with 250 ng of pGL3-DrIFN 1-pro-Luc plasmid or pGL3-Basic empty vector with 25 ng of pRL-TK vector (Promega) together with pCMV-Myc-zbRIG-I or pCMV-Myc and pCMV-Flag or pCMV-Flag-zbTRIM25 (250 ng per well) for 24 h.", [["MethodsHEK 293T cells", "ANATOMY", 107, 128], ["pCMV-Flag-zbTRIM25", "CHEMICAL", 346, 364], ["MethodsHEK 293T cells", "CELL", 107, 128], ["pGL3", "GENE_OR_GENE_PRODUCT", 192, 196], ["Luc", "GENE_OR_GENE_PRODUCT", 209, 212], ["pGL3", "GENE_OR_GENE_PRODUCT", 224, 228], ["pRL", "GENE_OR_GENE_PRODUCT", 262, 265], ["Promega", "ORGANISM", 277, 284], ["pCMV-Myc-zbRIG-I", "GENE_OR_GENE_PRODUCT", 300, 316], ["pCMV-Myc", "GENE_OR_GENE_PRODUCT", 320, 328], ["pCMV-Flag", "GENE_OR_GENE_PRODUCT", 333, 342], ["pCMV-Flag-zbTRIM25", "SIMPLE_CHEMICAL", 346, 364], ["qRT", "DNA", 27, 30], ["MethodsHEK 293T cells", "CELL_LINE", 107, 128], ["pGL3-DrIFN 1-pro-Luc plasmid", "DNA", 192, 220], ["pGL3-Basic empty vector", "DNA", 224, 247], ["pRL-TK vector", "DNA", 262, 275], ["pCMV", "PROTEIN", 300, 304], ["Myc-zbRIG", "PROTEIN", 305, 314], ["pCMV", "PROTEIN", 320, 324], ["Myc", "PROTEIN", 325, 328], ["pCMV", "PROTEIN", 333, 337], ["Flag", "PROTEIN", 338, 342], ["pCMV", "DNA", 346, 350], ["Flag-zbTRIM25", "DNA", 351, 364], ["Primers sequences", "TEST", 0, 17], ["qRT-PCR", "TEST", 27, 34], ["pGL3", "TEST", 192, 196], ["DrIFN", "TEST", 197, 202], ["Luc plasmid", "TREATMENT", 209, 220], ["pGL3", "TEST", 224, 228], ["Basic empty vector", "TREATMENT", 229, 247], ["pRL-TK vector (Promega)", "TREATMENT", 262, 285], ["pCMV", "TREATMENT", 300, 304], ["Myc-zbRIG", "TREATMENT", 305, 314], ["pCMV", "TREATMENT", 320, 324], ["Myc and pCMV", "TREATMENT", 325, 337], ["Flag", "TREATMENT", 338, 342], ["pCMV", "TREATMENT", 346, 350], ["Flag-zbTRIM25", "TREATMENT", 351, 364]]], ["Then, cells were incubated with poly I:C for 48 h and lysed.", [["cells", "ANATOMY", 6, 11], ["poly I:C", "CHEMICAL", 32, 40], ["poly I:C", "CHEMICAL", 32, 40], ["cells", "CELL", 6, 11], ["poly I:C", "SIMPLE_CHEMICAL", 32, 40]]], ["Luciferase activities were measured using the dual-luciferase reporter assay system (Promega).", [["luciferase", "GENE_OR_GENE_PRODUCT", 51, 61], ["Luciferase activities", "TEST", 0, 21]]], ["Relative luciferase activities were expressed as the ratio of firefly to Renilla luciferase activity.", [["luciferase", "GENE_OR_GENE_PRODUCT", 9, 19], ["luciferase", "GENE_OR_GENE_PRODUCT", 81, 91], ["luciferase", "PROTEIN", 9, 19], ["luciferase", "PROTEIN", 81, 91], ["Relative luciferase activities", "PROBLEM", 0, 30], ["luciferase activities", "OBSERVATION", 9, 30]]], ["The results were the representative of three independent experiments in triplicate.Dual Luciferase Reporter Assay ::: Materials and MethodsHEK 293T cells, pre-seeded in 24-well plates, were transfected with 250 ng of pGL3-DrIFN1-pro-Luc plasmid or pGL3-Basic empty vector with 25 ng of pRL-TK vector (Promega).", [["MethodsHEK 293T cells", "ANATOMY", 132, 153], ["MethodsHEK 293T cells", "CELL", 132, 153], ["pGL3", "GENE_OR_GENE_PRODUCT", 217, 221], ["DrIFN1", "GENE_OR_GENE_PRODUCT", 222, 228], ["Luc", "GENE_OR_GENE_PRODUCT", 233, 236], ["pGL3", "GENE_OR_GENE_PRODUCT", 248, 252], ["pRL", "GENE_OR_GENE_PRODUCT", 286, 289], ["Promega", "ORGANISM", 301, 308], ["MethodsHEK 293T cells", "CELL_LINE", 132, 153], ["pGL3-DrIFN1-pro-Luc plasmid", "DNA", 217, 244], ["pGL3-Basic empty vector", "DNA", 248, 271], ["pRL-TK vector", "DNA", 286, 299], ["pGL3", "TEST", 217, 221], ["Luc plasmid", "TREATMENT", 233, 244], ["pGL3", "TREATMENT", 248, 252], ["Basic empty vector", "TREATMENT", 253, 271], ["pRL-TK vector (Promega)", "TREATMENT", 286, 309]]], ["Meanwhile, pCMV-Myc-zbTRIM25, mutant zbRIG-I or empty control plasmids were co-transfected.", [["plasmids", "ANATOMY", 62, 70], ["pCMV-Myc-zbTRIM25", "GENE_OR_GENE_PRODUCT", 11, 28], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 37, 44], ["pCMV-Myc-zbTRIM25, mutant zbRIG-I or empty control plasmids", "DNA", 11, 70], ["pCMV", "TEST", 11, 15], ["Myc-zbTRIM25", "TREATMENT", 16, 28], ["mutant zbRIG", "TREATMENT", 30, 42], ["empty control plasmids", "TREATMENT", 48, 70]]], ["After being incubated with poly I:C for 48 h, cells were lysed for luciferase assay as described above.", [["cells", "ANATOMY", 46, 51], ["poly I:C", "CHEMICAL", 27, 35], ["poly I:C", "CHEMICAL", 27, 35], ["poly I:C", "SIMPLE_CHEMICAL", 27, 35], ["cells", "CELL", 46, 51], ["luciferase", "GENE_OR_GENE_PRODUCT", 67, 77], ["luciferase", "PROTEIN", 67, 77], ["luciferase assay", "TEST", 67, 83]]], ["At least three independent experiments were performed.Immunofluorescence Labeling and Confocal Microscopy ::: Materials and MethodsHEK 293T cells, seeded on glass cover slips, were transfected with pCMV-Myc-zbTRIM25 and pCMV-Flag-zbRIG-I plasmids.", [["293T cells", "ANATOMY", 135, 145], ["MethodsHEK 293T cells", "CELL", 124, 145], ["pCMV-Myc-zbTRIM25", "GENE_OR_GENE_PRODUCT", 198, 215], ["pCMV-Flag-zbRIG-I", "GENE_OR_GENE_PRODUCT", 220, 237], ["MethodsHEK 293T cells", "CELL_LINE", 124, 145], ["pCMV-Myc-zbTRIM25 and pCMV-Flag-zbRIG-I plasmids", "DNA", 198, 246], ["MethodsHEK 293T cells", "TREATMENT", 124, 145], ["glass cover slips", "TREATMENT", 157, 174], ["pCMV", "TREATMENT", 198, 202], ["Myc-zbTRIM25", "TREATMENT", 203, 215], ["pCMV", "TREATMENT", 220, 224], ["Flag", "TREATMENT", 225, 229], ["zbRIG-I plasmids", "TREATMENT", 230, 246]]], ["Twenty-four hours post-transfection, cells were washed with PBS three times and fixed with prechilled methanol and then permeabilized using 1% Triton X-100 in PBS for 10 min and blocked with 5% normal goat serum for 30 min at room temperature (RT).", [["cells", "ANATOMY", 37, 42], ["serum", "ANATOMY", 206, 211], ["Triton X-100", "CHEMICAL", 143, 155], ["methanol", "CHEMICAL", 102, 110], ["cells", "CELL", 37, 42], ["methanol", "SIMPLE_CHEMICAL", 102, 110], ["Triton X-100", "SIMPLE_CHEMICAL", 143, 155], ["goat", "ORGANISM", 201, 205], ["serum", "ORGANISM_SUBSTANCE", 206, 211], ["goat", "SPECIES", 201, 205], ["goat", "SPECIES", 201, 205], ["PBS", "TREATMENT", 60, 63], ["prechilled methanol", "TREATMENT", 91, 110], ["1% Triton", "TREATMENT", 140, 149]]], ["Cells were incubated with anti-Myc and anti-Flag antibodies for 60 min at RT.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["anti-Myc", "GENE_OR_GENE_PRODUCT", 26, 34], ["anti-Flag", "GENE_OR_GENE_PRODUCT", 39, 48], ["anti-Myc", "PROTEIN", 26, 34], ["anti-Flag antibodies", "PROTEIN", 39, 59], ["anti-Myc", "TREATMENT", 26, 34], ["anti-Flag antibodies", "TREATMENT", 39, 59]]], ["Finally, cells were washed with PBS and incubated with the appropriate Alexa Fluor 488 or 555 conjugated secondary antibodies for 1 h.", [["cells", "ANATOMY", 9, 14], ["Alexa Fluor 488", "CHEMICAL", 71, 86], ["cells", "CELL", 9, 14], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 71, 86], ["555 conjugated", "SIMPLE_CHEMICAL", 90, 104], ["Alexa Fluor 488 or 555 conjugated secondary antibodies", "PROTEIN", 71, 125], ["Alexa Fluor 488", "SPECIES", 71, 86], ["PBS", "TREATMENT", 32, 35]]], ["After cell nucleus was stained with Hoechst 33342, cells were observed by a confocal microscope (Zeiss, Germany).Coimmunoprecipitations (Co-IP) and Western Blotting Analysis ::: Materials and MethodsCo-IP and Western blotting experiments were performed as described previously (18).", [["cell nucleus", "ANATOMY", 6, 18], ["cells", "ANATOMY", 51, 56], ["Hoechst 33342", "CHEMICAL", 36, 49], ["Hoechst 33342", "CHEMICAL", 36, 49], ["cell nucleus", "CELLULAR_COMPONENT", 6, 18], ["Hoechst 33342", "SIMPLE_CHEMICAL", 36, 49], ["cells", "CELL", 51, 56], ["a confocal microscope", "TEST", 74, 95], ["Western blotting experiments", "TEST", 209, 237], ["cell nucleus", "OBSERVATION", 6, 18]]], ["HEK 293T cells in 75-cm2 flasks were co-transfected with 10 \u03bcg of different plasmid combinations for 48 h.", [["HEK 293T cells", "ANATOMY", 0, 14], ["plasmid", "ANATOMY", 76, 83], ["HEK 293T cells", "CELL", 0, 14], ["HEK 293T cells", "CELL_LINE", 0, 14], ["HEK", "TEST", 0, 3], ["cells", "TEST", 9, 14], ["different plasmid combinations", "TREATMENT", 66, 96], ["293T cells", "OBSERVATION", 4, 14]]], ["Then, the cells were lysed on ice with lysis buffer for 15 min and were immunoprecipitated with the indicated antibodies.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["antibodies", "PROTEIN", 110, 120], ["lysis buffer", "TREATMENT", 39, 51]]], ["The precipitated samples and whole-cell lysates (Input) were analyzed by immunoblotting with the indicated antibodies.His Fusion Protein Expression and Pull-Down Assays ::: Materials and MethodsEscherichia coli BL21(DE3) cells were transformed with pET-32a(+)-zbRIG-I or pET-32a(+) plasmids, respectively.", [["samples", "ANATOMY", 17, 24], ["whole-cell lysates", "ANATOMY", 29, 47], ["DE3) cells", "ANATOMY", 216, 226], ["pET-32a(+) plasmids", "ANATOMY", 271, 290], ["cell lysates", "ORGANISM_SUBSTANCE", 35, 47], ["MethodsEscherichia coli BL21", "GENE_OR_GENE_PRODUCT", 187, 215], ["DE3) cells", "CELL", 216, 226], ["pET-32a", "GENE_OR_GENE_PRODUCT", 249, 256], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 260, 267], ["pET-32a", "GENE_OR_GENE_PRODUCT", 271, 278], ["antibodies", "PROTEIN", 107, 117], ["MethodsEscherichia coli BL21(DE3) cells", "CELL_LINE", 187, 226], ["pET-32a(+)-zbRIG-I or pET-32a(+) plasmids", "DNA", 249, 290], ["MethodsEscherichia coli BL21", "SPECIES", 187, 215], ["MethodsEscherichia coli BL21", "SPECIES", 187, 215], ["The precipitated samples", "TEST", 0, 24], ["whole-cell lysates", "TREATMENT", 29, 47], ["immunoblotting", "TEST", 73, 87], ["His Fusion Protein Expression", "TREATMENT", 118, 147], ["MethodsEscherichia coli BL21(DE3) cells", "TEST", 187, 226], ["pET", "TEST", 249, 252], ["zbRIG", "TEST", 260, 265], ["pET", "TEST", 271, 274], ["coli BL21", "OBSERVATION", 206, 215]]], ["Then, cells were grown in 50 ml of LB medium (Beyotime) containing 0.5 mM isopropyl-1-thio-\u03b2-D-galactopyranoside (IPTG) (Sigma) at 18\u00b0C overnight with shaking at 120 rpm.", [["cells", "ANATOMY", 6, 11], ["isopropyl-1-thio-\u03b2-D-galactopyranoside", "CHEMICAL", 74, 112], ["IPTG", "CHEMICAL", 114, 118], ["isopropyl-1-thio-\u03b2-D-galactopyranoside", "CHEMICAL", 74, 112], ["IPTG", "CHEMICAL", 114, 118], ["cells", "CELL", 6, 11], ["isopropyl-1-thio-\u03b2-D-galactopyranoside", "SIMPLE_CHEMICAL", 74, 112], ["IPTG", "SIMPLE_CHEMICAL", 114, 118], ["isopropyl", "TEST", 74, 83], ["shaking", "PROBLEM", 151, 158]]], ["Cells were pelleted by centrifugation at 4,500 rpm for 30 min and lysed in 10 ml of lysis buffer (100 mM sodium phosphate, pH 8.0, 600 mM NaCl, and 0.02% Tween-20) (Beyotime) via sonication on ice.", [["Cells", "ANATOMY", 0, 5], ["sodium phosphate", "CHEMICAL", 105, 121], ["NaCl", "CHEMICAL", 138, 142], ["Tween-20", "CHEMICAL", 154, 162], ["sodium phosphate", "CHEMICAL", 105, 121], ["NaCl", "CHEMICAL", 138, 142], ["Tween-20", "CHEMICAL", 154, 162], ["Cells", "CELL", 0, 5], ["sodium phosphate", "SIMPLE_CHEMICAL", 105, 121], ["Beyotime", "SIMPLE_CHEMICAL", 165, 173], ["lysis buffer", "TREATMENT", 84, 96], ["sodium phosphate", "TEST", 105, 121], ["pH", "TEST", 123, 125], ["NaCl", "TEST", 138, 142], ["ice", "TREATMENT", 193, 196]]], ["The sonicated mixture was centrifuged at 15,000 rpm at 4\u00b0C for 20 min, and then the supernatant was affinity-purified with Dynabead His-Tag magnetic beads (Invitrogen) according to the manufacturer's instruction.His Fusion Protein Expression and Pull-Down Assays ::: Materials and MethodsHis pull-down assays were performed as described previously with some modifications (20).", [["supernatant", "ANATOMY", 84, 95], ["The sonicated mixture", "TREATMENT", 0, 21], ["Dynabead His-Tag magnetic beads (Invitrogen)", "TREATMENT", 123, 167], ["His Fusion Protein Expression", "TREATMENT", 212, 241], ["Methods", "TREATMENT", 281, 288], ["His pull-down assays", "TEST", 288, 308]]], ["His-zbRIG-I-magnetic beads were incubated with the lysates of HEK 293T cells transfected with pCMV-Flag-zbTRIM25 or pCMV-Flag empty vectors on a roller, respectively.", [["lysates", "ANATOMY", 51, 58], ["HEK 293T cells", "ANATOMY", 62, 76], ["His-zbRIG", "SIMPLE_CHEMICAL", 0, 9], ["lysates", "ORGANISM_SUBSTANCE", 51, 58], ["HEK 293T cells", "CELL", 62, 76], ["pCMV-Flag-zbTRIM25", "GENE_OR_GENE_PRODUCT", 94, 112], ["His-zbRIG", "PROTEIN", 0, 9], ["HEK 293T cells", "CELL_LINE", 62, 76], ["pCMV-Flag-zbTRIM25 or pCMV-Flag empty vectors", "DNA", 94, 139], ["His-zbRIG-I-magnetic beads", "TREATMENT", 0, 26], ["the lysates", "TEST", 47, 58], ["pCMV", "TEST", 94, 98], ["Flag-zbTRIM25", "TREATMENT", 99, 112], ["pCMV", "TREATMENT", 116, 120], ["Flag empty vectors", "TREATMENT", 121, 139]]], ["After incubation at 4\u00b0C overnight, the magnetic beads were washed three times with lysis buffer to remove unbound His-zbRIG-I and then analyzed via Western blotting using anti-Flag or anti-His antibodies.", [["His-zbRIG-I", "CHEMICAL", 114, 125], ["His", "CHEMICAL", 189, 192], ["His-zbRIG-I", "GENE_OR_GENE_PRODUCT", 114, 125], ["anti-Flag", "GENE_OR_GENE_PRODUCT", 171, 180], ["His-zbRIG", "PROTEIN", 114, 123], ["I", "PROTEIN", 124, 125], ["anti-Flag or anti-His antibodies", "PROTEIN", 171, 203], ["the magnetic beads", "TREATMENT", 35, 53], ["lysis buffer", "TREATMENT", 83, 95], ["anti-Flag", "TREATMENT", 171, 180]]], ["His tag protein alone was served as a negative control.Ubiquitination Assays ::: Materials and MethodsUbiquitination assays were performed as described previously with some modifications (21).", [["His", "CHEMICAL", 0, 3], ["tag protein", "PROTEIN", 4, 15], ["His tag protein", "TREATMENT", 0, 15], ["MethodsUbiquitination assays", "TEST", 95, 123]]], ["HEK 293T cells, pre-seeded in 75-cm2 flasks overnight, were co-transfected with 10 \u03bcg of different plasmid combinations.", [["HEK 293T cells", "ANATOMY", 0, 14], ["plasmid", "ANATOMY", 99, 106], ["HEK 293T cells", "CELL", 0, 14], ["HEK 293T cells", "CELL_LINE", 0, 14], ["cells", "TEST", 9, 14], ["different plasmid combinations", "TREATMENT", 89, 119], ["293T cells", "OBSERVATION", 4, 14]]], ["Cells were lysed at 24 h after transfection, and then GFP-zbRIG-I mutants were immunoprecipitated with anti-GFP antibodies as described above.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["GFP-zbRIG-I", "GENE_OR_GENE_PRODUCT", 54, 65], ["GFP", "PROTEIN", 54, 57], ["zbRIG", "PROTEIN", 58, 63], ["I mutants", "PROTEIN", 64, 73], ["anti-GFP antibodies", "PROTEIN", 103, 122], ["Cells", "TEST", 0, 5], ["transfection", "TEST", 31, 43], ["GFP", "TEST", 54, 57], ["zbRIG", "TEST", 58, 63], ["I mutants", "PROBLEM", 64, 73], ["anti-GFP antibodies", "PROBLEM", 103, 122]]], ["Immunoprecipitates or Input were analyzed by immunoblotting with the indicated antibodies.Statistics Analysis ::: Materials and MethodsAll statistics were calculated using SPSS version 20.", [["antibodies", "PROTEIN", 79, 89], ["immunoblotting", "TEST", 45, 59], ["Statistics Analysis", "TEST", 90, 109], ["SPSS version", "TEST", 172, 184]]], ["Differences between control and treatment groups were assessed by one-way ANOVA.", [["treatment groups", "TREATMENT", 32, 48]]], ["P < 0.01 was considered highly significant.zbTRIM25 Expression Is Down-Regulated During RGNNV Infection in vitro and in vivo ::: ResultsAs shown in Figure 1A, mRNA level of zbTRIM25 was down-regulated within 24 h after RGNNV infection.", [["infection", "DISEASE", 225, 234], ["Figure 1A", "GENE_OR_GENE_PRODUCT", 148, 157], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 173, 181], ["zbTRIM25", "PROTEIN", 173, 181], ["RGNNV", "SPECIES", 219, 224], ["mRNA level", "TEST", 159, 169], ["zbTRIM25", "TREATMENT", 173, 181], ["RGNNV infection", "PROBLEM", 219, 234], ["Infection", "OBSERVATION", 94, 103], ["infection", "OBSERVATION", 225, 234]]], ["Meanwhile, we also investigated the expression of zbTRIM25 in RGNNV-infected zebrafish embryos at 24 h, and the results were concordant with ZBE3 cells (Figure 1B).", [["embryos", "ANATOMY", 87, 94], ["ZBE3 cells", "ANATOMY", 141, 151], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 50, 58], ["RGNNV", "GENE_OR_GENE_PRODUCT", 62, 67], ["zebrafish", "ORGANISM", 77, 86], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 87, 94], ["ZBE3 cells", "CELL", 141, 151], ["zbTRIM25", "PROTEIN", 50, 58], ["ZBE3 cells", "CELL_LINE", 141, 151], ["zebrafish", "SPECIES", 77, 86], ["zebrafish", "SPECIES", 77, 86], ["zbTRIM25", "TREATMENT", 50, 58], ["infected zebrafish embryos", "PROBLEM", 68, 94], ["infected zebrafish embryos", "OBSERVATION", 68, 94]]], ["These data indicated a potential role of zbTRIM25 in innate immune response to RGNNV infection.zbTRIM25 Positively Regulates RLR Signaling Pathway in Zebrafish ::: ResultsIn mammals, TRIM25 has been suggested to promote IFN-\u03b2 production by functioning as a key upstream activator of RIG-I to activate the RLR signaling pathway (10).", [["zbTRIM25", "CHEMICAL", 41, 49], ["infection", "DISEASE", 85, 94], ["TRIM25", "CHEMICAL", 183, 189], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 41, 49], ["RGNNV", "GENE_OR_GENE_PRODUCT", 79, 84], ["zbTRIM25", "SIMPLE_CHEMICAL", 95, 103], ["RLR", "GENE_OR_GENE_PRODUCT", 125, 128], ["Zebrafish", "ORGANISM", 150, 159], ["TRIM25", "GENE_OR_GENE_PRODUCT", 183, 189], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 220, 225], ["RIG-I", "GENE_OR_GENE_PRODUCT", 283, 288], ["RLR", "GENE_OR_GENE_PRODUCT", 305, 308], ["zbTRIM25", "PROTEIN", 41, 49], ["zbTRIM25", "PROTEIN", 95, 103], ["RLR", "PROTEIN", 125, 128], ["TRIM25", "PROTEIN", 183, 189], ["IFN", "PROTEIN", 220, 223], ["\u03b2", "PROTEIN", 224, 225], ["RIG-I", "PROTEIN", 283, 288], ["RLR", "PROTEIN", 305, 308], ["RGNNV", "SPECIES", 79, 84], ["zbTRIM25", "TREATMENT", 41, 49], ["RGNNV infection", "PROBLEM", 79, 94], ["infection", "OBSERVATION", 85, 94]]], ["To investigate whether zbTRIM25 regulated RLR signaling pathway in zebrafish, the expression of several RLR signaling pathway-related genes was measured in zbTRIM25 overexpressing ZBE3 cells.", [["ZBE3 cells", "ANATOMY", 180, 190], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 23, 31], ["RLR", "GENE_OR_GENE_PRODUCT", 42, 45], ["zebrafish", "ORGANISM", 67, 76], ["RLR", "GENE_OR_GENE_PRODUCT", 104, 107], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 156, 164], ["ZBE3 cells", "CELL", 180, 190], ["zbTRIM25", "PROTEIN", 23, 31], ["RLR", "PROTEIN", 42, 45], ["RLR", "PROTEIN", 104, 107], ["zbTRIM25 overexpressing ZBE3 cells", "CELL_LINE", 156, 190], ["several RLR signaling pathway", "PROBLEM", 96, 125], ["ZBE3 cells", "OBSERVATION", 180, 190]]], ["As shown in Figure 2A, overexpression of zbTRIM25 markedly enhanced the expression of RIG-I, MAVS, TRAF3, IRF3, IFN 1, and ISG15 during RGNNV infection.", [["zbTRIM25", "CHEMICAL", 41, 49], ["infection", "DISEASE", 142, 151], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 41, 49], ["RIG-I", "GENE_OR_GENE_PRODUCT", 86, 91], ["MAVS", "GENE_OR_GENE_PRODUCT", 93, 97], ["TRAF3", "GENE_OR_GENE_PRODUCT", 99, 104], ["IRF3", "GENE_OR_GENE_PRODUCT", 106, 110], ["IFN 1", "GENE_OR_GENE_PRODUCT", 112, 117], ["ISG15", "GENE_OR_GENE_PRODUCT", 123, 128], ["RGNNV", "GENE_OR_GENE_PRODUCT", 136, 141], ["zbTRIM25", "PROTEIN", 41, 49], ["RIG-I", "PROTEIN", 86, 91], ["MAVS", "PROTEIN", 93, 97], ["TRAF3", "PROTEIN", 99, 104], ["IRF3", "PROTEIN", 106, 110], ["IFN 1", "PROTEIN", 112, 117], ["ISG15", "PROTEIN", 123, 128], ["RGNNV", "SPECIES", 136, 141], ["zbTRIM25", "TREATMENT", 41, 49], ["MAVS", "PROBLEM", 93, 97], ["TRAF3", "PROBLEM", 99, 104], ["IRF3", "TEST", 106, 110], ["IFN", "TEST", 112, 115], ["ISG15 during RGNNV infection", "PROBLEM", 123, 151], ["infection", "OBSERVATION", 142, 151]]], ["Similar results were detected in zbTRIM25 overexpressing ZBE3 cells treated with poly I:C (Figure 2B).", [["ZBE3 cells", "ANATOMY", 57, 67], ["poly I:C", "CHEMICAL", 81, 89], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 33, 41], ["ZBE3 cells", "CELL", 57, 67], ["zbTRIM25", "PROTEIN", 33, 41], ["ZBE3 cells", "CELL_LINE", 57, 67], ["poly I:C", "PROTEIN", 81, 89], ["zbTRIM25 overexpressing ZBE3 cells", "TREATMENT", 33, 67], ["poly I:C (Figure 2B", "TREATMENT", 81, 100]]], ["Furthermore, co-expression of zbTRIM25 with zbRIG-I induced a dose-dependent increase in IFN activation compared with the zbRIG-I overexpression alone (Figure 2C).", [["zbRIG-I", "CHEMICAL", 44, 51], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 30, 38], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 44, 51], ["IFN", "GENE_OR_GENE_PRODUCT", 89, 92], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 122, 129], ["zbTRIM25", "PROTEIN", 30, 38], ["zbRIG-I", "PROTEIN", 44, 51], ["IFN", "PROTEIN", 89, 92], ["zbRIG", "PROTEIN", 122, 127], ["zbTRIM25", "TREATMENT", 30, 38], ["zbRIG", "TREATMENT", 44, 49], ["IFN activation", "TREATMENT", 89, 103], ["dependent", "OBSERVATION_MODIFIER", 67, 76], ["increase", "OBSERVATION_MODIFIER", 77, 85]]], ["Overexpression of zbTRIM25 dose-dependently inhibited RGNNV replication (Figure 2D).", [["zbTRIM25", "CHEMICAL", 18, 26], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 18, 26], ["RGNNV", "SIMPLE_CHEMICAL", 54, 59], ["zbTRIM25", "PROTEIN", 18, 26], ["zbTRIM25 dose", "TREATMENT", 18, 31]]], ["On the contrary, knockdown of zbTRIM25 using siRNA increased the level of RDRP in RGNNV-infected ZBE3 cells (Figures 2E,F).", [["ZBE3 cells", "ANATOMY", 97, 107], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 30, 38], ["RDRP", "GENE_OR_GENE_PRODUCT", 74, 78], ["RGNNV", "GENE_OR_GENE_PRODUCT", 82, 87], ["ZBE3 cells", "CELL", 97, 107], ["zbTRIM25", "PROTEIN", 30, 38], ["RDRP", "PROTEIN", 74, 78], ["RGNNV-infected ZBE3 cells", "CELL_LINE", 82, 107], ["zbTRIM25", "TREATMENT", 30, 38], ["siRNA", "TREATMENT", 45, 50], ["RDRP", "TEST", 74, 78], ["RGNNV", "TEST", 82, 87], ["infected ZBE3 cells", "PROBLEM", 88, 107], ["infected", "OBSERVATION_MODIFIER", 88, 96], ["ZBE3 cells", "OBSERVATION", 97, 107]]], ["All these results demonstrate that zbTRIM25 is a positive regulator of RLR signaling pathway and functions as an antiviral factor during RGNNV infection in zebrafish.zbTRIM25 Interacts With zbRIG-I ::: ResultsTo elucidate the mechanism by which zbTRIM25 participates in RLR signaling pathway in zebrafish, the interaction of zbTRIM25 and zbRIG-I was investigated.", [["zbTRIM25", "CHEMICAL", 35, 43], ["infection", "DISEASE", 143, 152], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 35, 43], ["RLR", "GENE_OR_GENE_PRODUCT", 71, 74], ["RGNNV", "GENE_OR_GENE_PRODUCT", 137, 142], ["zebrafish.zbTRIM25", "SIMPLE_CHEMICAL", 156, 174], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 190, 197], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 245, 253], ["RLR", "GENE_OR_GENE_PRODUCT", 270, 273], ["zebrafish", "ORGANISM", 295, 304], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 325, 333], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 338, 345], ["zbTRIM25", "PROTEIN", 35, 43], ["RLR", "PROTEIN", 71, 74], ["antiviral factor", "PROTEIN", 113, 129], ["zebrafish.zbTRIM25", "PROTEIN", 156, 174], ["zbRIG-I", "PROTEIN", 190, 197], ["zbTRIM25", "PROTEIN", 245, 253], ["RLR", "PROTEIN", 270, 273], ["zbTRIM25", "PROTEIN", 325, 333], ["zbRIG", "PROTEIN", 338, 343], ["I", "PROTEIN", 344, 345], ["RGNNV", "SPECIES", 137, 142], ["zbTRIM25", "TREATMENT", 35, 43], ["an antiviral factor", "PROBLEM", 110, 129], ["RGNNV infection", "PROBLEM", 137, 152], ["zbTRIM25", "TREATMENT", 325, 333], ["zbRIG", "TREATMENT", 338, 343]]], ["We co-expressed Myc-zbTRIM25 and Flag-zbRIG-I plasmids in HEK 293T cells, and immunofluorescence imaging showed zbTRIM25 and zbRIG-I colocalized in the cytoplasm of HEK293T cells (Figure 3A).", [["HEK 293T cells", "ANATOMY", 58, 72], ["cytoplasm", "ANATOMY", 152, 161], ["HEK293T cells", "ANATOMY", 165, 178], ["Myc-zbTRIM25", "GENE_OR_GENE_PRODUCT", 16, 28], ["Flag-zbRIG-I", "GENE_OR_GENE_PRODUCT", 33, 45], ["HEK 293T cells", "CELL", 58, 72], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 112, 120], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 125, 132], ["cytoplasm", "ORGANISM_SUBSTANCE", 152, 161], ["HEK293T cells", "CELL", 165, 178], ["Figure 3A", "CELL", 180, 189], ["Myc-zbTRIM25 and Flag-zbRIG-I plasmids", "DNA", 16, 54], ["HEK 293T cells", "CELL_LINE", 58, 72], ["zbTRIM25", "PROTEIN", 112, 120], ["zbRIG", "PROTEIN", 125, 130], ["I", "PROTEIN", 131, 132], ["HEK293T cells", "CELL_LINE", 165, 178], ["Myc-zbTRIM25", "TEST", 16, 28], ["Flag", "TEST", 33, 37], ["zbRIG-I plasmids", "TREATMENT", 38, 54], ["immunofluorescence imaging", "TEST", 78, 104], ["zbTRIM25", "TREATMENT", 112, 120], ["zbRIG", "TEST", 125, 130], ["HEK293T cells", "OBSERVATION", 165, 178]]], ["Co-IP against the Myc tag revealed that zbTRIM25 could interact with full-length zbRIG-I but not with Flag-vector (Figure 3B).", [["zbTRIM25", "CHEMICAL", 40, 48], ["Co-IP", "GENE_OR_GENE_PRODUCT", 0, 5], ["Myc", "GENE_OR_GENE_PRODUCT", 18, 21], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 40, 48], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 81, 88], ["Flag", "GENE_OR_GENE_PRODUCT", 102, 106], ["Myc tag", "DNA", 18, 25], ["zbTRIM25", "PROTEIN", 40, 48], ["full-length zbRIG-I", "DNA", 69, 88], ["Flag", "PROTEIN", 102, 106], ["the Myc tag", "TEST", 14, 25], ["zbTRIM25", "TREATMENT", 40, 48]]], ["His pull-down analysis showed that zbTRIM25 was directly bound to zbRIG-I (Figure 3C).", [["zbTRIM25", "GENE_OR_GENE_PRODUCT", 35, 43], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 66, 73], ["zbTRIM25", "PROTEIN", 35, 43], ["zbRIG", "PROTEIN", 66, 71], ["His pull-down analysis", "TEST", 0, 22], ["zbTRIM25", "TREATMENT", 35, 43]]], ["All these data suggest that zbTRIM25 interacts with zbRIG-I.SPRY Domain of zbTRIM25 Interacts With 2CARD and RD Regions of zbRIG-I ::: ResultsTo identify the region involved in the zbRIG-I/zbTRIM25 interaction, firstly, zbRIG-I deletion mutants [pEGFP-zbRIG-I-2CARD, pEGFP-zbRIG-I-\u03942CARD, pEGFP-RIG-I-RD, and pEGFP-RIG-I-\u0394(2CARD+RD)] were constructed and co-transfected with Flag-zbTRIM25 in HEK 293T cells (Figure 4A). zbRIG-I-2CARD, zbRIG-I-\u03942CARD, and zbRIG-I-RD could bind to zbTRIM25 individually (Figures 4B\u2013D); however, zbRIG-I-\u0394(2CARD+RD) failed to co-precipitate with zbTRIM25 (Figure 4E).", [["HEK 293T cells", "ANATOMY", 392, 406], ["zbTRIM25", "CHEMICAL", 28, 36], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 28, 36], ["zbRIG", "GENE_OR_GENE_PRODUCT", 52, 57], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 75, 83], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 123, 130], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 181, 188], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 189, 197], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 220, 227], ["pEGFP-zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 246, 265], ["pEGFP-zbRIG-I", "GENE_OR_GENE_PRODUCT", 267, 280], ["pEGFP-RIG-I-RD", "GENE_OR_GENE_PRODUCT", 289, 303], ["pEGFP-RIG-I-\u0394", "GENE_OR_GENE_PRODUCT", 309, 322], ["2CARD+RD", "GENE_OR_GENE_PRODUCT", 323, 331], ["Flag-zbTRIM25", "GENE_OR_GENE_PRODUCT", 375, 388], ["HEK 293T cells", "CELL", 392, 406], ["Figure 4A", "CELL", 408, 417], ["zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 420, 433], ["zbRIG-I-\u03942CARD", "GENE_OR_GENE_PRODUCT", 435, 449], ["zbRIG-I-RD", "GENE_OR_GENE_PRODUCT", 455, 465], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 480, 488], ["zbRIG-I-\u0394", "GENE_OR_GENE_PRODUCT", 527, 536], ["2CARD+RD", "GENE_OR_GENE_PRODUCT", 537, 545], ["zbTRIM25", "PROTEIN", 28, 36], ["zbRIG", "PROTEIN", 52, 57], ["SPRY Domain", "PROTEIN", 60, 71], ["zbTRIM25", "PROTEIN", 75, 83], ["2CARD", "PROTEIN", 99, 104], ["zbRIG", "PROTEIN", 123, 128], ["zbRIG", "PROTEIN", 181, 186], ["zbTRIM25", "PROTEIN", 189, 197], ["zbRIG-I deletion mutants", "DNA", 220, 244], ["pEGFP", "PROTEIN", 246, 251], ["zbRIG", "PROTEIN", 252, 257], ["I", "PROTEIN", 258, 259], ["2CARD", "PROTEIN", 260, 265], ["pEGFP", "DNA", 267, 272], ["zbRIG", "DNA", 273, 278], ["I", "PROTEIN", 279, 280], ["\u03942CARD", "DNA", 281, 287], ["pEGFP", "DNA", 289, 294], ["RIG", "DNA", 295, 298], ["I", "DNA", 299, 300], ["RD", "DNA", 301, 303], ["pEGFP", "DNA", 309, 314], ["RIG", "DNA", 315, 318], ["I", "DNA", 319, 320], ["\u0394", "DNA", 321, 322], ["2CARD", "DNA", 323, 328], ["RD", "DNA", 329, 331], ["Flag", "PROTEIN", 375, 379], ["zbTRIM25", "PROTEIN", 380, 388], ["HEK 293T cells", "CELL_LINE", 392, 406], ["zbRIG", "PROTEIN", 420, 425], ["I", "PROTEIN", 426, 427], ["2CARD", "PROTEIN", 428, 433], ["zbRIG", "PROTEIN", 435, 440], ["I", "PROTEIN", 441, 442], ["\u03942CARD", "DNA", 443, 449], ["zbRIG", "DNA", 455, 460], ["I", "DNA", 461, 462], ["RD", "DNA", 463, 465], ["zbTRIM25", "DNA", 480, 488], ["zbRIG", "PROTEIN", 527, 532], ["I", "PROTEIN", 533, 534], ["\u0394", "DNA", 535, 536], ["2CARD", "PROTEIN", 537, 542], ["zbTRIM25", "PROTEIN", 577, 585], ["zbTRIM25", "TREATMENT", 75, 83], ["zbRIG", "TEST", 220, 225], ["pEGFP", "TEST", 246, 251], ["zbRIG", "TEST", 252, 257], ["pEGFP", "TEST", 267, 272], ["zbRIG", "TEST", 273, 278], ["I", "TEST", 279, 280], ["\u03942CARD", "TEST", 281, 287], ["pEGFP", "TEST", 289, 294], ["RIG", "TEST", 295, 298], ["pEGFP", "TEST", 309, 314], ["RIG", "TEST", 315, 318], ["Flag", "TEST", 375, 379], ["zbRIG", "TEST", 420, 425], ["zbRIG", "TEST", 435, 440], ["zbRIG", "TEST", 455, 460], ["zbRIG", "TEST", 527, 532], ["zbTRIM25", "TREATMENT", 577, 585]]], ["These results indicate that zbRIG-I binds to zbTRIM25 through its N-terminal 2CARD region and the C-terminal RD region.", [["N", "CHEMICAL", 66, 67], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 28, 35], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 45, 53], ["zbRIG", "PROTEIN", 28, 33], ["I", "PROTEIN", 34, 35], ["zbTRIM25", "PROTEIN", 45, 53], ["N-terminal 2CARD region", "DNA", 66, 89], ["C-terminal RD region", "DNA", 98, 118], ["zbRIG-I binds", "PROBLEM", 28, 41], ["zbTRIM25", "TREATMENT", 45, 53], ["terminal", "ANATOMY_MODIFIER", 68, 76], ["-terminal RD", "ANATOMY_MODIFIER", 99, 111], ["region", "ANATOMY_MODIFIER", 112, 118]]], ["Furthermore, we constructed two truncations of zbTRIM25 (zbTRIM25-SPRY and zbTRIM25-\u0394SPRY) co-transfected with zbRIG-I-2CARD or zbRIG-I-RD in HEK 293T cells, respectively (Figure 4F).", [["HEK 293T cells", "ANATOMY", 142, 156], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 47, 55], ["zbTRIM25-SPRY", "GENE_OR_GENE_PRODUCT", 57, 70], ["zbTRIM25-\u0394SPRY", "GENE_OR_GENE_PRODUCT", 75, 89], ["zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 111, 124], ["zbRIG-I-RD", "GENE_OR_GENE_PRODUCT", 128, 138], ["HEK 293T cells", "CELL", 142, 156], ["zbTRIM25", "PROTEIN", 47, 55], ["zbTRIM25", "PROTEIN", 57, 65], ["SPRY", "PROTEIN", 66, 70], ["zbTRIM25", "PROTEIN", 75, 83], ["\u0394SPRY", "PROTEIN", 84, 89], ["zbRIG", "PROTEIN", 111, 116], ["I-2CARD", "PROTEIN", 117, 124], ["zbRIG", "PROTEIN", 128, 133], ["I", "DNA", 134, 135], ["RD", "DNA", 136, 138], ["HEK 293T cells", "CELL_LINE", 142, 156], ["zbTRIM25", "TREATMENT", 47, 55], ["zbTRIM25", "TREATMENT", 57, 65], ["zbTRIM25", "TREATMENT", 75, 83], ["zbRIG", "TEST", 111, 116], ["zbRIG", "TEST", 128, 133]]], ["We found that the SPRY domain of zbTRIM25 interacted with 2CARD and RD regions of zbRIG-I (Figures 4G\u2013J).", [["zbTRIM25", "GENE_OR_GENE_PRODUCT", 33, 41], ["2CARD", "GENE_OR_GENE_PRODUCT", 58, 63], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 82, 89], ["SPRY domain", "PROTEIN", 18, 29], ["zbTRIM25", "PROTEIN", 33, 41], ["2CARD", "PROTEIN", 58, 63], ["RD regions", "PROTEIN", 68, 78], ["zbRIG", "PROTEIN", 82, 87], ["I (Figures 4G\u2013J", "PROTEIN", 88, 103], ["zbTRIM25", "TREATMENT", 33, 41]]], ["Collectively, these results indicate that the SPRY domain of zbTRIM25 is responsible for its interaction with 2CARD and RD regions of zbRIG-I.zbTRIM25 Ubiquitinates Both 2CARD and RD Regions of zbRIG-I ::: ResultsTo investigate whether the E3 ligase activity of zbTRIM25 is involved in the regulation of zbRIG-I, the ubiquitination of zbRIG-I was tested in zbTRIM25 overexpressing cells.", [["cells", "ANATOMY", 381, 386], ["SPRY", "GENE_OR_GENE_PRODUCT", 46, 50], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 61, 69], ["2CARD", "GENE_OR_GENE_PRODUCT", 110, 115], ["zbRIG-I.zbTRIM25", "GENE_OR_GENE_PRODUCT", 134, 150], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 194, 201], ["E3", "GENE_OR_GENE_PRODUCT", 240, 242], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 262, 270], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 304, 311], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 335, 342], ["zbTRIM25 overexpressing cells", "CELL", 357, 386], ["SPRY domain", "PROTEIN", 46, 57], ["zbTRIM25", "PROTEIN", 61, 69], ["2CARD", "PROTEIN", 110, 115], ["RD regions", "PROTEIN", 120, 130], ["zbRIG", "PROTEIN", 134, 139], ["I.zbTRIM25", "PROTEIN", 140, 150], ["2CARD", "PROTEIN", 170, 175], ["zbRIG-I", "PROTEIN", 194, 201], ["E3 ligase", "PROTEIN", 240, 249], ["zbTRIM25", "PROTEIN", 262, 270], ["zbRIG", "PROTEIN", 304, 309], ["zbRIG-I", "PROTEIN", 335, 342], ["zbTRIM25 overexpressing cells", "CELL_LINE", 357, 386], ["the SPRY domain of zbTRIM25", "TREATMENT", 42, 69], ["zbRIG", "TEST", 134, 139], ["zbTRIM25", "TREATMENT", 262, 270], ["overexpressing cells", "OBSERVATION", 366, 386]]], ["We found that zbTRIM25 markedly promoted the K63 polyubiquitination of zbRIG-I (Figure 5A).", [["zbTRIM25", "CHEMICAL", 14, 22], ["zbTRIM25", "CHEMICAL", 14, 22], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 14, 22], ["K63", "GENE_OR_GENE_PRODUCT", 45, 48], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 71, 78], ["zbTRIM25", "PROTEIN", 14, 22], ["K63", "PROTEIN", 45, 48], ["zbRIG", "PROTEIN", 71, 76], ["I", "PROTEIN", 77, 78], ["Figure 5A", "PROTEIN", 80, 89], ["zbTRIM25", "TREATMENT", 14, 22]]], ["Furthermore, HEK 293T cells were transfected with Flag-tagged zbTRIM25, zbRIG-I deletion mutants [GFP-zbRIG-I-2CARD, GFP-zbRIG-I-\u0394(2CARD+RD), and GFP-zbRIG-I-RD], and HA-tagged K63 ubiquitin, and our results showed that zbTRIM25 obviously enhanced the ubiquitination of zbRIG-I-2CARD and zbRIG-I-RD (Figures 5B,C), but not zbRIG-I-\u0394(2CARD+RD) (Figure 5D).", [["HEK 293T cells", "ANATOMY", 13, 27], ["zbTRIM25", "CHEMICAL", 220, 228], ["zbTRIM25", "CHEMICAL", 220, 228], ["HEK 293T cells", "CELL", 13, 27], ["Flag", "GENE_OR_GENE_PRODUCT", 50, 54], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 62, 70], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 72, 79], ["GFP-zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 98, 115], ["GFP-zbRIG-I-\u0394", "GENE_OR_GENE_PRODUCT", 117, 130], ["2CARD+RD", "GENE_OR_GENE_PRODUCT", 131, 139], ["GFP-zbRIG-I-RD", "GENE_OR_GENE_PRODUCT", 146, 160], ["HA-tagged K63 ubiquitin", "GENE_OR_GENE_PRODUCT", 167, 190], ["zbTRIM25", "SIMPLE_CHEMICAL", 220, 228], ["zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 270, 283], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 288, 295], ["C", "SIMPLE_CHEMICAL", 311, 312], ["zbRIG-I-\u0394", "GENE_OR_GENE_PRODUCT", 323, 332], ["HEK 293T cells", "CELL_LINE", 13, 27], ["Flag", "PROTEIN", 50, 54], ["zbTRIM25", "PROTEIN", 62, 70], ["zbRIG", "PROTEIN", 72, 77], ["I deletion mutants", "PROTEIN", 78, 96], ["GFP", "PROTEIN", 98, 101], ["zbRIG", "PROTEIN", 102, 107], ["I", "PROTEIN", 108, 109], ["2CARD", "PROTEIN", 110, 115], ["GFP", "PROTEIN", 117, 120], ["zbRIG", "PROTEIN", 121, 126], ["I", "PROTEIN", 127, 128], ["\u0394", "DNA", 129, 130], ["2CARD", "PROTEIN", 131, 136], ["RD", "PROTEIN", 137, 139], ["GFP", "DNA", 146, 149], ["zbRIG", "DNA", 150, 155], ["I", "DNA", 156, 157], ["RD", "DNA", 158, 160], ["HA", "DNA", 167, 169], ["K63 ubiquitin", "PROTEIN", 177, 190], ["zbTRIM25", "PROTEIN", 220, 228], ["zbRIG", "PROTEIN", 270, 275], ["I", "PROTEIN", 276, 277], ["2CARD", "PROTEIN", 278, 283], ["zbRIG", "PROTEIN", 288, 293], ["I", "PROTEIN", 294, 295], ["RD", "DNA", 296, 298], ["zbRIG", "DNA", 323, 328], ["I", "DNA", 329, 330], ["\u0394", "DNA", 331, 332], ["2CARD", "DNA", 333, 338], ["RD", "DNA", 339, 341], ["Flag", "TEST", 50, 54], ["zbTRIM25", "TEST", 62, 70], ["zbRIG", "TEST", 72, 77], ["GFP", "TEST", 98, 101], ["zbRIG", "TEST", 102, 107], ["I", "TEST", 108, 109], ["2CARD", "TEST", 110, 115], ["GFP", "TEST", 117, 120], ["zbRIG", "TEST", 121, 126], ["I", "TEST", 127, 128], ["\u0394", "TEST", 129, 130], ["2CARD", "TEST", 131, 136], ["GFP", "TEST", 146, 149], ["zbRIG", "TEST", 150, 155], ["HA", "TEST", 167, 169], ["zbRIG", "TEST", 270, 275], ["2CARD", "TEST", 278, 283], ["zbRIG", "TEST", 288, 293], ["zbRIG", "TEST", 323, 328]]], ["These data suggest that zbTRIM25 ubiquitinates both N-terminal 2CARD and C-terminal RD regions of zbRIG-I.zbTRIM25-Mediated Ubiquitination of zbRIG-I 2CARD and RD Regions Is Important for IFN Inducing ::: ResultsIt has been reported that ubiquitination of RIG-I by TRIM25 is vital for IFN signaling.", [["N", "CHEMICAL", 52, 53], ["C-", "CHEMICAL", 73, 75], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 24, 32], ["zbRIG-I.zbTRIM25", "GENE_OR_GENE_PRODUCT", 98, 114], ["zbRIG-I 2CARD", "GENE_OR_GENE_PRODUCT", 142, 155], ["RIG-I", "GENE_OR_GENE_PRODUCT", 256, 261], ["TRIM25", "GENE_OR_GENE_PRODUCT", 265, 271], ["IFN", "GENE_OR_GENE_PRODUCT", 285, 288], ["zbTRIM25", "PROTEIN", 24, 32], ["N-terminal 2CARD", "PROTEIN", 52, 68], ["C-terminal RD regions", "PROTEIN", 73, 94], ["zbRIG", "PROTEIN", 98, 103], ["I.zbTRIM25", "PROTEIN", 104, 114], ["zbRIG", "PROTEIN", 142, 147], ["I 2CARD", "PROTEIN", 148, 155], ["IFN", "PROTEIN", 188, 191], ["RIG-I", "PROTEIN", 256, 261], ["TRIM25", "PROTEIN", 265, 271], ["IFN", "PROTEIN", 285, 288], ["These data", "TEST", 0, 10], ["zbTRIM25 ubiquitinates", "PROBLEM", 24, 46], ["terminal 2CARD and C-terminal RD regions", "PROBLEM", 54, 94], ["zbRIG", "TEST", 98, 103], ["IFN signaling", "PROBLEM", 285, 298], ["ubiquitination", "OBSERVATION_MODIFIER", 238, 252]]], ["Thus, the effect of zbTRIM25-mediated zbRIG-I ubiquitination on zbRIG-I's IFN-inducing activities was assessed.", [["zbTRIM25", "CHEMICAL", 20, 28], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 20, 28], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 38, 45], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 64, 71], ["IFN", "GENE_OR_GENE_PRODUCT", 74, 77], ["zbTRIM25", "PROTEIN", 20, 28], ["zbRIG", "PROTEIN", 38, 43], ["zbRIG", "PROTEIN", 64, 69], ["IFN", "PROTEIN", 74, 77], ["zbTRIM25", "TREATMENT", 20, 28], ["zbRIG", "TEST", 64, 69]]], ["Our results showed that ectopic expression of zbRIG-I-2CARD and zbRIG-I-RD could enhance IFN promoter activity (Figure 6A), and this activation was markedly enhanced by zbTRIM25 overexpression (Figures 6B,C).", [["zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 46, 59], ["zbRIG-I-RD", "GENE_OR_GENE_PRODUCT", 64, 74], ["IFN", "GENE_OR_GENE_PRODUCT", 89, 92], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 169, 177], ["zbRIG", "PROTEIN", 46, 51], ["I-2CARD", "PROTEIN", 52, 59], ["zbRIG-I-RD", "DNA", 64, 74], ["IFN promoter", "DNA", 89, 101], ["zbTRIM25", "PROTEIN", 169, 177], ["ectopic expression", "PROBLEM", 24, 42], ["zbRIG", "TEST", 46, 51], ["zbRIG", "TEST", 64, 69], ["ectopic", "OBSERVATION", 24, 31]]], ["Furthermore, overexpression of K63-linked ubiquitin dose-dependently increased the promotion effect of zbTRIM25 on zbRIG-I-2CARD and RD mediated IFN 1 promoter activation (Figures 6B,C).", [["zbTRIM25", "CHEMICAL", 103, 111], ["K63", "GENE_OR_GENE_PRODUCT", 31, 34], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 42, 51], ["zbTRIM25", "SIMPLE_CHEMICAL", 103, 111], ["zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 115, 128], ["RD mediated IFN 1", "GENE_OR_GENE_PRODUCT", 133, 150], ["K63", "PROTEIN", 31, 34], ["zbTRIM25", "PROTEIN", 103, 111], ["zbRIG", "PROTEIN", 115, 120], ["IFN 1 promoter", "DNA", 145, 159], ["K63", "TEST", 31, 34], ["linked ubiquitin dose", "TREATMENT", 35, 56], ["zbTRIM25", "TREATMENT", 103, 111], ["zbRIG", "TREATMENT", 115, 120], ["I-2CARD and RD mediated IFN", "TREATMENT", 121, 148]]], ["These data confirm the importance of zbTRIM25-mediated K63 ubiquitination in the N-terminal 2CARD region and C-terminal RD region of zbRIG-I for zbRIG-I-mediated IFN induction.DiscussionRLR signaling pathway plays crucial roles in recognizing viral infections and initiating the antiviral immune response.", [["zbRIG-I-", "CHEMICAL", 145, 153], ["viral infections", "DISEASE", 243, 259], ["C", "CHEMICAL", 109, 110], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 37, 45], ["K63", "GENE_OR_GENE_PRODUCT", 55, 58], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 133, 140], ["zbRIG-I-", "GENE_OR_GENE_PRODUCT", 145, 153], ["IFN", "GENE_OR_GENE_PRODUCT", 162, 165], ["DiscussionRLR", "GENE_OR_GENE_PRODUCT", 176, 189], ["zbTRIM25", "PROTEIN", 37, 45], ["K63", "PROTEIN", 55, 58], ["N-terminal 2CARD region", "PROTEIN", 81, 104], ["C-terminal RD region", "DNA", 109, 129], ["zbRIG", "PROTEIN", 133, 138], ["zbRIG", "PROTEIN", 145, 150], ["IFN", "PROTEIN", 162, 165], ["DiscussionRLR", "PROTEIN", 176, 189], ["zbTRIM25-mediated K63 ubiquitination", "TREATMENT", 37, 73], ["the N-terminal 2CARD region", "TREATMENT", 77, 104], ["zbRIG", "PROBLEM", 145, 150], ["I-mediated IFN induction", "TREATMENT", 151, 175], ["recognizing viral infections", "PROBLEM", 231, 259], ["the antiviral immune response", "TREATMENT", 275, 304], ["viral infections", "OBSERVATION", 243, 259]]], ["RIG-I, as an important component of RLR signaling pathway, can detect viral dsRNAs in the cytoplasm and induce type I IFN production and the secretion of pro-inflammatory cytokines to suppress virus spread during virus infection (22).", [["cytoplasm", "ANATOMY", 90, 99], ["infection", "DISEASE", 219, 228], ["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["RLR", "GENE_OR_GENE_PRODUCT", 36, 39], ["cytoplasm", "ORGANISM_SUBSTANCE", 90, 99], ["type I IFN", "GENE_OR_GENE_PRODUCT", 111, 121], ["RIG-I", "PROTEIN", 0, 5], ["RLR", "PROTEIN", 36, 39], ["IFN", "PROTEIN", 118, 121], ["pro-inflammatory cytokines", "PROTEIN", 154, 180], ["viral dsRNAs in the cytoplasm", "PROBLEM", 70, 99], ["type I IFN production", "PROBLEM", 111, 132], ["pro-inflammatory cytokines", "PROBLEM", 154, 180], ["virus spread during virus infection", "PROBLEM", 193, 228], ["viral dsRNAs", "OBSERVATION", 70, 82]]], ["Multiple studies have demonstrated that the ubiquitination of RIG-I plays an important role in the RIG-I-mediated antiviral signaling pathway.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 62, 67], ["RIG-I", "GENE_OR_GENE_PRODUCT", 99, 104], ["RIG-I", "PROTEIN", 62, 67], ["RIG-I", "PROTEIN", 99, 104], ["Multiple studies", "TEST", 0, 16]]], ["For instance, TRIM25, TRIM4, and MEX3C positively regulate RIG-I-mediated signaling by targeting RIG-I for K63-linked polyubiquitination (23, 24).", [["TRIM25", "GENE_OR_GENE_PRODUCT", 14, 20], ["TRIM4", "GENE_OR_GENE_PRODUCT", 22, 27], ["MEX3C", "GENE_OR_GENE_PRODUCT", 33, 38], ["RIG-I-", "GENE_OR_GENE_PRODUCT", 59, 65], ["RIG-I", "GENE_OR_GENE_PRODUCT", 97, 102], ["K63", "GENE_OR_GENE_PRODUCT", 107, 110], ["TRIM25", "PROTEIN", 14, 20], ["TRIM4", "PROTEIN", 22, 27], ["MEX3C", "PROTEIN", 33, 38], ["RIG", "PROTEIN", 59, 62], ["RIG-I", "PROTEIN", 97, 102], ["K63", "PROTEIN", 107, 110], ["TRIM25", "TREATMENT", 14, 20], ["TRIM4", "TREATMENT", 22, 27], ["MEX3C", "TREATMENT", 33, 38], ["K63", "TEST", 107, 110], ["linked polyubiquitination", "PROBLEM", 111, 136], ["polyubiquitination", "OBSERVATION", 118, 136]]], ["TRIM25, well-known as an ubiquitin E3 ligase and an ISG15 E3 ligase, is widely involved in the regulation of innate immunity (10, 25).", [["TRIM25", "GENE_OR_GENE_PRODUCT", 0, 6], ["ISG15", "GENE_OR_GENE_PRODUCT", 52, 57], ["TRIM25", "PROTEIN", 0, 6], ["ubiquitin E3 ligase", "PROTEIN", 25, 44], ["ISG15 E3 ligase", "PROTEIN", 52, 67], ["an ubiquitin E3 ligase", "TREATMENT", 22, 44], ["an ISG15 E3 ligase", "TREATMENT", 49, 67], ["widely", "OBSERVATION_MODIFIER", 72, 78]]], ["In mammals, previous reports showed that TRIM25 enhanced RLRs antiviral pathway by binding viral RNA-activated RIG-I to induce its K63-linked polyubiquitination and subsequent IFNs and ISGs production (26).", [["TRIM25", "GENE_OR_GENE_PRODUCT", 41, 47], ["RLRs", "GENE_OR_GENE_PRODUCT", 57, 61], ["RIG-I", "GENE_OR_GENE_PRODUCT", 111, 116], ["K63", "GENE_OR_GENE_PRODUCT", 131, 134], ["IFNs", "GENE_OR_GENE_PRODUCT", 176, 180], ["TRIM25", "PROTEIN", 41, 47], ["RLRs", "PROTEIN", 57, 61], ["viral RNA", "RNA", 91, 100], ["RIG-I", "PROTEIN", 111, 116], ["K63", "PROTEIN", 131, 134], ["IFNs", "PROTEIN", 176, 180], ["ISGs", "PROTEIN", 185, 189], ["binding viral RNA", "PROBLEM", 83, 100], ["its K63", "TEST", 127, 134], ["linked polyubiquitination", "PROBLEM", 135, 160], ["subsequent IFNs and ISGs production", "PROBLEM", 165, 200], ["polyubiquitination", "OBSERVATION", 142, 160]]], ["In teleost fish, several TRIM25 homologs were reported to play a pivotal role in innate immunity (14, 15); however, the mechanisms by which fish TRIM25 modulates the innate immune response against viruses remain elusive.", [["TRIM25", "CHEMICAL", 145, 151], ["teleost fish", "ORGANISM", 3, 15], ["TRIM25", "GENE_OR_GENE_PRODUCT", 25, 31], ["fish", "ORGANISM", 140, 144], ["TRIM25", "GENE_OR_GENE_PRODUCT", 145, 151], ["TRIM25 homologs", "PROTEIN", 25, 40], ["TRIM25", "PROTEIN", 145, 151], ["viruses", "PROBLEM", 197, 204]]], ["Here, we found that zbTRIM25 positively regulated RLR signaling pathway and facilitated zbRIG-I-mediated IFN 1 promoter activation, and overexpression of zbTRIM25 inhibited RGNNV infection, indicating the conservative antiviral properties of TRIM25 in fish and mammals.DiscussionSeveral reports showed that TRIM25 was involved in the regulation of antiviral innate immunity by targeting RIG-I (10, 27).", [["zbTRIM25", "CHEMICAL", 20, 28], ["zbTRIM25", "CHEMICAL", 154, 162], ["infection", "DISEASE", 179, 188], ["TRIM25", "CHEMICAL", 242, 248], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 20, 28], ["RLR", "GENE_OR_GENE_PRODUCT", 50, 53], ["zbRIG-I-", "GENE_OR_GENE_PRODUCT", 88, 96], ["IFN 1", "GENE_OR_GENE_PRODUCT", 105, 110], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 154, 162], ["RGNNV", "GENE_OR_GENE_PRODUCT", 173, 178], ["TRIM25", "GENE_OR_GENE_PRODUCT", 242, 248], ["fish", "ORGANISM_SUBDIVISION", 252, 256], ["TRIM25", "GENE_OR_GENE_PRODUCT", 307, 313], ["RIG-I", "GENE_OR_GENE_PRODUCT", 387, 392], ["zbTRIM25", "PROTEIN", 20, 28], ["RLR", "PROTEIN", 50, 53], ["zbRIG", "PROTEIN", 88, 93], ["IFN 1 promoter", "DNA", 105, 119], ["zbTRIM25", "PROTEIN", 154, 162], ["TRIM25", "PROTEIN", 242, 248], ["TRIM25", "PROTEIN", 307, 313], ["RIG-I", "DNA", 387, 392], ["zbRIG", "TEST", 88, 93], ["zbTRIM25", "TREATMENT", 154, 162], ["RGNNV infection", "PROBLEM", 173, 188], ["the conservative antiviral properties of TRIM25", "TREATMENT", 201, 248], ["antiviral innate immunity", "TREATMENT", 348, 373], ["infection", "OBSERVATION", 179, 188]]], ["The mammal RIG-I protein contains two N-terminal CARD-like domains, a C-terminal RD region and an RNA helicase region (28).", [["C", "CHEMICAL", 70, 71], ["RIG-I", "GENE_OR_GENE_PRODUCT", 11, 16], ["mammal RIG-I protein", "PROTEIN", 4, 24], ["N-terminal CARD-like domains", "PROTEIN", 38, 66], ["C-terminal RD region", "PROTEIN", 70, 90], ["RNA helicase region", "PROTEIN", 98, 117], ["The mammal RIG-I protein", "TEST", 0, 24], ["two N-terminal CARD-like domains", "PROBLEM", 34, 66], ["a C-terminal RD region", "PROBLEM", 68, 90], ["an RNA helicase region", "PROBLEM", 95, 117], ["mammal", "OBSERVATION_MODIFIER", 4, 10], ["RIG", "OBSERVATION_MODIFIER", 11, 14], ["two", "OBSERVATION_MODIFIER", 34, 37], ["N-", "OBSERVATION_MODIFIER", 38, 40], ["terminal", "OBSERVATION_MODIFIER", 40, 48], ["CARD", "OBSERVATION", 49, 53], ["terminal", "ANATOMY_MODIFIER", 72, 80], ["RD", "ANATOMY", 81, 83], ["region", "ANATOMY_MODIFIER", 84, 90], ["RNA helicase", "OBSERVATION", 98, 110]]], ["In zebrafish, RIG-Ia (an insertion variant of RIG-I) and RIG-Ib (the typical RIG-I) were identified as two transcripts of RIG-I, and overexpression of RIG-Ib in cultured fish cells, but not RIG-Ia, activated zebrafish type I IFN and induced antiviral response (29).", [["fish cells", "ANATOMY", 170, 180], ["zebrafish", "ORGANISM", 3, 12], ["RIG-Ia", "GENE_OR_GENE_PRODUCT", 14, 20], ["RIG-I", "GENE_OR_GENE_PRODUCT", 46, 51], ["RIG-Ib", "GENE_OR_GENE_PRODUCT", 57, 63], ["RIG-I", "GENE_OR_GENE_PRODUCT", 77, 82], ["RIG-I", "GENE_OR_GENE_PRODUCT", 122, 127], ["RIG-Ib", "GENE_OR_GENE_PRODUCT", 151, 157], ["fish cells", "CELL", 170, 180], ["RIG-Ia", "GENE_OR_GENE_PRODUCT", 190, 196], ["zebrafish", "ORGANISM", 208, 217], ["type I IFN", "GENE_OR_GENE_PRODUCT", 218, 228], ["RIG-Ia", "DNA", 14, 20], ["RIG-I", "DNA", 46, 51], ["RIG-Ib", "DNA", 57, 63], ["RIG-I", "DNA", 77, 82], ["RIG-I", "DNA", 122, 127], ["RIG-Ib", "PROTEIN", 151, 157], ["cultured fish cells", "CELL_LINE", 161, 180], ["RIG-Ia", "PROTEIN", 190, 196], ["zebrafish type I IFN", "PROTEIN", 208, 228], ["zebrafish", "SPECIES", 3, 12], ["an insertion variant", "TREATMENT", 22, 42], ["RIG-Ib", "TREATMENT", 57, 63], ["RIG-Ib in cultured fish cells", "PROBLEM", 151, 180], ["RIG", "TEST", 190, 193], ["induced antiviral response", "PROBLEM", 233, 259], ["zebrafish", "ANATOMY", 3, 12], ["RIG", "OBSERVATION_MODIFIER", 14, 17], ["Ia", "ANATOMY", 18, 20], ["Ib", "ANATOMY", 61, 63], ["RIG", "ANATOMY", 151, 154], ["Ib", "ANATOMY", 155, 157], ["fish cells", "OBSERVATION", 170, 180]]], ["Thus, in this report, we investigated the interaction of zbTRIM25 and zbRIG-I (RIG-Ib), and our results showed that zbTRIM25 was directly associated with zbRIG-I and especially the 2CARD or RD region of zbRIG-I was sufficient for its interaction with zbTRIM25.", [["zbTRIM25", "GENE_OR_GENE_PRODUCT", 57, 65], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 70, 77], ["RIG-Ib", "GENE_OR_GENE_PRODUCT", 79, 85], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 116, 124], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 154, 161], ["2CARD", "GENE_OR_GENE_PRODUCT", 181, 186], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 203, 210], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 251, 259], ["zbTRIM25", "PROTEIN", 57, 65], ["zbRIG", "PROTEIN", 70, 75], ["I", "PROTEIN", 76, 77], ["RIG", "PROTEIN", 79, 82], ["Ib", "PROTEIN", 83, 85], ["zbTRIM25", "PROTEIN", 116, 124], ["zbRIG", "PROTEIN", 154, 159], ["2CARD or RD region", "DNA", 181, 199], ["zbRIG-I", "DNA", 203, 210], ["zbTRIM25", "PROTEIN", 251, 259], ["zbTRIM25", "TREATMENT", 57, 65], ["zbTRIM25", "TREATMENT", 116, 124], ["zbRIG-I", "PROBLEM", 154, 161], ["zbTRIM25", "TREATMENT", 251, 259]]], ["TRIM25 is characterized by an N-terminal region containing a catalytic RING domain, one or two B-box domains, a coiled-coil dimerization domain, and a C-terminal SPRY domain (30).", [["N", "CHEMICAL", 30, 31], ["C", "CHEMICAL", 151, 152], ["TRIM25", "GENE_OR_GENE_PRODUCT", 0, 6], ["TRIM25", "PROTEIN", 0, 6], ["N-terminal region", "PROTEIN", 30, 47], ["catalytic RING domain", "PROTEIN", 61, 82], ["B-box domains", "PROTEIN", 95, 108], ["coiled-coil dimerization domain", "PROTEIN", 112, 143], ["C-terminal SPRY domain", "PROTEIN", 151, 173], ["an N-terminal region", "PROBLEM", 27, 47], ["a catalytic RING domain", "TREATMENT", 59, 82], ["a coiled-coil dimerization domain", "TREATMENT", 110, 143], ["a C-terminal SPRY domain", "TREATMENT", 149, 173], ["terminal", "ANATOMY_MODIFIER", 32, 40], ["region", "ANATOMY_MODIFIER", 41, 47], ["catalytic RING", "OBSERVATION", 61, 75], ["coil dimerization", "OBSERVATION", 119, 136]]], ["Among these domains, SPRY was associated with protein\u2013protein interactions and/or RNA binding (31).", [["SPRY", "GENE_OR_GENE_PRODUCT", 21, 25], ["SPRY", "PROTEIN", 21, 25], ["protein\u2013protein interactions", "PROBLEM", 46, 74], ["RNA binding", "PROBLEM", 82, 93]]], ["Gack et al. reported that the C-terminal SPRY domain of TRIM25 interacted with the first CARD of RIG-I, but not the helicase region and RD of RIG-I, and this interaction delivered the K63-linked ubiquitin moieties to the second CARD of RIG-I, which facilitated the dimerization of RIG-I and subsequent interaction with MAVS to induce antiviral signal transduction (10).", [["C", "CHEMICAL", 30, 31], ["TRIM25", "GENE_OR_GENE_PRODUCT", 56, 62], ["CARD", "GENE_OR_GENE_PRODUCT", 89, 93], ["RIG-I", "GENE_OR_GENE_PRODUCT", 97, 102], ["RIG-I", "GENE_OR_GENE_PRODUCT", 142, 147], ["K63", "GENE_OR_GENE_PRODUCT", 184, 187], ["RIG-I", "GENE_OR_GENE_PRODUCT", 236, 241], ["RIG-I", "GENE_OR_GENE_PRODUCT", 281, 286], ["MAVS", "GENE_OR_GENE_PRODUCT", 319, 323], ["C-terminal SPRY domain", "PROTEIN", 30, 52], ["TRIM25", "PROTEIN", 56, 62], ["CARD", "PROTEIN", 89, 93], ["RIG-I", "PROTEIN", 97, 102], ["helicase region", "PROTEIN", 116, 131], ["RD", "PROTEIN", 136, 138], ["RIG-I", "PROTEIN", 142, 147], ["K63", "PROTEIN", 184, 187], ["ubiquitin moieties", "PROTEIN", 195, 213], ["CARD", "PROTEIN", 228, 232], ["RIG-I", "PROTEIN", 236, 241], ["RIG-I", "PROTEIN", 281, 286], ["MAVS", "PROTEIN", 319, 323], ["MAVS", "TREATMENT", 319, 323], ["antiviral signal transduction", "TREATMENT", 334, 363]]], ["We further investigate whether the SPRY domain of zbTRIM25 was responsible for its interaction with zbRIG-I.", [["SPRY", "GENE_OR_GENE_PRODUCT", 35, 39], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 50, 58], ["zbRIG-I.", "GENE_OR_GENE_PRODUCT", 100, 108], ["SPRY domain", "PROTEIN", 35, 46], ["zbTRIM25", "PROTEIN", 50, 58], ["zbRIG", "PROTEIN", 100, 105], ["the SPRY domain of zbTRIM25", "TREATMENT", 31, 58], ["zbRIG", "TREATMENT", 100, 105]]], ["Unlike previous studies, we found that the SPRY domain of zbTRIM25 interacted not only with 2CARD but also with RD regions of zbRIG-I.", [["SPRY", "GENE_OR_GENE_PRODUCT", 43, 47], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 58, 66], ["2CARD", "GENE_OR_GENE_PRODUCT", 92, 97], ["zbRIG-I.", "GENE_OR_GENE_PRODUCT", 126, 134], ["SPRY domain", "PROTEIN", 43, 54], ["zbTRIM25", "PROTEIN", 58, 66], ["2CARD", "PROTEIN", 92, 97], ["RD regions", "DNA", 112, 122], ["zbRIG", "PROTEIN", 126, 131], ["previous studies", "TEST", 7, 23], ["zbTRIM25", "TREATMENT", 58, 66], ["zbRIG", "TEST", 126, 131]]], ["In non-infected cells, RD covered the RNA-binding and helicase domains and CARDs folded over one another, which made RIG-I to exist in an auto-repressed conformation.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["CARDs", "GENE_OR_GENE_PRODUCT", 75, 80], ["RIG-I", "GENE_OR_GENE_PRODUCT", 117, 122], ["RNA-binding and helicase domains", "PROTEIN", 38, 70], ["CARDs", "PROTEIN", 75, 80], ["RIG-I", "PROTEIN", 117, 122], ["helicase domains", "TREATMENT", 54, 70], ["non-infected cells", "OBSERVATION", 3, 21]]], ["Upon virus infection, viral RNAs interacted with the RD and the helicase domain of RIG-I, which in turn exposed the CARDs for MAVS interaction, thereby triggering antiviral responses (32, 33).", [["infection", "DISEASE", 11, 20], ["RD", "GENE_OR_GENE_PRODUCT", 53, 55], ["RIG-I", "GENE_OR_GENE_PRODUCT", 83, 88], ["CARDs", "GENE_OR_GENE_PRODUCT", 116, 121], ["MAVS", "GENE_OR_GENE_PRODUCT", 126, 130], ["viral RNAs", "RNA", 22, 32], ["RD", "PROTEIN", 53, 55], ["helicase domain", "PROTEIN", 64, 79], ["RIG-I", "PROTEIN", 83, 88], ["MAVS", "PROTEIN", 126, 130], ["virus infection", "PROBLEM", 5, 20], ["MAVS interaction", "PROBLEM", 126, 142], ["virus", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 11, 20]]], ["Considering the interaction between RD of RIG-I and viral RNAs, we speculated that the interaction of zbTRIM25 and zbRIG-I RD might inhibit zbRIG-I sensing of viral RNAs.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 42, 47], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 102, 110], ["zbRIG-I RD", "GENE_OR_GENE_PRODUCT", 115, 125], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 140, 147], ["RIG-I and viral RNAs", "RNA", 42, 62], ["zbTRIM25", "PROTEIN", 102, 110], ["zbRIG", "PROTEIN", 115, 120], ["I RD", "PROTEIN", 121, 125], ["zbRIG", "PROTEIN", 140, 145], ["viral RNAs", "RNA", 159, 169], ["RIG-I and viral RNAs", "PROBLEM", 42, 62], ["zbTRIM25", "TREATMENT", 102, 110], ["zbRIG", "TREATMENT", 115, 120], ["viral RNAs", "PROBLEM", 159, 169], ["viral RNAs", "OBSERVATION", 52, 62], ["viral RNAs", "OBSERVATION", 159, 169]]], ["Meanwhile, it has been known that CARD domains of RIG-I are widely involved in its interaction with other proteins, such as MAVS, TRIM40, and virus proteins (27, 34, 35).", [["CARD", "GENE_OR_GENE_PRODUCT", 34, 38], ["RIG-I", "GENE_OR_GENE_PRODUCT", 50, 55], ["MAVS", "GENE_OR_GENE_PRODUCT", 124, 128], ["TRIM40", "GENE_OR_GENE_PRODUCT", 130, 136], ["CARD domains", "PROTEIN", 34, 46], ["RIG-I", "PROTEIN", 50, 55], ["MAVS", "PROTEIN", 124, 128], ["TRIM40", "PROTEIN", 130, 136], ["virus proteins", "PROTEIN", 142, 156], ["other proteins", "PROBLEM", 100, 114], ["MAVS", "TEST", 124, 128], ["TRIM40", "TEST", 130, 136], ["virus proteins", "TEST", 142, 156]]], ["Thus, the interaction of zbTRIM25 and zbRIG-I RD might also make room for other proteins to bind to 2CARD of zbRIG-I, zbTRIM25, and other proteins and will work cooperatively in regulation of RLR signaling pathway.", [["zbTRIM25", "GENE_OR_GENE_PRODUCT", 25, 33], ["zbRIG-I RD", "GENE_OR_GENE_PRODUCT", 38, 48], ["2CARD", "GENE_OR_GENE_PRODUCT", 100, 105], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 109, 116], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 118, 126], ["RLR", "GENE_OR_GENE_PRODUCT", 192, 195], ["zbTRIM25", "PROTEIN", 25, 33], ["zbRIG", "PROTEIN", 38, 43], ["I RD", "PROTEIN", 44, 48], ["2CARD", "PROTEIN", 100, 105], ["zbRIG", "PROTEIN", 109, 114], ["zbTRIM25", "PROTEIN", 118, 126], ["RLR", "PROTEIN", 192, 195], ["zbTRIM25", "TREATMENT", 25, 33], ["zbRIG", "TREATMENT", 109, 114], ["zbTRIM25", "TREATMENT", 118, 126]]], ["The differences between the findings for zbTRIM25 and TRIM25 in mammals indicate that zbTRIM25 may regulate RLR signaling pathway in various ways.DiscussionUbiquitination is a vital post-translational modification for the modulation of RIG-I activity.", [["zbTRIM25", "GENE_OR_GENE_PRODUCT", 41, 49], ["TRIM25", "GENE_OR_GENE_PRODUCT", 54, 60], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 86, 94], ["RLR", "GENE_OR_GENE_PRODUCT", 108, 111], ["RIG-I", "GENE_OR_GENE_PRODUCT", 236, 241], ["zbTRIM25", "PROTEIN", 41, 49], ["TRIM25", "PROTEIN", 54, 60], ["zbTRIM25", "PROTEIN", 86, 94], ["RLR", "PROTEIN", 108, 111], ["RIG", "PROTEIN", 236, 239], ["zbTRIM25", "TREATMENT", 41, 49], ["TRIM25", "TREATMENT", 54, 60], ["zbTRIM25", "TREATMENT", 86, 94], ["translational modification", "TREATMENT", 187, 213]]], ["Several E3 ubiquitin ligases that mediate K63-linked ubiquitination of RIG-I for its activation have been identified.", [["E3", "GENE_OR_GENE_PRODUCT", 8, 10], ["K63", "GENE_OR_GENE_PRODUCT", 42, 45], ["RIG-I", "GENE_OR_GENE_PRODUCT", 71, 76], ["E3 ubiquitin ligases", "PROTEIN", 8, 28], ["K63", "PROTEIN", 42, 45], ["RIG-I", "PROTEIN", 71, 76], ["Several E3 ubiquitin ligases", "TREATMENT", 0, 28], ["K63", "TEST", 42, 45], ["its activation", "PROBLEM", 81, 95], ["ubiquitin ligases", "OBSERVATION", 11, 28], ["ubiquitination", "OBSERVATION_MODIFIER", 53, 67]]], ["For instance, MEX3C overexpression caused the K63-linked ubiquitination of RIG-I-2CARD but not RIG-I-\u03942CARD, and lysines 48, 99, and 169 of RIG-I were required for RIG-I ubiquitination by MEX3C (23).", [["lysines", "CHEMICAL", 113, 120], ["MEX3C", "GENE_OR_GENE_PRODUCT", 14, 19], ["K63", "GENE_OR_GENE_PRODUCT", 46, 49], ["RIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 75, 86], ["RIG-I", "GENE_OR_GENE_PRODUCT", 95, 100], ["\u03942CARD", "GENE_OR_GENE_PRODUCT", 101, 107], ["RIG-I", "GENE_OR_GENE_PRODUCT", 140, 145], ["RIG-I", "GENE_OR_GENE_PRODUCT", 164, 169], ["MEX3C", "PROTEIN", 14, 19], ["K63", "PROTEIN", 46, 49], ["RIG", "PROTEIN", 75, 78], ["I", "PROTEIN", 79, 80], ["2CARD", "PROTEIN", 81, 86], ["RIG", "PROTEIN", 95, 98], ["\u03942CARD", "DNA", 101, 107], ["RIG-I", "DNA", 140, 145], ["the K63", "TEST", 42, 49], ["lysines", "TEST", 113, 120], ["RIG", "TEST", 140, 143], ["RIG", "TEST", 164, 167]]], ["RNF135 mediated the K63-linked polyubiquitination of RIG-I-RD, and lysines 849 and 851 residues of RIG-I were crucial for RNF135-mediated ubiquitination (36).", [["RNF135", "CHEMICAL", 0, 6], ["lysines", "CHEMICAL", 67, 74], ["RNF135", "GENE_OR_GENE_PRODUCT", 0, 6], ["K63", "GENE_OR_GENE_PRODUCT", 20, 23], ["RIG-I-RD", "GENE_OR_GENE_PRODUCT", 53, 61], ["RIG-I", "GENE_OR_GENE_PRODUCT", 99, 104], ["RNF135", "GENE_OR_GENE_PRODUCT", 122, 128], ["RNF135", "PROTEIN", 0, 6], ["K63", "PROTEIN", 20, 23], ["RIG", "PROTEIN", 53, 56], ["I", "PROTEIN", 57, 58], ["RD", "PROTEIN", 59, 61], ["RIG-I", "PROTEIN", 99, 104], ["RNF135", "PROTEIN", 122, 128], ["the K63", "TEST", 16, 23], ["lysines", "TEST", 67, 74], ["RIG", "TEST", 99, 102], ["polyubiquitination", "OBSERVATION", 31, 49]]], ["In contrast to RNF135, TRIM25 mediated the K63-linked polyubiquitination of RIG-I-2CARD, but not RIG-I-\u03942CARD, and the lysine 172 residue of RIG-I was critical for efficient TRIM25-mediated ubiquitination and the ability of RIG-I to activate antiviral signal transduction (10).", [["lysine", "CHEMICAL", 119, 125], ["lysine", "CHEMICAL", 119, 125], ["RNF135", "GENE_OR_GENE_PRODUCT", 15, 21], ["TRIM25", "GENE_OR_GENE_PRODUCT", 23, 29], ["K63", "GENE_OR_GENE_PRODUCT", 43, 46], ["RIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 76, 87], ["RIG-I-\u03942CARD", "GENE_OR_GENE_PRODUCT", 97, 109], ["RIG-I", "GENE_OR_GENE_PRODUCT", 141, 146], ["TRIM25", "GENE_OR_GENE_PRODUCT", 174, 180], ["RIG-I", "GENE_OR_GENE_PRODUCT", 224, 229], ["RNF135", "PROTEIN", 15, 21], ["TRIM25", "PROTEIN", 23, 29], ["K63", "PROTEIN", 43, 46], ["RIG", "PROTEIN", 76, 79], ["I-2CARD", "PROTEIN", 80, 87], ["RIG", "PROTEIN", 97, 100], ["I-\u03942CARD", "PROTEIN", 101, 109], ["RIG-I", "PROTEIN", 141, 146], ["TRIM25", "PROTEIN", 174, 180], ["RIG-I", "PROTEIN", 224, 229], ["the K63", "TEST", 39, 46], ["antiviral signal transduction", "TREATMENT", 242, 271], ["polyubiquitination", "OBSERVATION", 54, 72]]], ["Our results indicated that zbTRIM25 mediated K63-linked polyubiquitination of both 2CARD and RD regions of zbRIG-I, which is distinct from the findings in mammals that TRIM25 only targeted and promoted the K63-linked polyubiquitination of RIG-I 2CARD.", [["zbTRIM25", "CHEMICAL", 27, 35], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 27, 35], ["K63", "GENE_OR_GENE_PRODUCT", 45, 48], ["2CARD", "GENE_OR_GENE_PRODUCT", 83, 88], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 107, 114], ["TRIM25", "GENE_OR_GENE_PRODUCT", 168, 174], ["K63", "GENE_OR_GENE_PRODUCT", 206, 209], ["RIG-I 2CARD", "GENE_OR_GENE_PRODUCT", 239, 250], ["zbTRIM25", "PROTEIN", 27, 35], ["K63", "PROTEIN", 45, 48], ["2CARD and RD regions", "DNA", 83, 103], ["zbRIG", "PROTEIN", 107, 112], ["TRIM25", "PROTEIN", 168, 174], ["K63", "PROTEIN", 206, 209], ["RIG-I 2CARD", "PROTEIN", 239, 250], ["zbTRIM25 mediated K63", "TREATMENT", 27, 48], ["the K63", "TEST", 202, 209], ["polyubiquitination", "OBSERVATION_MODIFIER", 56, 74], ["polyubiquitination", "OBSERVATION", 217, 235]]], ["In addition, our reporter analysis showed that overexpression of zbRIG-I-2CARD led to the activation of IFN 1 promoter, which is similar with other reports (37).", [["zbRIG-I-", "CHEMICAL", 65, 73], ["zbRIG-I-2CARD", "GENE_OR_GENE_PRODUCT", 65, 78], ["IFN 1", "GENE_OR_GENE_PRODUCT", 104, 109], ["zbRIG", "PROTEIN", 65, 70], ["I-2CARD", "PROTEIN", 71, 78], ["IFN 1 promoter", "DNA", 104, 118], ["our reporter analysis", "TEST", 13, 34], ["zbRIG", "TEST", 65, 70]]], ["Overexpression of zbRIG-I-RD also resulted in the activation of IFN 1 promoter.", [["zbRIG-I-RD", "GENE_OR_GENE_PRODUCT", 18, 28], ["IFN 1", "GENE_OR_GENE_PRODUCT", 64, 69], ["zbRIG", "PROTEIN", 18, 23], ["I", "PROTEIN", 24, 25], ["RD", "PROTEIN", 26, 28], ["IFN 1 promoter", "DNA", 64, 78], ["IFN 1 promoter", "TREATMENT", 64, 78]]], ["Furthermore, K63-linked ubiquitin is essential for the zbTRIM25-mediated enhancement of zbRIG-I 2CARD and RD-dependent IFN 1 promoter activation. zbRIG-I possessed capacities in the induction of IFNs and ISGs to enhance the antiviral response (38).", [["K63", "GENE_OR_GENE_PRODUCT", 13, 16], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 24, 33], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 55, 63], ["zbRIG-I 2CARD", "GENE_OR_GENE_PRODUCT", 88, 101], ["RD-dependent IFN 1", "GENE_OR_GENE_PRODUCT", 106, 124], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 146, 153], ["IFNs", "GENE_OR_GENE_PRODUCT", 195, 199], ["K63", "PROTEIN", 13, 16], ["ubiquitin", "PROTEIN", 24, 33], ["zbTRIM25", "PROTEIN", 55, 63], ["zbRIG", "PROTEIN", 88, 93], ["I 2CARD", "PROTEIN", 94, 101], ["IFN 1 promoter", "DNA", 119, 133], ["zbRIG", "PROTEIN", 146, 151], ["IFNs", "PROTEIN", 195, 199], ["ISGs", "PROTEIN", 204, 208], ["K63", "TEST", 13, 16], ["the zbTRIM25", "TREATMENT", 51, 63], ["zbRIG", "TEST", 88, 93], ["RD-dependent IFN", "TREATMENT", 106, 122], ["zbRIG", "TEST", 146, 151], ["IFNs", "TREATMENT", 195, 199], ["ISGs", "TREATMENT", 204, 208], ["the antiviral response", "TEST", 220, 242]]], ["Taken together, these findings suggest that zbTRIM25-mediated ubiquitination of 2CARD and RD regions of zbRIG-I is crucial for its antiviral innate immune response.", [["zbTRIM25", "CHEMICAL", 44, 52], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 44, 52], ["2CARD", "GENE_OR_GENE_PRODUCT", 80, 85], ["zbRIG-I", "GENE_OR_GENE_PRODUCT", 104, 111], ["zbTRIM25", "PROTEIN", 44, 52], ["2CARD", "PROTEIN", 80, 85], ["RD regions", "PROTEIN", 90, 100], ["zbRIG-I", "PROTEIN", 104, 111], ["zbTRIM25", "TEST", 44, 52]]], ["However, due to the lack of TRIM25 or RIG-I-knockout zebrafish, we cannot assess the impact of the zebrafish TRIM25/RIG-I pathway at the in vivo level.", [["TRIM25", "GENE_OR_GENE_PRODUCT", 28, 34], ["RIG-I-", "GENE_OR_GENE_PRODUCT", 38, 44], ["zebrafish", "ORGANISM", 99, 108], ["TRIM25", "GENE_OR_GENE_PRODUCT", 109, 115], ["RIG-I", "GENE_OR_GENE_PRODUCT", 116, 121], ["TRIM25", "PROTEIN", 28, 34], ["RIG", "PROTEIN", 38, 41], ["TRIM25", "PROTEIN", 109, 115], ["RIG-I", "PROTEIN", 116, 121], ["TRIM25", "TEST", 28, 34], ["the zebrafish TRIM25", "TREATMENT", 95, 115]]], ["A recent study demonstrated that zebrafish RNF135 also interacted with and ubiquitinated zbRIG-I (39).", [["RNF135", "CHEMICAL", 43, 49], ["zebrafish", "ORGANISM", 33, 42], ["RNF135", "GENE_OR_GENE_PRODUCT", 43, 49], ["zbRIG-I (39)", "GENE_OR_GENE_PRODUCT", 89, 101], ["RNF135", "PROTEIN", 43, 49], ["zbRIG", "PROTEIN", 89, 94], ["I (39)", "PROTEIN", 95, 101], ["zebrafish", "SPECIES", 33, 42], ["A recent study", "TEST", 0, 14]]], ["Further studies will be performed to determine the precise architecture of the zebrafish TRIM25/RNF135/RIG-I protein complex and the mechanism by which zbTRIM25 and zbRNF135 worked together to regulate ubiquitination of zbRIG-I.DiscussionIt was known that several virus proteins could positively or negatively regulate RLR signaling pathway by targeting its key components or regulatory proteins (22).", [["zebrafish", "ORGANISM", 79, 88], ["TRIM25", "GENE_OR_GENE_PRODUCT", 89, 95], ["RNF135", "GENE_OR_GENE_PRODUCT", 96, 102], ["RIG-I", "GENE_OR_GENE_PRODUCT", 103, 108], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 152, 160], ["zbRNF135", "GENE_OR_GENE_PRODUCT", 165, 173], ["zbRIG", "GENE_OR_GENE_PRODUCT", 220, 225], ["RLR", "GENE_OR_GENE_PRODUCT", 319, 322], ["zebrafish TRIM25/RNF135/RIG-I protein complex", "PROTEIN", 79, 124], ["zbTRIM25", "PROTEIN", 152, 160], ["zbRNF135", "PROTEIN", 165, 173], ["zbRIG", "PROTEIN", 220, 225], ["virus proteins", "PROTEIN", 264, 278], ["RLR", "PROTEIN", 319, 322], ["regulatory proteins", "PROTEIN", 376, 395], ["Further studies", "TEST", 0, 15], ["zbTRIM25", "TREATMENT", 152, 160], ["zbRNF135", "TREATMENT", 165, 173], ["several virus proteins", "PROBLEM", 256, 278]]], ["For instance, paramyxovirus V proteins interacted with the RIG-I/TRIM25 regulatory complex and inhibited RIG-I signaling (27).", [["paramyxovirus V", "GENE_OR_GENE_PRODUCT", 14, 29], ["RIG-I", "GENE_OR_GENE_PRODUCT", 59, 64], ["TRIM25", "GENE_OR_GENE_PRODUCT", 65, 71], ["RIG-I", "GENE_OR_GENE_PRODUCT", 105, 110], ["paramyxovirus V proteins", "PROTEIN", 14, 38], ["RIG-I/TRIM25 regulatory complex", "PROTEIN", 59, 90], ["RIG-I", "PROTEIN", 105, 110], ["paramyxovirus V proteins", "PROBLEM", 14, 38]]], ["Influenza A virus NS1 protein bound to TRIM25 to block ubiquitination of the RIG-I (40).", [["Influenza A virus", "ORGANISM", 0, 17], ["NS1", "ORGANISM", 18, 21], ["TRIM25", "GENE_OR_GENE_PRODUCT", 39, 45], ["RIG-I", "GENE_OR_GENE_PRODUCT", 77, 82], ["Influenza A virus NS1 protein", "PROTEIN", 0, 29], ["TRIM25", "PROTEIN", 39, 45], ["RIG", "PROTEIN", 77, 80], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus NS1 protein bound", "PROBLEM", 0, 35]]], ["Severe acute respiratory syndrome nucleocapsid inhibited TRIM25-mediated RIG-I ubiquitination, causing the inhibition of IFN production (41).", [["acute respiratory syndrome", "DISEASE", 7, 33], ["TRIM25", "GENE_OR_GENE_PRODUCT", 57, 63], ["RIG-I", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFN", "GENE_OR_GENE_PRODUCT", 121, 124], ["TRIM25", "PROTEIN", 57, 63], ["RIG-I", "PROTEIN", 73, 78], ["IFN", "PROTEIN", 121, 124], ["Severe acute respiratory syndrome nucleocapsid", "SPECIES", 0, 46], ["Severe acute respiratory syndrome nucleocapsid", "PROBLEM", 0, 46], ["TRIM25", "TEST", 57, 63], ["the inhibition of IFN production", "PROBLEM", 103, 135], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["RIG-I ubiquitination", "OBSERVATION_MODIFIER", 73, 93]]], ["The RGNNV genome encodes a structural (capsid protein, CP) and a nonstructural (RNA-dependent RNA polymerase, RdRp) protein (3).", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 80, 108], ["RGNNV genome", "DNA", 4, 16], ["capsid protein", "PROTEIN", 39, 53], ["CP", "PROTEIN", 55, 57], ["nonstructural (RNA-dependent RNA polymerase, RdRp) protein", "PROTEIN", 65, 123], ["a structural (capsid protein", "PROBLEM", 25, 53], ["CP", "PROBLEM", 55, 57], ["a nonstructural (RNA-dependent RNA polymerase", "PROBLEM", 63, 108], ["RdRp) protein", "TEST", 110, 123], ["RGNNV genome", "OBSERVATION", 4, 16]]], ["Huang et al. reported that RDRP from OGNNV induced IFN by activating IRF3, the key regulatory component of RLRs-IFN signaling (42), indicating that RDRP might be a positive RLR signaling pathway.", [["OGNNV", "CHEMICAL", 37, 42], ["RDRP", "SIMPLE_CHEMICAL", 27, 31], ["OGNNV", "SIMPLE_CHEMICAL", 37, 42], ["IFN", "GENE_OR_GENE_PRODUCT", 51, 54], ["IRF3", "GENE_OR_GENE_PRODUCT", 69, 73], ["RLRs-IFN", "GENE_OR_GENE_PRODUCT", 107, 115], ["RDRP", "GENE_OR_GENE_PRODUCT", 148, 152], ["RLR", "GENE_OR_GENE_PRODUCT", 173, 176], ["RDRP", "PROTEIN", 27, 31], ["OGNNV", "PROTEIN", 37, 42], ["IFN", "PROTEIN", 51, 54], ["IRF3", "PROTEIN", 69, 73], ["RLRs", "PROTEIN", 107, 111], ["IFN", "PROTEIN", 112, 115], ["RDRP", "PROTEIN", 148, 152], ["RLR", "PROTEIN", 173, 176], ["RDRP", "PROBLEM", 27, 31], ["activating IRF3", "PROBLEM", 58, 73], ["RLRs", "TEST", 107, 111], ["IFN signaling", "TEST", 112, 125], ["RDRP", "PROBLEM", 148, 152], ["RDRP", "OBSERVATION", 27, 31], ["component", "OBSERVATION_MODIFIER", 94, 103], ["RDRP", "OBSERVATION", 148, 152]]], ["Whether RDRP targets the key components of RLR signaling pathway to exert its positive regulation role is a question that deserves further research.", [["RDRP", "CHEMICAL", 8, 12], ["RDRP", "GENE_OR_GENE_PRODUCT", 8, 12], ["RLR", "GENE_OR_GENE_PRODUCT", 43, 46], ["RDRP", "PROTEIN", 8, 12], ["RLR", "PROTEIN", 43, 46], ["RDRP", "PROBLEM", 8, 12]]], ["In addition, some miRNAs could target critical regulatory proteins of RLR pathway for immune evasion (43, 44); whether RGNNV infection-related miRNA was also involved in the regulation of RLR signaling pathway needs to be further investigated.DiscussionIn summary, zbTRIM25 is identified as a positive regulator of RLR signaling pathway by targeting zbRIG-I.", [["infection", "DISEASE", 125, 134], ["RLR", "GENE_OR_GENE_PRODUCT", 70, 73], ["RGNNV", "GENE_OR_GENE_PRODUCT", 119, 124], ["RLR", "GENE_OR_GENE_PRODUCT", 188, 191], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 265, 273], ["RLR", "GENE_OR_GENE_PRODUCT", 315, 318], ["zbRIG-I.", "GENE_OR_GENE_PRODUCT", 350, 358], ["regulatory proteins", "PROTEIN", 47, 66], ["RLR", "PROTEIN", 70, 73], ["RLR", "PROTEIN", 188, 191], ["zbTRIM25", "PROTEIN", 265, 273], ["RLR", "PROTEIN", 315, 318], ["zbRIG", "PROTEIN", 350, 355], ["immune evasion", "TEST", 86, 100], ["RGNNV infection", "PROBLEM", 119, 134], ["infection", "OBSERVATION", 125, 134]]], ["The SPRY domain of zbTRIM25 is required for its interaction with 2CARD and RD regions of zbRIG-I. zbTRIM25 promotes K63 polyubiquitination of both zbRIG-I 2CARD and RD regions, which subsequently induces the activation of downstream signaling event via MAVS and thereby inhibits viral infection (Figure 7).", [["viral infection", "DISEASE", 279, 294], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 19, 27], ["2CARD", "GENE_OR_GENE_PRODUCT", 65, 70], ["zbRIG-I.", "GENE_OR_GENE_PRODUCT", 89, 97], ["zbTRIM25", "GENE_OR_GENE_PRODUCT", 98, 106], ["K63", "GENE_OR_GENE_PRODUCT", 116, 119], ["zbRIG-I 2CARD", "GENE_OR_GENE_PRODUCT", 147, 160], ["MAVS", "GENE_OR_GENE_PRODUCT", 253, 257], ["SPRY domain", "PROTEIN", 4, 15], ["zbTRIM25", "PROTEIN", 19, 27], ["2CARD", "PROTEIN", 65, 70], ["RD regions", "PROTEIN", 75, 85], ["zbRIG", "PROTEIN", 89, 94], ["zbTRIM25", "PROTEIN", 98, 106], ["K63", "PROTEIN", 116, 119], ["zbRIG", "PROTEIN", 147, 152], ["I 2CARD", "PROTEIN", 153, 160], ["RD regions", "DNA", 165, 175], ["MAVS", "PROTEIN", 253, 257], ["The SPRY domain of zbTRIM25", "TREATMENT", 0, 27], ["2CARD and RD regions", "TREATMENT", 65, 85], ["zbRIG", "TREATMENT", 89, 94], ["zbTRIM25", "TREATMENT", 98, 106], ["MAVS", "PROBLEM", 253, 257], ["viral infection", "PROBLEM", 279, 294], ["viral", "OBSERVATION_MODIFIER", 279, 284], ["infection", "OBSERVATION", 285, 294]]], ["These findings represent a new mechanism underlying the regulation of RLR signaling pathway.Data Availability StatementAll datasets generated for this study are included in the article/Supplementary Material.Ethics StatementThe animal study was reviewed and approved by the Ethics Committee of Sun Yat-Sen University.Conflict of Interest ::: Author ContributionsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["RLR", "GENE_OR_GENE_PRODUCT", 70, 73], ["RLR", "PROTEIN", 70, 73], ["this study", "TEST", 146, 156], ["The animal study", "TEST", 224, 240], ["new", "OBSERVATION_MODIFIER", 27, 30]]]]}